[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Measure O-ADR O-ADR
the O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
) O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
Ferriprox O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
weekly O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
pulmonary O-ADR O-ADR
toxicity O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cough O-ADR O-ADR
and O-ADR O-ADR
dyspnea O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
periods O-ADR O-ADR
of O-ADR O-ADR
stress O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
COPD O-ADR O-ADR
exacerbation O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
asthma O-ADR O-ADR
attack O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
withdrawn O-ADR O-ADR
from O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
resume O-ADR O-ADR
oral O-ADR O-ADR
corticosteroids O-ADR O-ADR
( O-ADR O-ADR
in O-ADR O-ADR
large O-ADR O-ADR
doses O-ADR O-ADR
) O-ADR O-ADR
immediately O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
their O-ADR O-ADR
physicians O-ADR O-ADR
for O-ADR O-ADR
further O-ADR O-ADR
instruction O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
treatment O-ADR O-ADR
cycle O-ADR O-ADR
was O-ADR O-ADR
repeated O-ADR O-ADR
at O-ADR O-ADR
approximately O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
intervals O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
three O-ADR O-ADR
additional O-ADR O-ADR
times O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
maximum O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
total O-ADR O-ADR
injection O-ADR O-ADR
procedures O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
total O-ADR O-ADR
modeling O-ADR O-ADR
procedures O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
with O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
Insulin O-ADR O-ADR
Secretagogues O-ADR O-ADR
or O-ADR O-ADR
Insulin O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
when O-ADR O-ADR
TRULICITY O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
secretagogues O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
sulfonylureas O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
one O-ADR O-ADR
third O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
eye O-ADR O-ADR
examinations O-ADR O-ADR
performed O-ADR O-ADR
after O-ADR O-ADR
approximately O-ADR O-ADR
4 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
retinal B-ADR B-ADR
pigmentary I-ADR I-ADR
abnormalities I-ADR I-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
BLINCYTO O-ADR O-ADR
if O-ADR O-ADR
prolonged O-ADR O-ADR
neutropenia O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
for O-ADR O-ADR
females O-ADR O-ADR
: O-ADR O-ADR
Placebo O-ADR O-ADR
= O-ADR O-ADR
677 O-ADR O-ADR
, O-ADR O-ADR
FARXIGA O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
= O-ADR O-ADR
581 O-ADR O-ADR
, O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
= O-ADR O-ADR
598 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Corporal O-ADR O-ADR
Rupture O-ADR O-ADR
( O-ADR O-ADR
Penile O-ADR O-ADR
Fracture O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
Other O-ADR O-ADR
Serious O-ADR O-ADR
Injury O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
Penis O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Disease O-ADR O-ADR
Corporal B-ADR B-ADR
rupture I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
after O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
XIAFLEX O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Eye O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Optic B-ADR B-ADR
neuritis I-ADR I-ADR
, O-ADR O-ADR
retinal B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
uveitis B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
comprehensive O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
urologic O-ADR O-ADR
symptoms O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Suicidal B-ADR B-ADR
Behavior I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
. O-ADR O-ADR
Fractures B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
included O-ADR O-ADR
dystonia B-ADR B-ADR
, O-ADR O-ADR
oculogyration B-ADR B-ADR
, O-ADR O-ADR
dyskinesia B-ADR B-ADR
, O-ADR O-ADR
tardive B-ADR B-ADR
dyskinesia I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
rigidity I-ADR I-ADR
, O-ADR O-ADR
parkinsonism B-ADR B-ADR
, O-ADR O-ADR
tremor B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
extrapyramidal B-ADR B-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
akathisia B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
ovaries O-ADR O-ADR
normally O-ADR O-ADR
stop O-ADR O-ADR
making O-ADR O-ADR
estrogens O-ADR O-ADR
when O-ADR O-ADR
a O-ADR O-ADR
woman O-ADR O-ADR
is O-ADR O-ADR
between O-ADR O-ADR
45 O-ADR O-ADR
and O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Malignancies O-ADR O-ADR
Malignancies O-ADR O-ADR
in O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
Malignancies B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
among O-ADR O-ADR
children O-ADR O-ADR
, O-ADR O-ADR
adolescents O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
young O-ADR O-ADR
adults O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
FANAPT O-ADR O-ADR
experience O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
could O-ADR O-ADR
indicate O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
arrhythmias O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
dizziness O-ADR O-ADR
, O-ADR O-ADR
palpitations O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
syncope O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
prescriber O-ADR O-ADR
should O-ADR O-ADR
initiate O-ADR O-ADR
further O-ADR O-ADR
evaluation O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cardiac O-ADR O-ADR
monitoring O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
following O-ADR O-ADR
DOTAREM O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Asthma O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
parallel O-ADR O-ADR
- O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
to O-ADR O-ADR
76 O-ADR O-ADR
weeks O-ADR O-ADR
' O-ADR O-ADR
duration O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
enrolled O-ADR O-ADR
9 O-ADR O-ADR
, O-ADR O-ADR
969 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
Females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Monitored O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
- O-ADR O-ADR
Application O-ADR B-ADR
Site O-ADR I-ADR
Symptoms O-ADR I-ADR
Event O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
Vehicle O-ADR O-ADR
Application B-ADR B-ADR
site I-ADR I-ADR
Irritation I-ADR I-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
478 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
336 O-ADR O-ADR
) O-ADR O-ADR
Application B-ADR B-ADR
site I-ADR I-ADR
anesthesia I-ADR I-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
/ O-ADR O-ADR
478 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
336 O-ADR O-ADR
) O-ADR O-ADR
Pain B-ADR B-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
478 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
336 O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
subset O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
have O-ADR O-ADR
pruritus O-ADR O-ADR
, O-ADR O-ADR
erythema O-ADR O-ADR
, O-ADR O-ADR
edema O-ADR O-ADR
or O-ADR O-ADR
pyoderma O-ADR O-ADR
of O-ADR O-ADR
skin O-ADR O-ADR
and O-ADR O-ADR
scalp O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
ocular O-ADR O-ADR
irritation O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
assessed O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
Neuromuscular O-ADR O-ADR
Disorders O-ADR O-ADR
Individuals O-ADR O-ADR
with O-ADR O-ADR
peripheral O-ADR O-ADR
motor O-ADR O-ADR
neuropathic O-ADR O-ADR
diseases O-ADR O-ADR
, O-ADR O-ADR
amyotrophic O-ADR O-ADR
lateral O-ADR O-ADR
sclerosis O-ADR O-ADR
or O-ADR O-ADR
neuromuscular O-ADR O-ADR
junction O-ADR O-ADR
disorders O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
myasthenia O-ADR O-ADR
gravis O-ADR O-ADR
or O-ADR O-ADR
Lambert O-ADR O-ADR
- O-ADR O-ADR
Eaton O-ADR O-ADR
syndrome O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
particularly O-ADR O-ADR
closely O-ADR O-ADR
when O-ADR O-ADR
given O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
. O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
Adverse O-ADR O-ADR
Drug O-ADR O-ADR
ReactionsFrequencies O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
all O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
apparent O-ADR O-ADR
correlation O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
to O-ADR O-ADR
clinical O-ADR O-ADR
response O-ADR O-ADR
or O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Tuberculosis O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
tuberculosis I-ADR I-ADR
or O-ADR O-ADR
new B-ADR O-ADR
tuberculosis I-ADR B-ADR
infections I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
previously O-ADR O-ADR
received O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
or O-ADR O-ADR
active O-ADR O-ADR
tuberculosis O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
TECFIDERA O-ADR O-ADR
were O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
type O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
consistent O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
. O-ADR O-ADR
Polyoma B-ADR O-ADR
virus I-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
nephropathy I-ADR O-ADR
can O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
kidney B-ADR O-ADR
graft I-ADR O-ADR
loss I-ADR O-ADR
; O-ADR O-ADR
consider O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
immunosuppression O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
results O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
- O-ADR O-ADR
EXT O-ADR O-ADR
study O-ADR O-ADR
are O-ADR O-ADR
summarized O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
Doses O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
98 O-ADR O-ADR
Units O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
49 O-ADR O-ADR
Units O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
} O-ADR O-ADR
} O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Amgen O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
77 O-ADR O-ADR
- O-ADR O-ADR
AMGEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
772 O-ADR O-ADR
- O-ADR O-ADR
6436 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Administration O-ADR O-ADR
of O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
until O-ADR O-ADR
skin O-ADR O-ADR
is O-ADR O-ADR
healed O-ADR O-ADR
from O-ADR O-ADR
any O-ADR O-ADR
previous O-ADR O-ADR
drug O-ADR O-ADR
or O-ADR O-ADR
surgical O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Analyses O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
PRISTIQ O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
who O-ADR O-ADR
met O-ADR O-ADR
criteria O-ADR O-ADR
for O-ADR O-ADR
sustained O-ADR O-ADR
hypertension B-ADR O-ADR
revealed O-ADR O-ADR
a O-ADR O-ADR
consistent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
sustained O-ADR B-ADR
hypertension B-ADR I-ADR
. O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
- O-ADR O-ADR
depleting O-ADR O-ADR
therapies O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
acute O-ADR O-ADR
rejection O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
. O-ADR O-ADR
Serum O-ADR O-ADR
parathyroid O-ADR O-ADR
hormone O-ADR O-ADR
levels O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
25 O-ADR O-ADR
Vitamin O-ADR O-ADR
D O-ADR O-ADR
levels O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anaphylaxis O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
immediately O-ADR O-ADR
discontinue O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
d O-ADR O-ADR
Includes O-ADR O-ADR
squamous B-ADR B-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
skin I-ADR I-ADR
and O-ADR O-ADR
keratoacanthoma B-ADR B-ADR
. O-ADR O-ADR
This O-ADR O-ADR
product O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
label O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
updated O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
( I-ADR I-ADR
GI I-ADR I-ADR
) I-ADR I-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
ileus B-ADR B-ADR
, O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
neutropenic B-ADR B-ADR
enterocolitis I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JEVTANA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
including O-ADR O-ADR
tuberculosis B-ADR B-ADR
( O-ADR O-ADR
TB B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
bacterial B-ADR B-ADR
sepsis I-ADR I-ADR
, O-ADR O-ADR
invasive B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
histoplasmosis B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
infections B-ADR B-ADR
due I-ADR O-ADR
to I-ADR O-ADR
other I-ADR I-ADR
opportunistic I-ADR I-ADR
pathogens I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Immediate O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Immediate B-ADR O-ADR
hypersensitivity I-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
lips I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
bronchospasm B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
itching B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
experienced O-ADR O-ADR
by O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
sALCL O-ADR O-ADR
were O-ADR O-ADR
septic B-ADR B-ADR
shock I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
supraventricular B-ADR B-ADR
arrhythmia I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Measure O-ADR O-ADR
serum O-ADR O-ADR
ALT O-ADR O-ADR
, O-ADR O-ADR
AST O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
adjustment O-ADR O-ADR
phase O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
monthly O-ADR O-ADR
following O-ADR O-ADR
establishment O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
stable O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
narrow O-ADR O-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma O-ADR O-ADR
and O-ADR O-ADR
instruct O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
consult O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
this O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
Complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
( O-ADR O-ADR
with O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
differential O-ADR O-ADR
counts O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
obtained O-ADR O-ADR
at O-ADR O-ADR
pretreatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
Treatment O-ADR O-ADR
Weeks O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
closely O-ADR O-ADR
at O-ADR O-ADR
other O-ADR O-ADR
time O-ADR O-ADR
points O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
at O-ADR O-ADR
times O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
delays O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
Nutrition O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
appetite B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
diabetes B-ADR B-ADR
mellitus I-ADR I-ADR
, O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
hyperlipidemia B-ADR B-ADR
, O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
, O-ADR O-ADR
hypokalemia B-ADR B-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decreased I-ADR I-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
or O-ADR O-ADR
diabetes O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
glomerular O-ADR O-ADR
filtration O-ADR O-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
) O-ADR O-ADR
through O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS B-ADR B-ADR
AND O-ADR O-ADR
MALIGNANCY B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
appears O-ADR O-ADR
lower O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
, O-ADR O-ADR
moderate O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
59 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
little O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
any O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
, O-ADR O-ADR
mild O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
60 O-ADR O-ADR
to O-ADR O-ADR
89 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
You O-ADR O-ADR
may O-ADR O-ADR
report O-ADR O-ADR
side O-ADR O-ADR
effects O-ADR O-ADR
to O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
experienced O-ADR O-ADR
by O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
include O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pneumothorax B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyelonephritis B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
with O-ADR O-ADR
CYP2D6 O-ADR O-ADR
Administration O-ADR O-ADR
of O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
metabolized O-ADR O-ADR
by O-ADR O-ADR
CYP2D6 O-ADR O-ADR
may O-ADR O-ADR
significantly O-ADR O-ADR
increase O-ADR O-ADR
plasma O-ADR O-ADR
concentrations O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
coadministered O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
effects O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
an O-ADR O-ADR
ophthalmological O-ADR O-ADR
evaluation O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
best O-ADR O-ADR
corrected O-ADR O-ADR
visual O-ADR O-ADR
acuity O-ADR O-ADR
, O-ADR O-ADR
retinal O-ADR O-ADR
photographs O-ADR O-ADR
, O-ADR O-ADR
visual O-ADR O-ADR
fields O-ADR O-ADR
, O-ADR O-ADR
optical O-ADR O-ADR
coherence O-ADR O-ADR
tomography O-ADR O-ADR
( O-ADR O-ADR
OCT O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
evaluations O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
for O-ADR O-ADR
new O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
visual O-ADR B-ADR
loss O-ADR I-ADR
. O-ADR O-ADR
For O-ADR O-ADR
additional O-ADR O-ADR
information O-ADR O-ADR
, O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
consult O-ADR O-ADR
the O-ADR O-ADR
VIREAD O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
not O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
ITP O-ADR O-ADR
undergoing O-ADR O-ADR
elective O-ADR O-ADR
invasive O-ADR O-ADR
procedures O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
292 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thrombotic B-ADR B-ADR
events I-ADR I-ADR
was O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Per O-ADR O-ADR
Patient O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Assessed O-ADR O-ADR
as O-ADR O-ADR
Possibly O-ADR O-ADR
, O-ADR O-ADR
Probably O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
Definitely O-ADR O-ADR
Related O-ADR O-ADR
to O-ADR O-ADR
VORAXAZE O-ADR O-ADR
Excluding O-ADR O-ADR
Hematologic O-ADR O-ADR
, O-ADR O-ADR
Hepatic O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
Renal O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
1 O-ADR O-ADR
This O-ADR O-ADR
incidence O-ADR O-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
feeling B-ADR B-ADR
hot I-ADR I-ADR
, O-ADR O-ADR
burning B-ADR B-ADR
sensation I-ADR I-ADR
. O-ADR O-ADR
Counsel O-ADR O-ADR
patients O-ADR O-ADR
regarding O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
tumors O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
at O-ADR O-ADR
all O-ADR O-ADR
doses O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
suggestion O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
at O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
neutropenia O-ADR O-ADR
, O-ADR O-ADR
frequent O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
counts O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
on O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
JEVTANA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Bone B-ADR B-ADR
marrow I-ADR I-ADR
suppression I-ADR I-ADR
( O-ADR O-ADR
particularly O-ADR O-ADR
neutropenia B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
its O-ADR O-ADR
clinical O-ADR O-ADR
consequences O-ADR O-ADR
( O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
, O-ADR O-ADR
neutropenic B-ADR B-ADR
infections I-ADR I-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
frequently O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
if O-ADR O-ADR
dosage O-ADR O-ADR
modification O-ADR O-ADR
or O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
is O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
Gamma O-ADR O-ADR
Glutamyltransferase O-ADR O-ADR
( O-ADR O-ADR
GGT O-ADR O-ADR
) O-ADR O-ADR
Increase O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
increased B-ADR B-ADR
GGT I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
group O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
is O-ADR O-ADR
an O-ADR O-ADR
ongoing O-ADR O-ADR
expanded O-ADR O-ADR
access O-ADR O-ADR
program O-ADR O-ADR
. O-ADR O-ADR
Hepatitis O-ADR O-ADR
B O-ADR O-ADR
Virus O-ADR O-ADR
Reactivation O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
hepatitis I-ADR I-ADR
B I-ADR I-ADR
virus I-ADR I-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
carriers O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
surface O-ADR O-ADR
antigen O-ADR O-ADR
positive O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
demonstrating O-ADR O-ADR
effectiveness O-ADR O-ADR
, O-ADR O-ADR
1529 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
TECFIDERA O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
overall O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
2244 O-ADR O-ADR
person O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
infections B-ADR B-ADR
were O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
CRNM O-ADR B-ADR
= O-ADR O-ADR
clinically O-ADR B-ADR
relevant O-ADR I-ADR
nonmajor O-ADR I-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
liver O-ADR O-ADR
transplant O-ADR O-ADR
patients O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
graft O-ADR O-ADR
loss O-ADR O-ADR
and O-ADR O-ADR
death O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
displays O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Ptosis O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
XEOMIN O-ADR O-ADR
for O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dosage O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
smaller O-ADR O-ADR
neck O-ADR O-ADR
muscle O-ADR O-ADR
mass O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
require O-ADR O-ADR
bilateral O-ADR O-ADR
injections O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
sternocleidomastoid O-ADR O-ADR
muscles O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
dysphagia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
taking O-ADR O-ADR
a O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
fingolimod O-ADR O-ADR
( O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
received O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
corticosteroid O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
suspected O-ADR O-ADR
MS O-ADR O-ADR
relapses O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
variety O-ADR O-ADR
of O-ADR O-ADR
sources O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
registries O-ADR O-ADR
and O-ADR O-ADR
spontaneous O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
reports O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
persistent O-ADR O-ADR
QTc O-ADR O-ADR
measurements O-ADR O-ADR
> O-ADR O-ADR
500 O-ADR O-ADR
msec O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
partial O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
seizures O-ADR O-ADR
[ O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
365 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
225 O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
longer O-ADR O-ADR
than O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
134 O-ADR O-ADR
for O-ADR O-ADR
longer O-ADR O-ADR
than O-ADR O-ADR
24 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
MS O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
72 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
transient O-ADR O-ADR
and O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
limited O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
are O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
. O-ADR O-ADR
Assure O-ADR O-ADR
good O-ADR O-ADR
venous O-ADR O-ADR
access O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
starting O-ADR O-ADR
TREANDA O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
site O-ADR O-ADR
for O-ADR O-ADR
redness O-ADR O-ADR
, O-ADR O-ADR
swelling O-ADR O-ADR
, O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
necrosis O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
TREANDA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
renal B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
Discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
renal B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
distance O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
z O-ADR O-ADR
- O-ADR O-ADR
score O-ADR O-ADR
from O-ADR O-ADR
0 O-ADR O-ADR
represents O-ADR O-ADR
the O-ADR O-ADR
distance O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
percentile O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
, O-ADR O-ADR
measured O-ADR O-ADR
in O-ADR O-ADR
standard O-ADR O-ADR
deviations O-ADR O-ADR
( O-ADR O-ADR
SD O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
serious O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
through O-ADR O-ADR
Year O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
: O-ADR O-ADR
Bleeding B-ADR B-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
. O-ADR O-ADR
Anti O-ADR O-ADR
- O-ADR O-ADR
belatacept O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
altered O-ADR O-ADR
clearance O-ADR O-ADR
of O-ADR O-ADR
belatacept O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
sulfonylurea O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR B-ADR
in O-ADR O-ADR
this O-ADR O-ADR
setting O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
pulmonary O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
hold O-ADR O-ADR
ADCETRIS O-ADR O-ADR
dosing O-ADR O-ADR
during O-ADR O-ADR
evaluation O-ADR O-ADR
and O-ADR O-ADR
until O-ADR O-ADR
symptomatic O-ADR O-ADR
improvement O-ADR O-ADR
. O-ADR O-ADR
Psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
bruxism B-ADR B-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
obsessive B-ADR B-ADR
- O-ADR O-ADR
compulsive O-ADR O-ADR
disorder I-ADR I-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
the O-ADR O-ADR
protein O-ADR O-ADR
components O-ADR O-ADR
in O-ADR O-ADR
XIAFLEX O-ADR O-ADR
( O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
and O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
some O-ADR O-ADR
sequence O-ADR O-ADR
homology O-ADR O-ADR
with O-ADR O-ADR
human O-ADR O-ADR
matrix O-ADR O-ADR
metalloproteinases O-ADR O-ADR
( O-ADR O-ADR
MMPs O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
product O-ADR O-ADR
antibodies O-ADR O-ADR
could O-ADR O-ADR
theoretically O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
human O-ADR O-ADR
MMPs O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Liver B-ADR B-ADR
disease I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
Natazia O-ADR O-ADR
if O-ADR O-ADR
jaundice O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
SJS O-ADR O-ADR
or O-ADR O-ADR
TEN O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
ADCETRIS O-ADR O-ADR
and O-ADR O-ADR
administer O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Stop O-ADR O-ADR
Natazia O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
before O-ADR O-ADR
and O-ADR O-ADR
through O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
major O-ADR O-ADR
surgery O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Retinal O-ADR O-ADR
Abnormalities O-ADR O-ADR
and O-ADR O-ADR
Potential O-ADR O-ADR
Vision O-ADR O-ADR
Loss O-ADR O-ADR
POTIGA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
abnormalities B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
retina I-ADR I-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Male O-ADR O-ADR
genital O-ADR O-ADR
mycotic O-ADR O-ADR
infectionsGenital O-ADR O-ADR
mycotic B-ADR B-ADR
infections I-ADR I-ADR
include I-ADR O-ADR
the I-ADR O-ADR
following I-ADR O-ADR
adverse I-ADR O-ADR
reactions I-ADR O-ADR
, I-ADR O-ADR
listed I-ADR O-ADR
in I-ADR O-ADR
order I-ADR O-ADR
of I-ADR O-ADR
frequency I-ADR O-ADR
reported I-ADR O-ADR
for I-ADR O-ADR
males I-ADR O-ADR
: O-ADR O-ADR
balanitis B-ADR B-ADR
, O-ADR O-ADR
fungal B-ADR B-ADR
genital I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
balanitis B-ADR B-ADR
candida I-ADR I-ADR
, O-ADR O-ADR
genital B-ADR B-ADR
candidiasis I-ADR I-ADR
, O-ADR O-ADR
genital B-ADR B-ADR
infection I-ADR I-ADR
male I-ADR I-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
balanoposthitis B-ADR B-ADR
, O-ADR O-ADR
balanoposthitis B-ADR B-ADR
infective I-ADR I-ADR
, O-ADR O-ADR
genital B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
posthitis B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
presents O-ADR O-ADR
selected O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
from O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
arms O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
over O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
gp100 O-ADR O-ADR
arm O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
- O-ADR O-ADR
grade O-ADR O-ADR
events O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
incidence O-ADR O-ADR
over O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
Case O-ADR O-ADR
reports O-ADR O-ADR
and O-ADR O-ADR
epidemiological O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
case O-ADR O-ADR
- O-ADR O-ADR
control O-ADR O-ADR
and O-ADR O-ADR
cohort O-ADR O-ADR
design O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
demonstrated O-ADR O-ADR
an O-ADR O-ADR
association O-ADR O-ADR
between O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
serotonin O-ADR O-ADR
reuptake O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
gastrointestinal B-ADR B-ADR
bleeding I-ADR I-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
retinal B-ADR B-ADR
pigmentary I-ADR I-ADR
abnormalities I-ADR I-ADR
had O-ADR O-ADR
no O-ADR O-ADR
such O-ADR O-ADR
discoloration B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
historically O-ADR O-ADR
controlled O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
skin B-ADR B-ADR
laceration I-ADR I-ADR
( O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
two O-ADR O-ADR
concurrent O-ADR O-ADR
injections O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
three O-ADR O-ADR
single O-ADR O-ADR
injections O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
premarketing O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Exposure O-ADR O-ADR
to O-ADR O-ADR
YERVOY O-ADR O-ADR
3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
for O-ADR O-ADR
4 O-ADR O-ADR
doses O-ADR O-ADR
given O-ADR O-ADR
by O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
in O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
unresectable O-ADR O-ADR
or O-ADR O-ADR
metastatic O-ADR O-ADR
melanoma O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
111 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
pemetrexed O-ADR O-ADR
/ O-ADR O-ADR
cisplatin O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
association O-ADR O-ADR
between O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
titer O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
effect O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pooled O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1085 O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
eGFR O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
baseline O-ADR O-ADR
eGFR O-ADR O-ADR
48 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
dedicated O-ADR O-ADR
trial O-ADR O-ADR
but O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
incident O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
significant O-ADR O-ADR
renal B-ADR B-ADR
function I-ADR I-ADR
decline I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
was O-ADR O-ADR
still O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
cardiac O-ADR B-ADR
complications O-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
pooled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
exposure O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
was O-ADR O-ADR
52 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
51 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Reduce O-ADR O-ADR
or O-ADR O-ADR
withhold O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Merck O-ADR O-ADR
Sharp O-ADR O-ADR
& O-ADR O-ADR
Dohme O-ADR O-ADR
Corp O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
subsidiary O-ADR O-ADR
of O-ADR O-ADR
Merck O-ADR O-ADR
& O-ADR O-ADR
Co O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
4231 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
ERWINAZE O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
hemorrhagic O-ADR O-ADR
pancreatitis O-ADR O-ADR
manifested O-ADR O-ADR
by O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
> O-ADR O-ADR
72 O-ADR O-ADR
hours O-ADR O-ADR
and O-ADR O-ADR
amylase O-ADR O-ADR
elevation O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
x O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
Varicella O-ADR O-ADR
Zoster O-ADR O-ADR
Virus O-ADR O-ADR
Antibody O-ADR O-ADR
Testing O-ADR O-ADR
/ O-ADR O-ADR
Vaccination O-ADR O-ADR
Patients O-ADR O-ADR
without O-ADR O-ADR
a O-ADR O-ADR
healthcare O-ADR O-ADR
professional O-ADR O-ADR
confirmed O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
chickenpox O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
documentation O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
full O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
vaccination O-ADR O-ADR
against O-ADR O-ADR
varicella O-ADR O-ADR
zoster O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
VZV O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
VZV O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
half O-ADR O-ADR
the O-ADR O-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
lymphomas B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
Hodgkin O-ADR O-ADR
' I-ADR I-ADR
s O-ADR O-ADR
lymphoma I-ADR I-ADR
. O-ADR O-ADR
When O-ADR O-ADR
distant O-ADR O-ADR
effects O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
additional O-ADR O-ADR
respiratory O-ADR O-ADR
muscles O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
involved O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antihistamines O-ADR O-ADR
, O-ADR O-ADR
antipyretics O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
corticosteroids O-ADR O-ADR
still O-ADR O-ADR
experienced O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
neuromuscular O-ADR O-ADR
disorders O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
effects O-ADR O-ADR
including O-ADR O-ADR
severe O-ADR O-ADR
dysphagia B-ADR B-ADR
and O-ADR O-ADR
respiratory B-ADR B-ADR
compromise I-ADR I-ADR
from O-ADR O-ADR
typical O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
cimetidine O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
examined O-ADR O-ADR
by O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
pharmacokinetic O-ADR O-ADR
interaction O-ADR O-ADR
is O-ADR O-ADR
expected O-ADR O-ADR
, O-ADR O-ADR
albeit O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
that O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
blinded O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
141 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
19 O-ADR O-ADR
- O-ADR O-ADR
451 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
60 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
21 O-ADR O-ADR
- O-ADR O-ADR
295 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Kyprolis O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
and O-ADR O-ADR
findings O-ADR O-ADR
in O-ADR O-ADR
animals O-ADR O-ADR
. O-ADR O-ADR
Eleven O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
163 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
10 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
245 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
adjustments O-ADR O-ADR
( O-ADR O-ADR
interruptions O-ADR O-ADR
or O-ADR O-ADR
reductions O-ADR O-ADR
) O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
52 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
701 O-ADR O-ADR
subjects O-ADR O-ADR
received O-ADR O-ADR
STRIBILD O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
two O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
and O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
Vizamyl O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
290n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Paresthesias B-ADR B-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Flushing B-ADR B-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Nausea O-ADR O-ADR
/ O-ADR O-ADR
Vomiting O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Hypotension B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Blurred B-ADR B-ADR
Vision I-ADR I-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Diarrhea B-ADR B-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Hypertension B-ADR B-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Rash B-ADR B-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Throat B-ADR O-ADR
irritation O-ADR O-ADR
/ O-ADR O-ADR
Throat O-ADR O-ADR
tightness B-ADR B-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Tremor B-ADR B-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
immunogenicity O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XALKORI O-ADR O-ADR
arm O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
171 O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
XALKORI O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
documented O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
, O-ADR O-ADR
intolerance O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
determined O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
longer O-ADR O-ADR
experiencing O-ADR O-ADR
clinical O-ADR O-ADR
benefit O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Fetal B-ADR B-ADR
harm I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
QT O-ADR O-ADR
Prolongation O-ADR O-ADR
The O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
/ O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
were O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
dedicated O-ADR O-ADR
adult O-ADR O-ADR
QT O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
cutaneous B-ADR B-ADR
squamous I-ADR I-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
were O-ADR O-ADR
required O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
per O-ADR O-ADR
protocol O-ADR O-ADR
. O-ADR O-ADR
Selected O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
3 O-ADR O-ADR
Trials O-ADR O-ADR
( O-ADR O-ADR
Number O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
) O-ADR O-ADR
Dalbavancin O-ADR O-ADR
Comparator O-ADR O-ADR
* O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1778 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1224 O-ADR O-ADR
) O-ADR O-ADR
Nausea B-ADR B-ADR
98 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
78 O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
Vomiting B-ADR B-ADR
50 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
37 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
Diarrhea B-ADR B-ADR
79 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
72 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
83 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
59 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
Rash B-ADR B-ADR
48 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
30 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
Pruritus B-ADR B-ADR
38 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
41 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Comparators O-ADR O-ADR
included O-ADR O-ADR
linezolid O-ADR O-ADR
, O-ADR O-ADR
cefazolin O-ADR O-ADR
, O-ADR O-ADR
cephalexin O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vancomycin O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
joint B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
, O-ADR O-ADR
hot B-ADR B-ADR
flush I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
and O-ADR O-ADR
contusion B-ADR B-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
FOR O-ADR O-ADR
HEPATIC B-ADR B-ADR
DECOMPENSATION I-ADR I-ADR
IN O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
CHRONIC O-ADR O-ADR
HEPATITIS O-ADR O-ADR
C O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
FOR O-ADR O-ADR
HEPATIC B-ADR B-ADR
DECOMPENSATION I-ADR I-ADR
IN O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
CHRONIC O-ADR O-ADR
HEPATITIS O-ADR O-ADR
C O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
, O-ADR O-ADR
PROMACTA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
interferon O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hepatic B-ADR B-ADR
decompensation I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
CIMZIA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
need O-ADR O-ADR
of O-ADR O-ADR
emergency O-ADR O-ADR
cardiorespiratory O-ADR O-ADR
support O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Nephrogenic O-ADR O-ADR
Systemic O-ADR O-ADR
Fibrosis O-ADR O-ADR
( O-ADR O-ADR
NSF O-ADR O-ADR
) O-ADR O-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
nephrogenic B-ADR B-ADR
systemic I-ADR I-ADR
fibrosis I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
highest O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
Gadavist O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
allow O-ADR O-ADR
a O-ADR O-ADR
sufficient O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
body O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Serious O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Thrombotic B-ADR B-ADR
microangiopathy I-ADR I-ADR
with O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
f O-ADR O-ADR
NA O-ADR O-ADR
= O-ADR O-ADR
not O-ADR O-ADR
applicable O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
animal O-ADR O-ADR
reproduction O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
oral O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
crizotinib O-ADR O-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
rats O-ADR O-ADR
during O-ADR O-ADR
organogenesis O-ADR O-ADR
at O-ADR O-ADR
exposures O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
recommended O-ADR O-ADR
human O-ADR O-ADR
dose O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
embryotoxicity B-ADR B-ADR
and O-ADR O-ADR
fetotoxicity B-ADR B-ADR
. O-ADR O-ADR
Small O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
creatinine I-ADR I-ADR
levels I-ADR I-ADR
( O-ADR O-ADR
about O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
following O-ADR O-ADR
dronedarone O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
creatinine O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
tubular O-ADR O-ADR
secretion O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
intraocular I-ADR I-ADR
pressure I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
seen O-ADR O-ADR
within O-ADR O-ADR
60 O-ADR O-ADR
minutes O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
intravitreal O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
data O-ADR O-ADR
cut O-ADR O-ADR
- O-ADR O-ADR
off O-ADR O-ADR
, O-ADR O-ADR
243 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
enrolled O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
was O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
141 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Vaccinations O-ADR O-ADR
: O-ADR O-ADR
Avoid O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
and O-ADR O-ADR
close O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
radiological O-ADR O-ADR
changes O-ADR O-ADR
; O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
169 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
chemotherapy O-ADR O-ADR
arm O-ADR O-ADR
received O-ADR O-ADR
pemetrexed O-ADR O-ADR
500 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
cisplatin O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
91 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
carboplatin O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
calculated O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
an O-ADR O-ADR
area O-ADR O-ADR
under O-ADR O-ADR
the O-ADR O-ADR
concentration O-ADR O-ADR
- O-ADR O-ADR
time O-ADR O-ADR
curve O-ADR O-ADR
( O-ADR O-ADR
AUC O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
mg O-ADR O-ADR
? O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
78 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Eye B-ADR B-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
severe O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
chemical B-ADR B-ADR
conjunctivitis I-ADR I-ADR
, O-ADR O-ADR
corneal B-ADR B-ADR
burn I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
, O-ADR O-ADR
periorbital B-ADR B-ADR
edema I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
exposure O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
One O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
classified O-ADR O-ADR
as O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
three O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
six O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
in O-ADR O-ADR
duration O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
treating O-ADR O-ADR
physician O-ADR O-ADR
as O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Events O-ADR O-ADR
and O-ADR O-ADR
event O-ADR O-ADR
rates O-ADR O-ADR
include O-ADR O-ADR
one O-ADR O-ADR
enoxaparin O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
in O-ADR O-ADR
ADVANCE O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
who O-ADR O-ADR
also O-ADR O-ADR
had O-ADR O-ADR
intracranial B-ADR B-ADR
hemorrhage I-ADR I-ADR
. O-ADR O-ADR
AFINITOR O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
reintroduced O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
daily O-ADR O-ADR
dose O-ADR O-ADR
approximately O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
previously O-ADR O-ADR
administered O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
in O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
DIFICID O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GE O-ADR O-ADR
Healthcare O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
654 O-ADR O-ADR
- O-ADR O-ADR
0118 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Cardiomyopathy O-ADR O-ADR
Cardiomyopathy B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
[ O-ADR O-ADR
refer O-ADR O-ADR
to O-ADR O-ADR
Full O-ADR O-ADR
Prescribing O-ADR O-ADR
Information O-ADR O-ADR
for O-ADR O-ADR
trametinib O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
bleeding B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
219 O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
ELIQUIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
72 O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
of O-ADR O-ADR
short O-ADR O-ADR
duration O-ADR O-ADR
. O-ADR O-ADR
Appendicitis O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
appendicitis B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
among O-ADR O-ADR
all O-ADR O-ADR
comparators O-ADR O-ADR
. O-ADR O-ADR
Subjects O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
evidence O-ADR O-ADR
to O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
high O-ADR O-ADR
sustained O-ADR O-ADR
titers O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
antibodies O-ADR O-ADR
may O-ADR O-ADR
experience O-ADR O-ADR
reduced O-ADR O-ADR
clinical O-ADR O-ADR
efficacy O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
treatment O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
profile O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
9 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
40 O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
regularly O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
driving B-ADR B-ADR
impairment I-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
HORIZANT O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
within O-ADR O-ADR
hours O-ADR O-ADR
to O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
injection O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
Week O-ADR O-ADR
Trials O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
evaluated O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
in O-ADR O-ADR
adolescent O-ADR O-ADR
and O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
ILD B-ADR B-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Include O-ADR O-ADR
disseminated O-ADR O-ADR
herpetic O-ADR O-ADR
infections O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
differential O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
and O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
atypical O-ADR O-ADR
MS O-ADR O-ADR
relapse O-ADR O-ADR
or O-ADR O-ADR
multiorgan O-ADR O-ADR
failure O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
also O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Concomitant O-ADR O-ADR
neuromuscular O-ADR O-ADR
disorders O-ADR O-ADR
may O-ADR O-ADR
exacerbate O-ADR O-ADR
clinical O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
JEVTANA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
female O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
C O-ADR O-ADR
ontraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
W O-ADR O-ADR
arnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Assessment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
formation O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
table O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
safety O-ADR O-ADR
information O-ADR O-ADR
from O-ADR O-ADR
769 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
240 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
and O-ADR O-ADR
771 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Other O-ADR O-ADR
Malignancies B-ADR B-ADR
: O-ADR O-ADR
malignant B-ADR B-ADR
diseases I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
TRULICITY O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
personal O-ADR O-ADR
or O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Multiple O-ADR O-ADR
Endocrine O-ADR O-ADR
Neoplasia O-ADR O-ADR
syndrome O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
MEN O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Episodes O-ADR O-ADR
of O-ADR O-ADR
sinus B-ADR B-ADR
tachycardia I-ADR I-ADR
, O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
concomitant O-ADR O-ADR
increase B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
heart I-ADR I-ADR
rate I-ADR I-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
15 O-ADR O-ADR
beats O-ADR O-ADR
per O-ADR O-ADR
minute O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
TRULICITY O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Chronic O-ADR O-ADR
antipsychotic O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
generally O-ADR O-ADR
be O-ADR O-ADR
reserved O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
suffer O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
chronic O-ADR O-ADR
illness O-ADR O-ADR
that O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
respond O-ADR O-ADR
to O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
whom O-ADR O-ADR
alternative O-ADR O-ADR
, O-ADR O-ADR
equally O-ADR O-ADR
effective O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
potentially O-ADR O-ADR
less O-ADR O-ADR
harmful O-ADR O-ADR
treatments O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
or O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Back B-ADR B-ADR
pain I-ADR I-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Increased O-ADR O-ADR
urinationIncreased O-ADR O-ADR
urination B-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
frequency O-ADR O-ADR
reported O-ADR O-ADR
: O-ADR O-ADR
pollakiuria B-ADR B-ADR
, O-ADR O-ADR
polyuria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urine B-ADR B-ADR
output I-ADR I-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
evaluating O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
serum O-ADR O-ADR
glucose O-ADR O-ADR
or O-ADR O-ADR
potassium O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
diarrhea O-ADR O-ADR
or O-ADR O-ADR
colitis O-ADR O-ADR
. O-ADR O-ADR
Start O-ADR O-ADR
Natazia O-ADR O-ADR
no O-ADR O-ADR
earlier O-ADR O-ADR
than O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
delivery O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
breastfeeding O-ADR O-ADR
. O-ADR O-ADR
Half O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
POTIGA O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hallucinations B-ADR B-ADR
or O-ADR O-ADR
psychosis B-ADR B-ADR
required O-ADR O-ADR
hospitalization O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
this O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
HPA O-ADR O-ADR
suppression O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
exhibit O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
adrenal O-ADR B-ADR
insufficiency O-ADR I-ADR
when O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
trauma O-ADR O-ADR
, O-ADR O-ADR
surgery O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
infection O-ADR O-ADR
( O-ADR O-ADR
particularly O-ADR O-ADR
gastroenteritis O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
electrolyte O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
In O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
age O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
with O-ADR O-ADR
ITP O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rhinitis B-ADR B-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
pregnancy O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
venous B-ADR B-ADR
thromboembolism I-ADR I-ADR
as O-ADR O-ADR
much O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
COCs O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
( O-ADR O-ADR
warfarin O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
, O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
II O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
MEDY O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
study O-ADR O-ADR
( O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
SONATE O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
. O-ADR O-ADR
Reproductive O-ADR O-ADR
system O-ADR O-ADR
and O-ADR O-ADR
breast O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Menstrual B-ADR B-ADR
disorder I-ADR I-ADR
. O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Infections B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
appropriately O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
shows O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
FARXIGA O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
these O-ADR O-ADR
confounders O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
hyperglycemia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
completely O-ADR O-ADR
understood O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
despite O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
have O-ADR O-ADR
had O-ADR O-ADR
more O-ADR O-ADR
extensive O-ADR O-ADR
diagnostic O-ADR O-ADR
retinal O-ADR O-ADR
evaluations O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
presenting O-ADR O-ADR
as O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
gastrointestinal B-ADR B-ADR
symptoms I-ADR I-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
during O-ADR O-ADR
infusions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
LEO O-ADR O-ADR
Pharma O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
494 O-ADR O-ADR
- O-ADR O-ADR
4536 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
potassium O-ADR O-ADR
excretion O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
potassium O-ADR O-ADR
- O-ADR O-ADR
sparing O-ADR O-ADR
diuretics O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
- O-ADR O-ADR
aldosterone O-ADR O-ADR
system O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
hyperkalemia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
14 O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
66 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
62 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
comparator O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
4550 O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
osteoporosis O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
in O-ADR O-ADR
serum O-ADR O-ADR
calcium O-ADR O-ADR
level O-ADR O-ADR
10 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
Prolia O-ADR O-ADR
dosing O-ADR O-ADR
was O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
. O-ADR O-ADR
Endocarditis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
no O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
Five O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
9 O-ADR O-ADR
SIRTURO O-ADR O-ADR
deaths B-ADR B-ADR
and O-ADR O-ADR
the O-ADR O-ADR
2 O-ADR O-ADR
placebo O-ADR O-ADR
deaths B-ADR B-ADR
were O-ADR O-ADR
tuberculosis O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
Cabazitaxel O-ADR O-ADR
is O-ADR O-ADR
extensively O-ADR O-ADR
metabolized O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
liver O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
when O-ADR O-ADR
TREANDA O-ADR O-ADR
was O-ADR O-ADR
given O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
anticancer O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
Controlled O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Qutenza O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
erythema I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
pruritus I-ADR I-ADR
and O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
papules I-ADR I-ADR
. O-ADR O-ADR
Rare O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
hepatosplenic B-ADR B-ADR
T I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
lymphoma I-ADR I-ADR
( O-ADR O-ADR
HSTCL B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ENDOMETRIAL B-ADR B-ADR
CANCER I-ADR I-ADR
, O-ADR O-ADR
CARDIOVASCULAR B-ADR B-ADR
DISORDERS I-ADR I-ADR
, O-ADR O-ADR
AND O-ADR O-ADR
PROBABLE O-ADR O-ADR
DEMENTIA B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
immediate O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
further O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
therapy O-ADR O-ADR
immediately O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
in O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Schizophrenia O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
, O-ADR O-ADR
rounded O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
nearest O-ADR O-ADR
percent O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
SAPHRIS O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
acute O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
75 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
cUTI O-ADR O-ADR
trial O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
most O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
58 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
cIAI O-ADR O-ADR
trial O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormality O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
* O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
and O-ADR O-ADR
diabetes B-ADR O-ADR
mellitus I-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hyperglycemia O-ADR O-ADR
including O-ADR O-ADR
polydipsia O-ADR O-ADR
, O-ADR O-ADR
polyuria O-ADR O-ADR
, O-ADR O-ADR
polyphagia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weakness O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Concomitant O-ADR O-ADR
Administration O-ADR O-ADR
with O-ADR O-ADR
CYP3A4 O-ADR O-ADR
Inhibitors O-ADR O-ADR
* O-ADR O-ADR
Doses O-ADR O-ADR
of O-ADR O-ADR
Toviaz O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
a O-ADR O-ADR
potent O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitor O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
ketoconazole O-ADR O-ADR
, O-ADR O-ADR
itraconazole O-ADR O-ADR
, O-ADR O-ADR
clarithromycin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Intradermal O-ADR O-ADR
Immune O-ADR O-ADR
Reaction O-ADR O-ADR
The O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
immune O-ADR O-ADR
reaction O-ADR O-ADR
when O-ADR O-ADR
injected O-ADR O-ADR
intradermally O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
Month O-ADR O-ADR
Trials O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
two O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Trials O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
; O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
633 O-ADR O-ADR
and O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
622 O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Within O-ADR O-ADR
each O-ADR O-ADR
MedDRA O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
decreasing O-ADR O-ADR
frequency O-ADR O-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
all O-ADR O-ADR
CAPS O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
ILARIS O-ADR O-ADR
in O-ADR O-ADR
Part O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
controlled O-ADR O-ADR
data O-ADR O-ADR
on O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
AEs O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
section O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
BLINCYTO O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
212 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
or O-ADR O-ADR
refractory O-ADR O-ADR
ALL O-ADR O-ADR
received O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
28 O-ADR O-ADR
mcg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
JARDIANCE O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
for O-ADR O-ADR
volume O-ADR O-ADR
contraction O-ADR O-ADR
and O-ADR O-ADR
correct O-ADR O-ADR
volume O-ADR O-ADR
status O-ADR O-ADR
if O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
were O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anaphylactic O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
immediately O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
Neutropenia O-ADR B-ADR
: O-ADR O-ADR
Neutropenic B-ADR B-ADR
deaths B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
peri O-ADR O-ADR
- O-ADR O-ADR
surgical O-ADR O-ADR
period O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
Including O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
: O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Other O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
: O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
protozoal B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
and O-ADR O-ADR
tuberculosis B-ADR B-ADR
. O-ADR O-ADR
One O-ADR O-ADR
subject O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
761 O-ADR O-ADR
administered O-ADR O-ADR
Vizamyl O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
with O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
and O-ADR O-ADR
chest B-ADR B-ADR
pressure I-ADR I-ADR
within O-ADR O-ADR
minutes O-ADR O-ADR
following O-ADR O-ADR
Vizamyl O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
recovered O-ADR O-ADR
with O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
liver O-ADR O-ADR
transplant O-ADR O-ADR
patients O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
graft O-ADR O-ADR
loss O-ADR O-ADR
and O-ADR O-ADR
death O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
subjects O-ADR O-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
subject O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
all O-ADR O-ADR
- O-ADR O-ADR
comparator O-ADR O-ADR
group O-ADR O-ADR
experienced O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
ALT B-ADR B-ADR
increase I-ADR I-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
1346 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
AdreView O-ADR O-ADR
, O-ADR O-ADR
251 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
or O-ADR O-ADR
suspected O-ADR O-ADR
pheochromocytoma O-ADR O-ADR
or O-ADR O-ADR
neuroblastoma O-ADR O-ADR
, O-ADR O-ADR
985 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
110 O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
parallel O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
was O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
previously O-ADR O-ADR
untreated O-ADR O-ADR
CHC O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
genotype O-ADR O-ADR
1 O-ADR O-ADR
infection O-ADR O-ADR
to O-ADR O-ADR
compare O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
ESA O-ADR O-ADR
versus O-ADR O-ADR
ribavirin O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
for O-ADR O-ADR
initial O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
anemia O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
2b O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Pulmonary O-ADR O-ADR
Toxicity O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
including O-ADR O-ADR
pneumonitis B-ADR B-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
setting O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
20 O-ADR O-ADR
or O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
for O-ADR O-ADR
periods O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
106 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
: O-ADR O-ADR
61 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
that O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Initiate O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Fat O-ADR O-ADR
Redistribution O-ADR O-ADR
buffalo B-ADR B-ADR
hump I-ADR I-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
wasting I-ADR I-ADR
, O-ADR O-ADR
breast B-ADR B-ADR
enlargement I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
cushingoid B-ADR B-ADR
appearance I-ADR I-ADR
' O-ADR O-ADR
' O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
procoagulant O-ADR O-ADR
reversal O-ADR O-ADR
agents O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
prothrombin O-ADR O-ADR
complex O-ADR O-ADR
concentrate O-ADR O-ADR
, O-ADR O-ADR
activated O-ADR O-ADR
prothrombin O-ADR O-ADR
complex O-ADR O-ADR
concentrate O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
recombinant O-ADR O-ADR
factor O-ADR O-ADR
VIIa O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
but O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Dronedarone O-ADR O-ADR
caused O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
in O-ADR O-ADR
animal O-ADR O-ADR
studies O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
equivalent O-ADR O-ADR
to O-ADR O-ADR
recommended O-ADR O-ADR
human O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
agent O-ADR O-ADR
ADCETRIS O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Recrudescence O-ADR O-ADR
Food O-ADR O-ADR
enhances O-ADR O-ADR
absorption O-ADR O-ADR
of O-ADR O-ADR
artemether O-ADR O-ADR
and O-ADR O-ADR
lumefantrine O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Immediate O-ADR B-ADR
hypersensitivity B-ADR I-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
at O-ADR O-ADR
once O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
alternatives O-ADR O-ADR
if O-ADR O-ADR
immediate O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
angioedema O-ADR O-ADR
, O-ADR O-ADR
bronchospasm O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
anaphylaxis O-ADR O-ADR
, O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
After O-ADR O-ADR
opening O-ADR O-ADR
the O-ADR O-ADR
foil O-ADR O-ADR
pouch O-ADR O-ADR
the O-ADR O-ADR
DUAVEE O-ADR O-ADR
blisters O-ADR O-ADR
come O-ADR O-ADR
in O-ADR O-ADR
, O-ADR O-ADR
DUAVEE O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
within O-ADR O-ADR
60 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
hemorrhagic O-ADR O-ADR
events O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
hemorrhagic O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
improve O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
KALBITOR O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
setting O-ADR O-ADR
equipped O-ADR O-ADR
to O-ADR O-ADR
manage O-ADR O-ADR
anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
hereditary O-ADR O-ADR
angioedema O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
although O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Development O-ADR O-ADR
of O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Resistant O-ADR O-ADR
Bacteria O-ADR O-ADR
Prescribing O-ADR O-ADR
DIFICID O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
proven O-ADR O-ADR
or O-ADR O-ADR
strongly O-ADR O-ADR
suspected O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
unlikely O-ADR O-ADR
to O-ADR O-ADR
provide O-ADR O-ADR
benefit O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
resistant O-ADR O-ADR
bacteria O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
disorders I-ADR I-ADR
: O-ADR O-ADR
Nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Routine O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
or O-ADR O-ADR
using O-ADR O-ADR
thyroid O-ADR O-ADR
ultrasound O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
value O-ADR O-ADR
for O-ADR O-ADR
early O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneously O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
if O-ADR O-ADR
body O-ADR O-ADR
weight O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
15 O-ADR O-ADR
kg O-ADR O-ADR
and O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
40 O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Aspiration B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
from O-ADR O-ADR
severe O-ADR O-ADR
dysphagia B-ADR B-ADR
and O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
particular O-ADR O-ADR
risk O-ADR O-ADR
when O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
swallowing O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
is O-ADR O-ADR
already O-ADR O-ADR
compromised O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
: O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
excluded O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
risk O-ADR O-ADR
factor O-ADR O-ADR
for O-ADR O-ADR
macular O-ADR O-ADR
edema O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
below O-ADR O-ADR
Macular O-ADR O-ADR
Edema O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
History O-ADR O-ADR
of O-ADR O-ADR
Uveitis O-ADR O-ADR
or O-ADR O-ADR
Diabetes O-ADR O-ADR
Mellitus O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
Doses O-ADR O-ADR
of O-ADR O-ADR
Toviaz O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
In O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
) O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
in O-ADR O-ADR
Any O-ADR O-ADR
Treatment O-ADR O-ADR
Arm O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
102 O-ADR O-ADR
and O-ADR O-ADR
103 O-ADR O-ADR
( O-ADR O-ADR
Week O-ADR O-ADR
144 O-ADR O-ADR
analysis O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremities I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
upper B-ADR B-ADR
abdominal I-ADR I-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Genzyme O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
745 O-ADR O-ADR
- O-ADR O-ADR
4447 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
included O-ADR O-ADR
: O-ADR O-ADR
dystonia B-ADR B-ADR
, O-ADR O-ADR
blepharospasm B-ADR B-ADR
, O-ADR O-ADR
torticollis B-ADR B-ADR
, O-ADR O-ADR
dyskinesia B-ADR B-ADR
, O-ADR O-ADR
tardive B-ADR B-ADR
dyskinesia I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
rigidity I-ADR I-ADR
, O-ADR O-ADR
parkinsonism B-ADR B-ADR
, O-ADR O-ADR
gait B-ADR B-ADR
disturbance I-ADR I-ADR
, O-ADR O-ADR
masked B-ADR B-ADR
facies I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tremor B-ADR B-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
akathisia B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
rate O-ADR O-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
6 O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
treatment O-ADR O-ADR
by O-ADR O-ADR
intravenous O-ADR O-ADR
administration O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
developed O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
ERWINAZE O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Even O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
leukemia O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Inhalation O-ADR O-ADR
of O-ADR O-ADR
airborne O-ADR O-ADR
capsaicin O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
coughing B-ADR B-ADR
or O-ADR O-ADR
sneezing B-ADR B-ADR
. O-ADR O-ADR
JEVTANA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
> O-ADR O-ADR
3 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
had O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
corrected O-ADR O-ADR
declines B-ADR B-ADR
in I-ADR I-ADR
BMD I-ADR I-ADR
at I-ADR I-ADR
the I-ADR I-ADR
total I-ADR I-ADR
hip I-ADR I-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
52 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
primarily O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
decrease O-ADR B-ADR
from O-ADR I-ADR
baseline O-ADR I-ADR
of O-ADR I-ADR
total O-ADR I-ADR
cholesterol O-ADR I-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
decrease O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
of O-ADR O-ADR
fasting O-ADR O-ADR
triglycerides O-ADR O-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
WM O-ADR O-ADR
trial O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
starting O-ADR O-ADR
FULYZAQ O-ADR O-ADR
, O-ADR O-ADR
rule O-ADR O-ADR
out O-ADR O-ADR
infectious O-ADR O-ADR
etiologies O-ADR O-ADR
of O-ADR O-ADR
diarrhea O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GlaxoSmithKline O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
825 O-ADR O-ADR
- O-ADR O-ADR
5249 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
hundred O-ADR O-ADR
thirty O-ADR O-ADR
- O-ADR O-ADR
one O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
57 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
male O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
YERVOY O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
, O-ADR O-ADR
380 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
56 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
61 O-ADR O-ADR
% O-ADR O-ADR
male O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
YERVOY O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
investigational O-ADR O-ADR
gp100 O-ADR O-ADR
peptide O-ADR O-ADR
vaccine O-ADR O-ADR
( O-ADR O-ADR
gp100 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
132 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
57 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
54 O-ADR O-ADR
% O-ADR O-ADR
male O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
gp100 O-ADR O-ADR
peptide O-ADR O-ADR
vaccine O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
) O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
, O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Drug B-ADR B-ADR
reaction I-ADR B-ADR
with I-ADR I-ADR
eosinophilia I-ADR I-ADR
and I-ADR I-ADR
systemic I-ADR I-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
DRESS B-ADR B-ADR
syndrome I-ADR I-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
1024 O-ADR O-ADR
evaluable O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
ipilimumab O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
electrochemiluminescent O-ADR O-ADR
( O-ADR O-ADR
ECL O-ADR O-ADR
) O-ADR O-ADR
based O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
3 O-ADR O-ADR
+ O-ADR O-ADR
proteinuria B-ADR B-ADR
( O-ADR O-ADR
< O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
studies O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
point O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
4 O-ADR O-ADR
+ O-ADR O-ADR
proteinuria B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
Hypokalemia O-ADR O-ADR
and O-ADR O-ADR
Hyperglycemia O-ADR O-ADR
Beta O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonist O-ADR O-ADR
medicines O-ADR O-ADR
may O-ADR O-ADR
produce O-ADR O-ADR
significant O-ADR O-ADR
hypokalemia B-ADR B-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
possibly O-ADR O-ADR
through O-ADR O-ADR
intracellular O-ADR O-ADR
shunting O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
has O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
adverse O-ADR B-ADR
cardiovascular O-ADR I-ADR
effects O-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
saline O-ADR O-ADR
formulation O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
given O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
methotrexate O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Effects B-ADR O-ADR
on I-ADR O-ADR
Ability I-ADR O-ADR
to I-ADR O-ADR
Drive I-ADR O-ADR
: O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
refrain O-ADR O-ADR
from O-ADR O-ADR
driving O-ADR O-ADR
and O-ADR O-ADR
engaging O-ADR O-ADR
in O-ADR O-ADR
hazardous O-ADR O-ADR
occupations O-ADR O-ADR
or O-ADR O-ADR
activities O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
operating O-ADR O-ADR
heavy O-ADR O-ADR
or O-ADR O-ADR
potentially O-ADR O-ADR
dangerous O-ADR O-ADR
machinery O-ADR O-ADR
while O-ADR O-ADR
BLINCYTO O-ADR O-ADR
is O-ADR O-ADR
being O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
for O-ADR O-ADR
perforation O-ADR O-ADR
or O-ADR O-ADR
for O-ADR O-ADR
fistula O-ADR O-ADR
formation O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Injection O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
into O-ADR O-ADR
ligaments B-ADR O-ADR
of I-ADR O-ADR
the I-ADR O-ADR
hand I-ADR O-ADR
may I-ADR I-ADR
result I-ADR I-ADR
in I-ADR I-ADR
damage I-ADR I-ADR
to O-ADR O-ADR
those O-ADR O-ADR
structures O-ADR O-ADR
and O-ADR O-ADR
possible O-ADR O-ADR
permanent B-ADR O-ADR
injury I-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
tendon B-ADR O-ADR
rupture I-ADR O-ADR
or O-ADR O-ADR
ligament B-ADR O-ADR
damage I-ADR O-ADR
. O-ADR O-ADR
Rapid O-ADR O-ADR
titration O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
psychosis B-ADR O-ADR
and O-ADR O-ADR
hallucinations B-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
Ferriprox O-ADR O-ADR
therapy O-ADR O-ADR
if O-ADR O-ADR
neutropenia O-ADR O-ADR
develops O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
electrocardiograms O-ADR O-ADR
and O-ADR O-ADR
electrolytes O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
bradyarrhythmias O-ADR O-ADR
, O-ADR O-ADR
electrolyte O-ADR O-ADR
abnormalities O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
hepatic O-ADR O-ADR
function O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
lower O-ADR O-ADR
mean O-ADR O-ADR
triglyceride O-ADR O-ADR
values O-ADR O-ADR
in O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
one O-ADR O-ADR
and O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
Decompensation I-ADR I-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Chronic O-ADR O-ADR
Hepatitis O-ADR O-ADR
C O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Thromboembolic B-ADR B-ADR
Complications I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Cataracts B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
In O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ITP O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
shows O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
ZYTIGA O-ADR O-ADR
arm O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
absolute O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
frequency O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
either O-ADR O-ADR
HALAVEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
on O-ADR O-ADR
Days O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
21 O-ADR O-ADR
- O-ADR O-ADR
day O-ADR O-ADR
cycle O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
treatment O-ADR O-ADR
chosen O-ADR O-ADR
by O-ADR O-ADR
their O-ADR O-ADR
physician O-ADR O-ADR
( O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Emergency O-ADR O-ADR
resuscitation O-ADR O-ADR
equipment O-ADR O-ADR
and O-ADR O-ADR
personnel O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
immediately O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
shows O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
category O-ADR O-ADR
of O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
any O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in O-ADR O-ADR
ESCAPE O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
ESCAPE O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
where O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
on O-ADR O-ADR
Cleviprex O-ADR O-ADR
exceeded O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
by O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Figure O-ADR O-ADR
1 O-ADR O-ADR
Adjudicated O-ADR O-ADR
Major O-ADR O-ADR
Bleeding B-ADR B-ADR
by O-ADR O-ADR
Baseline O-ADR O-ADR
Characteristics O-ADR O-ADR
Including O-ADR O-ADR
Hemorrhagic O-ADR O-ADR
Stroke O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
Note O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
figure O-ADR O-ADR
above O-ADR O-ADR
presents O-ADR O-ADR
effects O-ADR O-ADR
in O-ADR O-ADR
various O-ADR O-ADR
subgroups O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
are O-ADR O-ADR
baseline O-ADR O-ADR
characteristics O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
specified O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
. O-ADR O-ADR
YERVOY O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
MTC B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
clinically O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
drug O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
52 O-ADR O-ADR
weeks O-ADR O-ADR
in O-ADR O-ADR
duration O-ADR O-ADR
were O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
pioglitazone O-ADR O-ADR
and O-ADR O-ADR
metformin O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
metformin O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
glipizide O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
when O-ADR O-ADR
receiving O-ADR O-ADR
TREANDA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
combined O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
Toviaz O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Toviaz O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
were O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Hospitalizations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
in I-ADR I-ADR
the I-ADR I-ADR
abdomen I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
medication O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
within O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
medication O-ADR O-ADR
or O-ADR O-ADR
events O-ADR O-ADR
present O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
that O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
medication O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
females B-ADR B-ADR
, I-ADR I-ADR
discontinuation I-ADR I-ADR
due I-ADR I-ADR
to I-ADR I-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Whether O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
products O-ADR O-ADR
differ O-ADR O-ADR
in O-ADR O-ADR
their O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
Tardive B-ADR O-ADR
Dyskinesia I-ADR O-ADR
( O-ADR O-ADR
TD B-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
are O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
experience O-ADR O-ADR
certain O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Imatinib O-ADR O-ADR
- O-ADR O-ADR
Resistant O-ADR O-ADR
or O-ADR O-ADR
- O-ADR O-ADR
Intolerant O-ADR O-ADR
Ph O-ADR O-ADR
+ O-ADR O-ADR
Chronic O-ADR O-ADR
Phase O-ADR O-ADR
( O-ADR O-ADR
CP O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Accelerated O-ADR O-ADR
Phase O-ADR O-ADR
( O-ADR O-ADR
AP O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Blast O-ADR O-ADR
Phase O-ADR O-ADR
( O-ADR O-ADR
BP O-ADR O-ADR
) O-ADR O-ADR
CML O-ADR O-ADR
The O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
Phase O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
2 O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Ph O-ADR O-ADR
+ O-ADR O-ADR
chronic O-ADR O-ADR
, O-ADR O-ADR
accelerated O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
blast O-ADR O-ADR
phase O-ADR O-ADR
chronic O-ADR O-ADR
myelogenous O-ADR O-ADR
leukemia O-ADR O-ADR
( O-ADR O-ADR
CML O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
resistance O-ADR O-ADR
or O-ADR O-ADR
intolerance O-ADR O-ADR
to O-ADR O-ADR
prior O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
66 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
86 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Dysphagia O-ADR O-ADR
and O-ADR O-ADR
Breathing O-ADR O-ADR
Difficulties O-ADR O-ADR
in O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
Cervical O-ADR O-ADR
Dystonia O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
XEOMIN O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
. O-ADR O-ADR
Aspiration B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
from O-ADR O-ADR
severe O-ADR O-ADR
dysphagia B-ADR B-ADR
and O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
particular O-ADR O-ADR
risk O-ADR O-ADR
when O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
swallowing O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
is O-ADR O-ADR
already O-ADR O-ADR
compromised O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Nephrogenic O-ADR O-ADR
Systemic O-ADR O-ADR
Fibrosis O-ADR O-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
nephrogenic B-ADR B-ADR
systemic I-ADR I-ADR
fibrosis I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
following O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
hand B-ADR B-ADR
- O-ADR O-ADR
foot O-ADR O-ADR
) I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
on O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
Twice O-ADR O-ADR
Daily O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Than O-ADR O-ADR
That O-ADR O-ADR
Observed O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
on O-ADR O-ADR
Placebo O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
Day O-ADR O-ADR
112 O-ADR O-ADR
( O-ADR O-ADR
Week O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
reported O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
subject O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
nausea B-ADR B-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
in O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
; O-ADR O-ADR
1 O-ADR O-ADR
subject O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
diarrhea B-ADR B-ADR
; O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
serum O-ADR O-ADR
potassium O-ADR O-ADR
and O-ADR O-ADR
magnesium O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
electrolyte O-ADR O-ADR
disturbances O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
belimumab O-ADR O-ADR
antibodies O-ADR O-ADR
experienced O-ADR O-ADR
mild O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
of O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
erythematous B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
; O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
96 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
229 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
was O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
evaluated O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
in O-ADR O-ADR
adolescent O-ADR O-ADR
and O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
liver B-ADR B-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Impairment B-ADR B-ADR
in I-ADR I-ADR
renal I-ADR I-ADR
function I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
106 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
) O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
were O-ADR O-ADR
administered O-ADR O-ADR
intravenously O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
doses O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
specified O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
530 O-ADR O-ADR
, O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
185 O-ADR O-ADR
MBq O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
mCi O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
prolonged O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
UV O-ADR O-ADR
light O-ADR O-ADR
and O-ADR O-ADR
sunlight O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
accidental O-ADR O-ADR
transfer O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
eyes O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
periocular O-ADR O-ADR
area O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Worsening O-ADR O-ADR
of O-ADR O-ADR
Urinary O-ADR O-ADR
Retention O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
urinary O-ADR O-ADR
retention O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
low O-ADR O-ADR
albumin O-ADR O-ADR
levels O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
Model O-ADR O-ADR
for O-ADR O-ADR
End O-ADR O-ADR
- O-ADR O-ADR
Stage O-ADR O-ADR
Liver O-ADR O-ADR
Disease O-ADR O-ADR
( O-ADR O-ADR
MELD O-ADR O-ADR
) O-ADR O-ADR
score O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
hepatic B-ADR B-ADR
decompensation I-ADR I-ADR
on O-ADR O-ADR
the O-ADR O-ADR
arm O-ADR O-ADR
receiving O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
plus O-ADR O-ADR
antivirals O-ADR O-ADR
. O-ADR O-ADR
Hepatobiliary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
cholelithiasis O-ADR O-ADR
/ O-ADR O-ADR
cholecystitis O-ADR O-ADR
, O-ADR O-ADR
hepatic B-ADR B-ADR
steatosis I-ADR I-ADR
, O-ADR O-ADR
hepatitis B-ADR B-ADR
, O-ADR O-ADR
hepatomegaly B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
average O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimens O-ADR O-ADR
was O-ADR O-ADR
49 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
79 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
over O-ADR O-ADR
a O-ADR O-ADR
24 O-ADR O-ADR
hour O-ADR O-ADR
period O-ADR O-ADR
following O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
41 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
current O-ADR O-ADR
or O-ADR O-ADR
previous O-ADR O-ADR
smokers O-ADR O-ADR
. O-ADR O-ADR
Should O-ADR O-ADR
a O-ADR O-ADR
stroke O-ADR O-ADR
occur O-ADR O-ADR
or O-ADR O-ADR
be O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
elevation O-ADR O-ADR
has O-ADR O-ADR
a O-ADR O-ADR
rapid O-ADR O-ADR
onset O-ADR O-ADR
, O-ADR O-ADR
reaches O-ADR O-ADR
a O-ADR O-ADR
plateau O-ADR O-ADR
after O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
reversible O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
histoplasmosis O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infections O-ADR O-ADR
may O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
disseminated O-ADR O-ADR
, O-ADR O-ADR
rather O-ADR O-ADR
than O-ADR O-ADR
localized O-ADR O-ADR
, O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mechanism O-ADR O-ADR
and O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
consequences O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
currently O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Protamine O-ADR O-ADR
sulfate O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
K O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
affect O-ADR O-ADR
the O-ADR O-ADR
anticoagulant O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
apixaban O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
QTc O-ADR O-ADR
including O-ADR O-ADR
Class O-ADR O-ADR
1A O-ADR O-ADR
antiarrhythmics O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
quinidine O-ADR O-ADR
, O-ADR O-ADR
procainamide O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
Class O-ADR O-ADR
3 O-ADR O-ADR
antiarrhythmics O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
amiodarone O-ADR O-ADR
, O-ADR O-ADR
sotalol O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
antipsychotic O-ADR O-ADR
medications O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
ziprasidone O-ADR O-ADR
, O-ADR O-ADR
chlorpromazine O-ADR O-ADR
, O-ADR O-ADR
thioridazine O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
antibiotics O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
gatifloxacin O-ADR O-ADR
, O-ADR O-ADR
moxifloxacin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Cataracts B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
toxicology O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
eltrombopag O-ADR O-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Invasive B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
histoplasmosis B-ADR B-ADR
, O-ADR O-ADR
coccidioidomycosis B-ADR B-ADR
, O-ADR O-ADR
candidiasis B-ADR B-ADR
, O-ADR O-ADR
aspergillosis B-ADR B-ADR
, O-ADR O-ADR
blastomycosis B-ADR B-ADR
and O-ADR O-ADR
pneumocystosis B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Thromboembolic O-ADR O-ADR
Events O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
ATEs B-ADR O-ADR
) O-ADR O-ADR
following O-ADR O-ADR
intravitreal O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
VEGF O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
EYLEA O-ADR O-ADR
. O-ADR O-ADR
CNS B-ADR B-ADR
PTLD I-ADR I-ADR
, O-ADR O-ADR
PML B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
CNS B-ADR B-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
higher O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
; O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Hepatic O-ADR O-ADR
and O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
for O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
randomized O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
adjudicated O-ADR O-ADR
APTC O-ADR O-ADR
events O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
Placebo O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
00 O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ULORIC O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
00 O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
08 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ULORIC O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
09 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
44 O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
allopurinol O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
60 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
percent O-ADR O-ADR
demonstrated O-ADR O-ADR
a O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
LVEF I-ADR I-ADR
below O-ADR O-ADR
institutional O-ADR O-ADR
lower O-ADR O-ADR
limits O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
absolute B-ADR B-ADR
decrease I-ADR I-ADR
in I-ADR I-ADR
LVEF I-ADR I-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
below O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
appropriate O-ADR O-ADR
empiric O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
take O-ADR O-ADR
into O-ADR O-ADR
account O-ADR O-ADR
both O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
fungal O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
while O-ADR O-ADR
a O-ADR O-ADR
diagnostic O-ADR O-ADR
workup O-ADR O-ADR
is O-ADR O-ADR
being O-ADR O-ADR
performed O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
accidental O-ADR O-ADR
exposure O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
flush O-ADR O-ADR
eyes O-ADR O-ADR
with O-ADR O-ADR
water O-ADR O-ADR
and O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
population O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
to O-ADR O-ADR
85 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
underlying O-ADR O-ADR
malignancies O-ADR O-ADR
were O-ADR O-ADR
osteosarcoma O-ADR O-ADR
/ O-ADR O-ADR
sarcomas O-ADR O-ADR
in O-ADR O-ADR
32 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
leukemia O-ADR B-ADR
or O-ADR O-ADR
lymphoma O-ADR B-ADR
in O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
tuberculosis O-ADR O-ADR
therapy O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
past O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
latent O-ADR O-ADR
or O-ADR O-ADR
active O-ADR O-ADR
tuberculosis O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
an O-ADR O-ADR
adequate O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
negative O-ADR O-ADR
test O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
but O-ADR O-ADR
having O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
761 O-ADR O-ADR
adults O-ADR O-ADR
( O-ADR O-ADR
367 O-ADR O-ADR
men O-ADR O-ADR
and O-ADR O-ADR
394 O-ADR O-ADR
women O-ADR O-ADR
, O-ADR O-ADR
91 O-ADR O-ADR
% O-ADR O-ADR
Caucasian O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
62 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
18 O-ADR O-ADR
- O-ADR O-ADR
93 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
Vizamyl O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
290 O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
8 O-ADR O-ADR
deaths B-ADR B-ADR
within O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
exposure O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
progressive O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THYROID B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
CELL O-ADR O-ADR
TUMORS I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THYROID B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
CELL O-ADR O-ADR
TUMORS I-ADR I-ADR
* O-ADR O-ADR
Carcinogenicity O-ADR O-ADR
of O-ADR O-ADR
albiglutide O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
other O-ADR O-ADR
glucagon O-ADR O-ADR
- O-ADR O-ADR
like O-ADR O-ADR
peptide O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
receptor O-ADR O-ADR
agonists O-ADR O-ADR
have O-ADR O-ADR
caused O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
at O-ADR O-ADR
clinically O-ADR O-ADR
relevant O-ADR O-ADR
exposures O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
neutropenia O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
dose O-ADR O-ADR
delays O-ADR O-ADR
, O-ADR O-ADR
reductions O-ADR O-ADR
, O-ADR O-ADR
discontinuation O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
subsequent O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PML B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
NULOJIX O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
cumulative O-ADR O-ADR
doses O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
along O-ADR O-ADR
with O-ADR O-ADR
mycophenolate O-ADR O-ADR
mofetil O-ADR O-ADR
( O-ADR O-ADR
MMF O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
corticosteroids O-ADR O-ADR
; O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
recipient O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
case O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
liver O-ADR O-ADR
transplant O-ADR O-ADR
recipient O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
theoretical O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
Creutzfeldt B-ADR B-ADR
- O-ADR O-ADR
Jakob O-ADR O-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
CJD B-ADR B-ADR
) O-ADR O-ADR
is O-ADR O-ADR
also O-ADR O-ADR
considered O-ADR O-ADR
extremely O-ADR O-ADR
remote O-ADR O-ADR
. O-ADR O-ADR
They O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
64 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
smoking O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
46 O-ADR O-ADR
pack O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
44 O-ADR O-ADR
% O-ADR O-ADR
identified O-ADR O-ADR
as O-ADR O-ADR
current O-ADR O-ADR
smokers O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
TIVICAY O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
suspect O-ADR O-ADR
agents O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
develop O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
delay O-ADR O-ADR
in O-ADR O-ADR
stopping O-ADR O-ADR
treatment O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
Neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Virologically O-ADR O-ADR
- O-ADR O-ADR
Suppressed O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
Infected O-ADR O-ADR
Subjects O-ADR O-ADR
No O-ADR O-ADR
new O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
STRIBILD O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
48 O-ADR O-ADR
were O-ADR O-ADR
identified O-ADR O-ADR
in O-ADR O-ADR
584 O-ADR O-ADR
virologically O-ADR O-ADR
stably O-ADR O-ADR
suppressed O-ADR O-ADR
subjects O-ADR O-ADR
switching O-ADR O-ADR
to O-ADR O-ADR
STRIBILD O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
regimen O-ADR O-ADR
containing O-ADR O-ADR
a O-ADR O-ADR
RTV O-ADR O-ADR
- O-ADR O-ADR
boosted O-ADR O-ADR
protease O-ADR O-ADR
inhibitor O-ADR O-ADR
( O-ADR O-ADR
PI O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
nucleoside O-ADR O-ADR
reverse O-ADR O-ADR
transcriptase O-ADR O-ADR
inhibitor O-ADR O-ADR
( O-ADR O-ADR
NNRTI O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
48 O-ADR O-ADR
to O-ADR O-ADR
50 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
92 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
across O-ADR O-ADR
treatment O-ADR O-ADR
arms O-ADR O-ADR
and O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
included O-ADR O-ADR
783 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
429 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxins O-ADR O-ADR
may O-ADR O-ADR
weaken B-ADR B-ADR
neck I-ADR I-ADR
muscles I-ADR I-ADR
that O-ADR O-ADR
serve O-ADR O-ADR
as O-ADR O-ADR
accessory O-ADR O-ADR
muscles O-ADR O-ADR
of O-ADR O-ADR
ventilation O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Gadavist O-ADR O-ADR
were O-ADR O-ADR
usually O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
transient O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
judged O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
not O-ADR O-ADR
related O-ADR O-ADR
or O-ADR O-ADR
unlikely O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
medication O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
, O-ADR O-ADR
except O-ADR O-ADR
for O-ADR O-ADR
four O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Toviaz O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
one O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
each O-ADR O-ADR
: O-ADR O-ADR
angina B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
gastroenteritis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
on O-ADR I-ADR
ECG O-ADR I-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
nonfatal O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
frequent O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
eGFR O-ADR O-ADR
below O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
rare O-ADR O-ADR
instances O-ADR O-ADR
severe O-ADR O-ADR
anaphylactoid B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
and O-ADR O-ADR
subsequent O-ADR O-ADR
cycles O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Chronic O-ADR O-ADR
Lymphocytic O-ADR O-ADR
Leukemia O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
label O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
48 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
CLL O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
391 O-ADR O-ADR
randomized O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
CLL O-ADR O-ADR
or O-ADR O-ADR
SLL O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
Gender O-ADR O-ADR
and O-ADR O-ADR
Race O-ADR O-ADR
No O-ADR O-ADR
significant O-ADR O-ADR
gender O-ADR O-ADR
differences O-ADR O-ADR
were O-ADR O-ADR
noted O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
hemoglobin O-ADR O-ADR
A1c O-ADR O-ADR
( O-ADR O-ADR
HbA1c O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
established O-ADR O-ADR
microvascular O-ADR O-ADR
complications O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Pfizer O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
438 O-ADR O-ADR
- O-ADR O-ADR
1985 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
trough O-ADR O-ADR
levels O-ADR O-ADR
of O-ADR O-ADR
ipilimumab O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
ECL O-ADR O-ADR
assay O-ADR O-ADR
results O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
subset O-ADR O-ADR
analysis O-ADR O-ADR
was O-ADR O-ADR
performed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
cohort O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
lowest O-ADR O-ADR
trough O-ADR O-ADR
levels O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
neurological O-ADR O-ADR
toxicities O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
interrupt O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
BLINCYTO O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
PR O-ADR O-ADR
Interval O-ADR O-ADR
Prolongation O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
of O-ADR O-ADR
First O-ADR O-ADR
Degree O-ADR O-ADR
Atrioventricular O-ADR O-ADR
( O-ADR O-ADR
AV O-ADR O-ADR
) O-ADR O-ADR
Block O-ADR O-ADR
A O-ADR O-ADR
mean O-ADR O-ADR
increase B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
PR I-ADR I-ADR
interval I-ADR I-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
milliseconds O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
TRULICITY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
contrast O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
decrease O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
millisecond O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Urinary B-ADR B-ADR
retention I-ADR I-ADR
was O-ADR O-ADR
generally O-ADR O-ADR
reported O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
observed O-ADR O-ADR
later O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
adequate O-ADR O-ADR
and O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
. O-ADR O-ADR
Consequently O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
provide O-ADR O-ADR
a O-ADR O-ADR
meaningful O-ADR O-ADR
estimate O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
individuals O-ADR O-ADR
experiencing O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
grouped O-ADR O-ADR
in O-ADR O-ADR
standardized O-ADR O-ADR
categories O-ADR O-ADR
using O-ADR O-ADR
MedDRA O-ADR O-ADR
terminology O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
AGRANULOCYTOSIS B-ADR O-ADR
/ O-ADR O-ADR
NEUTROPENIA O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
LY O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
drug O-ADR O-ADR
hypersensitivity B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pruritus B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
allergic B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PRADAXA O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
Connective O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
myopathy B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
rhabdomyolysis B-ADR B-ADR
. O-ADR O-ADR
Significantly O-ADR O-ADR
elevated O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
value O-ADR O-ADR
may O-ADR O-ADR
indicate O-ADR O-ADR
MTC O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MTC O-ADR O-ADR
usually O-ADR O-ADR
have O-ADR O-ADR
calcitonin O-ADR O-ADR
values O-ADR O-ADR
> O-ADR O-ADR
50 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
503 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
HALAVEN O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
247 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
received O-ADR O-ADR
therapy O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
chemotherapy O-ADR O-ADR
[ O-ADR O-ADR
total O-ADR O-ADR
97 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
anthracyclines O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
capecitabine O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
gemcitabine O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
taxanes O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
vinorelbine O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
chemotherapies O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
hormonal O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
were O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
penile B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
HALAVEN O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
microtubule O-ADR O-ADR
inhibitor O-ADR O-ADR
; O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
show O-ADR O-ADR
sustained O-ADR O-ADR
improvement O-ADR O-ADR
or O-ADR O-ADR
return O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
initiate O-ADR O-ADR
corticosteroid O-ADR O-ADR
tapering O-ADR O-ADR
and O-ADR O-ADR
continue O-ADR O-ADR
to O-ADR O-ADR
taper O-ADR O-ADR
over O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
Bleeding B-ADR B-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
SONATE O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
Note O-ADR O-ADR
: O-ADR O-ADR
MBE B-ADR B-ADR
can O-ADR O-ADR
belong O-ADR O-ADR
to O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
criterion O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
to O-ADR O-ADR
rinse O-ADR O-ADR
his O-ADR O-ADR
/ O-ADR O-ADR
her O-ADR O-ADR
mouth O-ADR O-ADR
with O-ADR O-ADR
water O-ADR O-ADR
without O-ADR O-ADR
swallowing O-ADR O-ADR
following O-ADR O-ADR
inhalation O-ADR O-ADR
to O-ADR O-ADR
help O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
oropharyngeal O-ADR O-ADR
candidiasis O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
QTc B-ADR B-ADR
interval I-ADR I-ADR
increase I-ADR I-ADR
over O-ADR O-ADR
baseline O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
msec O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Ferriprox O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Neutropenia B-ADR B-ADR
: O-ADR O-ADR
monitor O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
rash B-ADR B-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
Hodgkin O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
lymphoma O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
52 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
88 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
function O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
FARXIGA O-ADR O-ADR
and O-ADR O-ADR
monitored O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
SPINAL O-ADR O-ADR
/ O-ADR O-ADR
EPIDURAL O-ADR O-ADR
HEMATOMA O-ADR O-ADR
: O-ADR O-ADR
spinal B-ADR B-ADR
hematomas I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PRADAXA O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
receiving O-ADR O-ADR
neuraxial O-ADR O-ADR
anesthesia O-ADR O-ADR
or O-ADR O-ADR
undergoing O-ADR O-ADR
spinal O-ADR O-ADR
puncture O-ADR O-ADR
. O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
GI O-ADR O-ADR
fistulas I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
changes O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
abnormal B-ADR B-ADR
thyroid I-ADR I-ADR
function I-ADR I-ADR
tests O-ADR O-ADR
suggesting O-ADR O-ADR
hypothyroidism B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
subset O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
recurrence O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
when O-ADR O-ADR
restarting O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
drug O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
different O-ADR O-ADR
DPP O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
inhibitor O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
occurred O-ADR O-ADR
as O-ADR O-ADR
late O-ADR O-ADR
into O-ADR O-ADR
treatment O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
47 O-ADR O-ADR
th O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
no O-ADR O-ADR
longer O-ADR O-ADR
controls O-ADR O-ADR
the O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
bronchoconstriction O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
becomes O-ADR O-ADR
less O-ADR O-ADR
effective O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
needs O-ADR O-ADR
more O-ADR O-ADR
inhalation O-ADR O-ADR
of O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
than O-ADR O-ADR
usual O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
markers O-ADR O-ADR
of O-ADR O-ADR
deterioration O-ADR O-ADR
of O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
HbA1C O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
established O-ADR O-ADR
microvascular O-ADR O-ADR
complications O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Retrospective O-ADR O-ADR
Case O-ADR O-ADR
Series O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
Infections B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
tonsilitis B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
ear B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inducers O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
rifamycins O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rifampin O-ADR O-ADR
, O-ADR O-ADR
rifapentine O-ADR O-ADR
and O-ADR O-ADR
rifabutin O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
moderate O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inducers O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
efavirenz O-ADR O-ADR
, O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SIRTURO O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Pancreatitis O-ADR O-ADR
Pancreatitis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
time O-ADR O-ADR
from O-ADR O-ADR
product O-ADR O-ADR
administration O-ADR O-ADR
to O-ADR O-ADR
event O-ADR O-ADR
occurrence O-ADR O-ADR
was O-ADR O-ADR
variable O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
on O-ADR O-ADR
thyroid O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
higher O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Withdrawal O-ADR O-ADR
Seizures O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
AEDs O-ADR O-ADR
, O-ADR O-ADR
when O-ADR O-ADR
POTIGA O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
withdrawn O-ADR O-ADR
gradually O-ADR O-ADR
when O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR O-ADR
seizure O-ADR O-ADR
frequency O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
rates O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
rate O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
depression B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
suicidal B-ADR B-ADR
ideation I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
bipolar B-ADR B-ADR
I I-ADR I-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
depressive B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
men O-ADR O-ADR
with O-ADR O-ADR
osteoporosis O-ADR O-ADR
are O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
. O-ADR O-ADR
3Includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
upper I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
lower I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
abdominal B-ADR B-ADR
discomfort I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
When O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
, O-ADR O-ADR
only O-ADR O-ADR
prescribe O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
not O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
medication O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
ICS O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
whose O-ADR O-ADR
disease O-ADR O-ADR
severity O-ADR O-ADR
clearly O-ADR O-ADR
warrants O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
both O-ADR O-ADR
an O-ADR O-ADR
ICS O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
LABA O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
: O-ADR O-ADR
Percentage O-ADR O-ADR
of O-ADR O-ADR
EPS B-ADR B-ADR
Compared O-ADR O-ADR
to O-ADR O-ADR
Placebo O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
FANAPT O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
FANAPT O-ADR O-ADR
20 O-ADR O-ADR
- O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
Event O-ADR O-ADR
Term O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
587 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
483 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
391 O-ADR O-ADR
) O-ADR O-ADR
All O-ADR O-ADR
EPS O-ADR B-ADR
events O-ADR I-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Akathisia B-ADR B-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Bradykinesia B-ADR B-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Dyskinesia B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
Dystonia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Parkinsonism B-ADR B-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Tremor B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Associated O-ADR O-ADR
with O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
difference O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
between O-ADR O-ADR
FANAPT O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
led O-ADR O-ADR
to O-ADR O-ADR
withdrawal O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Acute O-ADR O-ADR
Rejection O-ADR O-ADR
and O-ADR O-ADR
Graft B-ADR O-ADR
Loss I-ADR O-ADR
with I-ADR O-ADR
Corticosteroid I-ADR O-ADR
Minimization I-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
4 O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
HLA O-ADR O-ADR
mismatches O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
with O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Several O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
GILENYA O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
unexplained O-ADR O-ADR
dyspnea B-ADR B-ADR
during O-ADR O-ADR
the O-ADR O-ADR
extension O-ADR O-ADR
( O-ADR O-ADR
uncontrolled O-ADR O-ADR
) O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
combined O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
fingolimod O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
MS O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
uveitis O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
without O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
uveitis O-ADR O-ADR
. O-ADR O-ADR
Isolated O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
aspergillosis B-ADR B-ADR
, O-ADR O-ADR
herpes B-ADR B-ADR
zoster I-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
ILARIS O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
GILENYA O-ADR O-ADR
exposure O-ADR O-ADR
is O-ADR O-ADR
doubled O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
is O-ADR O-ADR
greater O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Currently O-ADR O-ADR
available O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
inadequate O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
concurrent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
drugs O-ADR O-ADR
mitigates O-ADR O-ADR
the O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
from O-ADR O-ADR
LABA O-ADR O-ADR
. O-ADR O-ADR
Rates O-ADR O-ADR
of O-ADR O-ADR
seroconversion O-ADR O-ADR
increased O-ADR O-ADR
with O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
. O-ADR O-ADR
Specifically O-ADR O-ADR
, O-ADR O-ADR
nocturia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
MULTAQ O-ADR O-ADR
should O-ADR O-ADR
only O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
sinus O-ADR O-ADR
rhythm O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
receiving O-ADR O-ADR
appropriate O-ADR O-ADR
antithrombotic O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
QTcF B-ADR B-ADR
was I-ADR I-ADR
increased I-ADR I-ADR
more O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
msec O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
liver O-ADR O-ADR
diseaseand O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
not O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
ITP O-ADR O-ADR
, O-ADR O-ADR
six O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
developed O-ADR O-ADR
portal B-ADR B-ADR
vein I-ADR I-ADR
thromboses I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
25 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ADCETRIS O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Hypertriglyceridemia O-ADR O-ADR
In O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
hypertriglyceridemia O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
estrogens O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
plasma I-ADR I-ADR
triglycerides I-ADR I-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
pancreatitis B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
extension O-ADR O-ADR
chronic O-ADR O-ADR
ITP O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
additional O-ADR O-ADR
patient O-ADR O-ADR
had O-ADR O-ADR
PROMACTA O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
liver B-ADR B-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
Effects I-ADR I-ADR
: O-ADR O-ADR
Postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Delayed O-ADR O-ADR
reactions O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
several O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
EOVIST O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
prior O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
Vizamyl O-ADR O-ADR
. O-ADR O-ADR
Hematuria O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
hematuria B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
those O-ADR O-ADR
requiring O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
JEVTANA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
immunomodulatory O-ADR O-ADR
therapies O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ILARIS O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
active O-ADR O-ADR
and O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
might O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
this O-ADR O-ADR
factor O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
cardiac O-ADR O-ADR
dysfunction O-ADR O-ADR
or O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
warrant O-ADR O-ADR
careful O-ADR O-ADR
observation O-ADR O-ADR
when O-ADR O-ADR
estrogens O-ADR O-ADR
are O-ADR O-ADR
prescribed O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
new O-ADR O-ADR
cuSCC B-ADR B-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
developed O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
cuSCC B-ADR B-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Exclusive O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
uncommon O-ADR O-ADR
, O-ADR O-ADR
mild O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
no O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
11 O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
choline O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Concomitant O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ONJ O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
ONJ O-ADR B-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
hyperglycemia O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
excessive O-ADR O-ADR
thirst O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
volume O-ADR O-ADR
or O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
urination O-ADR O-ADR
. O-ADR O-ADR
Graft B-ADR B-ADR
loss I-ADR I-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Oral O-ADR O-ADR
Ulceration O-ADR O-ADR
Mouth B-ADR B-ADR
ulcers I-ADR I-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
oral B-ADR B-ADR
mucositis I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
AFINITOR O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
44 O-ADR O-ADR
% O-ADR O-ADR
- O-ADR O-ADR
78 O-ADR O-ADR
% O-ADR O-ADR
across O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED O-ADR B-ADR
MORTALITY B-ADR I-ADR
IN O-ADR O-ADR
ELDERLY O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DEMENTIA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
PSYCHOSIS O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED O-ADR B-ADR
MORTALITY B-ADR I-ADR
IN O-ADR O-ADR
ELDERLY O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DEMENTIA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
PSYCHOSIS O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
ranged O-ADR O-ADR
in O-ADR O-ADR
age O-ADR O-ADR
from O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
83 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
overall O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
51 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
event O-ADR O-ADR
data O-ADR O-ADR
collected O-ADR O-ADR
from O-ADR O-ADR
those O-ADR O-ADR
trials O-ADR O-ADR
showed O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
EPS B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
as O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
Side O-ADR O-ADR
- O-ADR O-ADR
by O-ADR O-ADR
- O-ADR O-ADR
side O-ADR O-ADR
tabulation O-ADR O-ADR
is O-ADR O-ADR
to O-ADR O-ADR
simplify O-ADR O-ADR
presentation O-ADR O-ADR
; O-ADR O-ADR
direct O-ADR O-ADR
comparisons O-ADR O-ADR
across O-ADR O-ADR
trials O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
differing O-ADR O-ADR
trial O-ADR O-ADR
designs O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
or O-ADR O-ADR
loss O-ADR B-ADR
of O-ADR I-ADR
virologic O-ADR I-ADR
response O-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
interactions O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
known O-ADR O-ADR
or O-ADR O-ADR
potentially O-ADR O-ADR
significant O-ADR O-ADR
drug O-ADR O-ADR
interactions O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
therapeutic O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
and O-ADR O-ADR
possible O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
resistance O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
possible O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
from O-ADR O-ADR
greater O-ADR O-ADR
exposures O-ADR O-ADR
of O-ADR O-ADR
concomitant O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
4 O-ADR O-ADR
suicides B-ADR B-ADR
in O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
is O-ADR O-ADR
too O-ADR O-ADR
small O-ADR O-ADR
to O-ADR O-ADR
allow O-ADR O-ADR
any O-ADR O-ADR
conclusion O-ADR O-ADR
about O-ADR O-ADR
drug O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
suicide B-ADR B-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
ADRs O-ADR O-ADR
in O-ADR O-ADR
VIKING O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
similar O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
observations O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
50 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
- O-ADR O-ADR
daily O-ADR O-ADR
dose O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
plausible O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
that O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3300 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Edarbi O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
listed O-ADR O-ADR
below O-ADR O-ADR
: O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
nausea B-ADR B-ADR
General O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Site O-ADR O-ADR
Conditions O-ADR O-ADR
: O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
Connective O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
muscle B-ADR B-ADR
spasm I-ADR I-ADR
Nervous O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
postural I-ADR I-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
Thoracic O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Mediastinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
cough B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clinical O-ADR O-ADR
Laboratory O-ADR O-ADR
Findings O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
clinically O-ADR O-ADR
relevant O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
standard O-ADR O-ADR
laboratory O-ADR O-ADR
parameters O-ADR O-ADR
were O-ADR O-ADR
uncommon O-ADR O-ADR
with O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Edarbi O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Estrogens O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
chances O-ADR O-ADR
of O-ADR O-ADR
getting O-ADR O-ADR
certain O-ADR O-ADR
types O-ADR O-ADR
of O-ADR O-ADR
cancers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cancer O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
breast O-ADR O-ADR
or O-ADR O-ADR
uterus O-ADR O-ADR
. O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
When O-ADR O-ADR
the O-ADR O-ADR
estrogen O-ADR O-ADR
levels O-ADR O-ADR
begin O-ADR O-ADR
dropping O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
women O-ADR O-ADR
get O-ADR O-ADR
very O-ADR O-ADR
uncomfortable O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
feelings O-ADR O-ADR
of O-ADR O-ADR
warmth O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
face O-ADR O-ADR
, O-ADR O-ADR
neck O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
chest O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
sudden O-ADR O-ADR
intense O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
heat O-ADR O-ADR
and O-ADR O-ADR
sweating O-ADR B-ADR
( O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
hot O-ADR B-ADR
flashes O-ADR I-ADR
' O-ADR O-ADR
' O-ADR O-ADR
or O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
hot O-ADR B-ADR
flushes O-ADR I-ADR
' O-ADR O-ADR
' O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Osteonecrosis O-ADR B-ADR
of O-ADR I-ADR
the O-ADR I-ADR
Jaw O-ADR I-ADR
No O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
ONJ B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
diplopia B-ADR B-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
and O-ADR O-ADR
carbamazepine O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
without O-ADR O-ADR
carbamazepine O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Analyses O-ADR O-ADR
of O-ADR O-ADR
17 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
modal O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
largely O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
revealed O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
between O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
times O-ADR O-ADR
that O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
Atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
and O-ADR O-ADR
atrial B-ADR B-ADR
flutter I-ADR I-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cardiac O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
acute O-ADR O-ADR
infections O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
previous O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
31 O-ADR O-ADR
- O-ADR O-ADR
84 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
female O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
hemorrhagic B-ADR B-ADR
events I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
ERWINAZE O-ADR O-ADR
courses O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
fail O-ADR O-ADR
to O-ADR O-ADR
show O-ADR O-ADR
substantial O-ADR O-ADR
clinical O-ADR O-ADR
benefit O-ADR O-ADR
after O-ADR O-ADR
adequate O-ADR O-ADR
titration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
from O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
tendency O-ADR O-ADR
to O-ADR O-ADR
chloasma O-ADR O-ADR
should O-ADR O-ADR
avoid O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
sun O-ADR O-ADR
or O-ADR O-ADR
ultraviolet O-ADR O-ADR
radiation O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
COCs O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Suicide O-ADR O-ADR
The O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
suicide O-ADR O-ADR
attempt O-ADR O-ADR
is O-ADR O-ADR
inherent O-ADR O-ADR
in O-ADR O-ADR
psychotic O-ADR O-ADR
illness O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
close O-ADR O-ADR
supervision O-ADR O-ADR
of O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
accompany O-ADR O-ADR
drug O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Antibody O-ADR O-ADR
formation O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
lowered O-ADR O-ADR
drug O-ADR O-ADR
plasma O-ADR O-ADR
concentration O-ADR O-ADR
and O-ADR O-ADR
reduced O-ADR O-ADR
efficacy O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
too O-ADR O-ADR
few O-ADR O-ADR
cases O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
is O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
FARXIGA O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
832 O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
551 O-ADR O-ADR
and O-ADR O-ADR
281 O-ADR O-ADR
received O-ADR O-ADR
XIAFLEX O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
and O-ADR O-ADR
modify O-ADR O-ADR
, O-ADR O-ADR
interrupt O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
ZYTIGA O-ADR O-ADR
dosing O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Bleeding B-ADR B-ADR
site O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
investigator O-ADR O-ADR
assessment O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
Ferriprox O-ADR O-ADR
to O-ADR O-ADR
immediately O-ADR O-ADR
interrupt O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
report O-ADR O-ADR
to O-ADR O-ADR
their O-ADR O-ADR
physician O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
experience O-ADR O-ADR
any O-ADR O-ADR
symptoms O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicity I-ADR I-ADR
and O-ADR O-ADR
teratogenicity B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
that O-ADR O-ADR
received O-ADR O-ADR
eribulin O-ADR O-ADR
mesylate O-ADR O-ADR
at O-ADR O-ADR
approximately O-ADR O-ADR
half O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
human O-ADR O-ADR
dose O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
body O-ADR O-ADR
surface O-ADR O-ADR
area O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Tumor O-ADR O-ADR
Lysis O-ADR O-ADR
Syndrome O-ADR O-ADR
Tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
Beleodaq O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
or O-ADR O-ADR
refractory O-ADR O-ADR
PTCL O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
extensive O-ADR O-ADR
or O-ADR O-ADR
intensive O-ADR O-ADR
chemotherapy O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
infections O-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Radiation O-ADR O-ADR
Risk O-ADR O-ADR
Neuraceq O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
radiopharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
overall O-ADR O-ADR
long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
. O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
SONATE O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
684 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
following O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
18 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
oral O-ADR O-ADR
anticoagulant O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
medically O-ADR O-ADR
feasible O-ADR O-ADR
, O-ADR O-ADR
stop O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
before O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
withdrawal O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
grade O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
hypertension B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
grade O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
hypokalemia B-ADR B-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
grade O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
edema B-ADR B-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RA O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
developed O-ADR O-ADR
ANA B-ADR B-ADR
. O-ADR O-ADR
To O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
concurrent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
dabigatran O-ADR O-ADR
and O-ADR O-ADR
epidural O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
anesthesia O-ADR O-ADR
/ O-ADR O-ADR
analgesia O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
puncture O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
pharmacokinetic O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
dabigatran O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Aspiration O-ADR B-ADR
pneumonia O-ADR I-ADR
is O-ADR O-ADR
a O-ADR O-ADR
common O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
morbidity O-ADR B-ADR
and O-ADR O-ADR
mortality O-ADR B-ADR
in O-ADR O-ADR
elderly O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
particular O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
Alzheimer O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
dementia O-ADR O-ADR
. O-ADR O-ADR
About O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
United O-ADR O-ADR
States O-ADR O-ADR
and O-ADR O-ADR
75 O-ADR O-ADR
% O-ADR O-ADR
from O-ADR O-ADR
other O-ADR O-ADR
countries O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
and O-ADR O-ADR
elevated B-ADR B-ADR
bilirubin I-ADR I-ADR
without O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
obstruction O-ADR O-ADR
is O-ADR O-ADR
generally O-ADR O-ADR
recognized O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
important O-ADR O-ADR
predictor O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
liver B-ADR O-ADR
injury I-ADR O-ADR
. O-ADR O-ADR
BEPREVE O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
contact O-ADR O-ADR
lens O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
irritation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Interstitial B-ADR B-ADR
Lung I-ADR I-ADR
Disease I-ADR I-ADR
( O-ADR O-ADR
ILD B-ADR B-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
Pneumonitis O-ADR O-ADR
: O-ADR O-ADR
Occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
setting O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
COPD O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
undertaken O-ADR O-ADR
at O-ADR O-ADR
once O-ADR O-ADR
. O-ADR O-ADR
Pancreatitis O-ADR O-ADR
Pancreatitis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
Record O-ADR O-ADR
the O-ADR O-ADR
specific O-ADR O-ADR
GBCA O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
54 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Rd O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
other O-ADR O-ADR
women O-ADR O-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
severe O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Associated O-ADR O-ADR
with O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
: O-ADR O-ADR
Approximately O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
/ O-ADR O-ADR
158 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
about O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
/ O-ADR O-ADR
166 O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Prolactin O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
adult O-ADR O-ADR
schizophrenia O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
were O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Toviaz O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
bladder O-ADR O-ADR
outlet O-ADR O-ADR
obstruction O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
urinary O-ADR O-ADR
retention O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
HORIZANT O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
prodrug O-ADR O-ADR
of O-ADR O-ADR
gabapentin O-ADR O-ADR
, O-ADR O-ADR
HORIZANT O-ADR O-ADR
also O-ADR O-ADR
increases O-ADR O-ADR
this O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
suspended O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
patient O-ADR O-ADR
who O-ADR O-ADR
develops O-ADR O-ADR
clinical O-ADR O-ADR
or O-ADR O-ADR
laboratory O-ADR O-ADR
findings O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
lactic O-ADR O-ADR
acidosis O-ADR O-ADR
or O-ADR O-ADR
pronounced O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
( O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
hepatomegaly O-ADR O-ADR
and O-ADR O-ADR
steatosis O-ADR O-ADR
even O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
marked O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
and O-ADR O-ADR
clinical O-ADR O-ADR
chemistries O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
before O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ILD B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
paronychia B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
for O-ADR O-ADR
Cleviprex O-ADR O-ADR
in O-ADR O-ADR
severe O-ADR O-ADR
hypertension O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Posterior O-ADR O-ADR
Reversible O-ADR O-ADR
Encephalopathy O-ADR O-ADR
Syndrome O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
rare O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
posterior B-ADR B-ADR
reversible I-ADR I-ADR
encephalopathy I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PRES B-ADR B-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Osteonecrosis O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Jaw O-ADR O-ADR
Osteonecrosis O-ADR B-ADR
of O-ADR I-ADR
the O-ADR I-ADR
jaw O-ADR I-ADR
( O-ADR O-ADR
ONJ O-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
spontaneously O-ADR O-ADR
, O-ADR O-ADR
is O-ADR O-ADR
generally O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
tooth O-ADR B-ADR
extraction O-ADR I-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
local O-ADR B-ADR
infection O-ADR I-ADR
with O-ADR O-ADR
delayed O-ADR B-ADR
healing O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Liver O-ADR O-ADR
Injury O-ADR O-ADR
Elevations B-ADR B-ADR
of I-ADR I-ADR
liver I-ADR I-ADR
enzymes I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
Glucose O-ADR O-ADR
and O-ADR O-ADR
Lipids O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
hyperlipidemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
AFINITOR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Twenty O-ADR O-ADR
- O-ADR O-ADR
two O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
JEVTANA O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
, O-ADR O-ADR
infection B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
sepsis B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Acute O-ADR O-ADR
Respiratory O-ADR O-ADR
Distress O-ADR O-ADR
Syndrome O-ADR O-ADR
( O-ADR O-ADR
ARDS O-ADR O-ADR
) O-ADR O-ADR
Acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
ARDS B-ADR B-ADR
) O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
human O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Bausch O-ADR O-ADR
& O-ADR O-ADR
Lomb O-ADR O-ADR
Incorporated O-ADR O-ADR
. O-ADR O-ADR
Ribavirin O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
started O-ADR O-ADR
unless O-ADR O-ADR
a O-ADR O-ADR
report O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
negative O-ADR O-ADR
pregnancy O-ADR O-ADR
test O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
obtained O-ADR O-ADR
immediately O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
generalized I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
pruritic I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
erythematous I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
papular I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
vesicular I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
macular I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
maculo I-ADR I-ADR
- O-ADR O-ADR
papular O-ADR O-ADR
. O-ADR O-ADR
Prescriptions O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
written O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
smallest O-ADR O-ADR
quantity O-ADR O-ADR
of O-ADR O-ADR
tablets O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
good O-ADR O-ADR
patient O-ADR O-ADR
management O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
overdose O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
25 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
serum O-ADR O-ADR
glucose O-ADR O-ADR
levels O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
diabetes O-ADR O-ADR
or O-ADR O-ADR
hyperglycemia O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
examination O-ADR O-ADR
reveals O-ADR O-ADR
papilledema O-ADR O-ADR
or O-ADR O-ADR
retinal O-ADR O-ADR
vascular O-ADR O-ADR
lesions O-ADR O-ADR
, O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
four O-ADR O-ADR
week O-ADR O-ADR
lead O-ADR O-ADR
- O-ADR O-ADR
in O-ADR O-ADR
period O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
, O-ADR O-ADR
28 O-ADR O-ADR
/ O-ADR O-ADR
1263 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
experienced O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
further O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Pooled O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
( O-ADR O-ADR
four O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
in O-ADR O-ADR
ABSSSI O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
in O-ADR O-ADR
CABP O-ADR O-ADR
) O-ADR O-ADR
Teflaro O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1300 O-ADR O-ADR
) O-ADR O-ADR
Pooled O-ADR O-ADR
Comparators O-ADR O-ADR
a O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1297 O-ADR O-ADR
) O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
Diarrhea B-ADR B-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Nausea B-ADR B-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Constipation B-ADR B-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Vomiting B-ADR B-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Laboratory O-ADR O-ADR
Investigations O-ADR O-ADR
Increased B-ADR B-ADR
transaminases I-ADR I-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
Nutrition O-ADR O-ADR
disorders O-ADR O-ADR
Hypokalemia B-ADR B-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
Rash B-ADR B-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Vascular O-ADR O-ADR
Disorders O-ADR O-ADR
Phlebitis B-ADR B-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Observed O-ADR O-ADR
During O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
of O-ADR O-ADR
Teflaro O-ADR O-ADR
Following O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
list O-ADR O-ADR
of O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
1740 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Teflaro O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
incidences O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Eleven O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ADCETRIS O-ADR O-ADR
experienced O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
of O-ADR O-ADR
neuropathy B-ADR B-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
for O-ADR O-ADR
intolerable O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
rash O-ADR O-ADR
not O-ADR O-ADR
improving O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
despite O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
chills B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cough B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Serotonin O-ADR O-ADR
Syndrome O-ADR O-ADR
The O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
potentially O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
SNRIs O-ADR O-ADR
and O-ADR O-ADR
SSRIs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
PRISTIQ O-ADR O-ADR
, O-ADR O-ADR
alone O-ADR O-ADR
but O-ADR O-ADR
particularly O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
serotonergic O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
triptans O-ADR O-ADR
, O-ADR O-ADR
tricyclic O-ADR O-ADR
antidepressants O-ADR O-ADR
, O-ADR O-ADR
fentanyl O-ADR O-ADR
, O-ADR O-ADR
lithium O-ADR O-ADR
, O-ADR O-ADR
tramadol O-ADR O-ADR
, O-ADR O-ADR
tryptophan O-ADR O-ADR
, O-ADR O-ADR
buspirone O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
St O-ADR O-ADR
. O-ADR O-ADR
John O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Wort O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
impair O-ADR B-ADR
metabolism O-ADR I-ADR
of O-ADR I-ADR
serotonin O-ADR I-ADR
( O-ADR O-ADR
in O-ADR O-ADR
particular O-ADR O-ADR
, O-ADR O-ADR
MAOIs O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
those O-ADR O-ADR
intended O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
also O-ADR O-ADR
others O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
linezolid O-ADR O-ADR
and O-ADR O-ADR
intravenous O-ADR O-ADR
methylene O-ADR O-ADR
blue O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
related O-ADR O-ADR
directly O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
factors O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
SEGA O-ADR O-ADR
that O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
require O-ADR O-ADR
immediate O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
complete O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
childhood O-ADR O-ADR
series O-ADR O-ADR
of O-ADR O-ADR
live O-ADR O-ADR
virus O-ADR O-ADR
vaccinations O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
American O-ADR O-ADR
Council O-ADR O-ADR
on O-ADR O-ADR
Immunization O-ADR O-ADR
Practices O-ADR O-ADR
( O-ADR O-ADR
ACIP O-ADR O-ADR
) O-ADR O-ADR
guidelines O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Serotonin B-ADR B-ADR
Syndrome I-ADR I-ADR
: O-ADR O-ADR
Serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
SSRIs O-ADR O-ADR
and O-ADR O-ADR
SNRIs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
when O-ADR O-ADR
taken O-ADR O-ADR
alone O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
especially O-ADR O-ADR
when O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
serotonergic O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
triptans O-ADR O-ADR
, O-ADR O-ADR
tricyclic O-ADR O-ADR
antidepressants O-ADR O-ADR
, O-ADR O-ADR
fentanyl O-ADR O-ADR
, O-ADR O-ADR
lithium O-ADR O-ADR
, O-ADR O-ADR
tramadol O-ADR O-ADR
, O-ADR O-ADR
tryptophan O-ADR O-ADR
, O-ADR O-ADR
buspirone O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
St O-ADR O-ADR
. O-ADR O-ADR
John O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Wort O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Infections B-ADR B-ADR
, O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
instances O-ADR O-ADR
serious O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
Coadministration O-ADR O-ADR
of O-ADR O-ADR
ILARIS O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
inhibitors O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
because O-ADR O-ADR
this O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
of O-ADR O-ADR
fasting O-ADR O-ADR
serum O-ADR O-ADR
glucose O-ADR O-ADR
and O-ADR O-ADR
lipid O-ADR O-ADR
profile O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
management O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
chemotherapy O-ADR O-ADR
, O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
angiogenesis O-ADR O-ADR
inhibitors O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
poor O-ADR O-ADR
oral O-ADR O-ADR
hygiene O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
morbid O-ADR O-ADR
disorders O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
bleeding B-ADR B-ADR
is O-ADR O-ADR
an O-ADR O-ADR
adjudicated O-ADR O-ADR
death B-ADR B-ADR
with O-ADR O-ADR
the O-ADR O-ADR
primary O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
as O-ADR O-ADR
intracranial B-ADR B-ADR
bleeding I-ADR I-ADR
or O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
intracranial O-ADR O-ADR
bleeding I-ADR I-ADR
during O-ADR O-ADR
the O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
two O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
among O-ADR O-ADR
the O-ADR O-ADR
140 O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
limited O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
duration O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
Cleviprex O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
tachycardia O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Live O-ADR O-ADR
vaccines O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
concurrently O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
POTENTIAL O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
MYOCARDIAL B-ADR B-ADR
INFARCTION I-ADR I-ADR
WITH O-ADR O-ADR
LONG O-ADR B-ADR
- O-ADR O-ADR
TERM O-ADR O-ADR
USE O-ADR O-ADR
: O-ADR O-ADR
FOR O-ADR O-ADR
SHORT O-ADR B-ADR
- O-ADR O-ADR
TERM O-ADR O-ADR
HOSPITAL O-ADR I-ADR
USE O-ADR I-ADR
ONLY O-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
POTENTIAL O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
MYOCARDIAL B-ADR B-ADR
INFARCTION I-ADR I-ADR
WITH O-ADR O-ADR
LONG O-ADR B-ADR
- O-ADR O-ADR
TERM O-ADR O-ADR
USE O-ADR O-ADR
: O-ADR O-ADR
FOR O-ADR O-ADR
SHORT O-ADR O-ADR
- O-ADR O-ADR
TERM O-ADR O-ADR
HOSPITAL O-ADR O-ADR
USE O-ADR O-ADR
ONLY O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
in O-ADR O-ADR
alvimopan O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
patient O-ADR O-ADR
presenting O-ADR O-ADR
with O-ADR O-ADR
new O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
or O-ADR O-ADR
deteriorating O-ADR O-ADR
neurological O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
consult O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
neurologist O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
appropriate O-ADR O-ADR
specialist O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
GILOTRIF O-ADR O-ADR
if O-ADR O-ADR
ILD O-ADR O-ADR
is O-ADR O-ADR
diagnosed O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
than O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
versus O-ADR O-ADR
none O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
other O-ADR O-ADR
SAPHRIS O-ADR O-ADR
dose O-ADR O-ADR
groups O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
: O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
Monotherapy O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Kyprolis O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
598 O-ADR O-ADR
) O-ADR O-ADR
Decreased B-ADR B-ADR
Platelets I-ADR I-ADR
184 O-ADR O-ADR
( O-ADR O-ADR
31 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Decreased B-ADR B-ADR
Lymphocytes I-ADR I-ADR
151 O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Decreased B-ADR B-ADR
Hemoglobin I-ADR I-ADR
132 O-ADR O-ADR
( O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Decreased B-ADR B-ADR
Total I-ADR I-ADR
White I-ADR I-ADR
Blood I-ADR I-ADR
Cell I-ADR I-ADR
Count I-ADR I-ADR
71 O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Decreased B-ADR B-ADR
Sodium I-ADR I-ADR
69 O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Decreased B-ADR B-ADR
Absolute I-ADR I-ADR
Neutrophil I-ADR I-ADR
Count I-ADR I-ADR
67 O-ADR I-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
information O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
interpretation O-ADR O-ADR
of O-ADR O-ADR
Amyvid O-ADR O-ADR
images O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
errors O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
women O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
symptoms O-ADR O-ADR
are O-ADR O-ADR
mild O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
they O-ADR O-ADR
will O-ADR O-ADR
not O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
medicines O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
factors O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR B-ADR
are O-ADR O-ADR
repeated O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
GBCA O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
degree O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Potential O-ADR O-ADR
worsening B-ADR B-ADR
of I-ADR I-ADR
infections I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
dose O-ADR O-ADR
decrease O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
INLYTA O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
class O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Dermatologic O-ADR O-ADR
Reactions O-ADR O-ADR
dermal B-ADR B-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
dermatitis B-ADR B-ADR
, O-ADR O-ADR
eczema B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rashes B-ADR B-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
estradiol B-ADR O-ADR
, I-ADR O-ADR
may I-ADR O-ADR
be I-ADR O-ADR
decreased I-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
BioMarin O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
866 O-ADR O-ADR
- O-ADR O-ADR
906 O-ADR O-ADR
- O-ADR O-ADR
6100 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Impairment O-ADR B-ADR
in O-ADR I-ADR
Renal O-ADR I-ADR
Function O-ADR I-ADR
INVOKANA O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
a O-ADR O-ADR
concomitant O-ADR O-ADR
fall B-ADR B-ADR
in I-ADR I-ADR
estimated I-ADR I-ADR
GFR I-ADR I-ADR
( O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
anaphylactic O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
allergic O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
further O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
and O-ADR O-ADR
take O-ADR O-ADR
appropriate O-ADR O-ADR
precautions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
tumor O-ADR O-ADR
lysis O-ADR O-ADR
syndrome O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
but O-ADR O-ADR
as O-ADR O-ADR
late O-ADR O-ADR
as O-ADR O-ADR
six O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
aspiration O-ADR O-ADR
pneumonia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
patients O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
367 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
RA O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
developed O-ADR O-ADR
clinical O-ADR O-ADR
signs O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
lupus B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
Pregnancy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
ruled O-ADR O-ADR
out O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
amenorrhea O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
consecutive O-ADR O-ADR
cycles O-ADR O-ADR
. O-ADR O-ADR
POTIGA O-ADR O-ADR
should O-ADR O-ADR
only O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
responded O-ADR O-ADR
inadequately O-ADR O-ADR
to O-ADR O-ADR
several O-ADR O-ADR
alternative O-ADR O-ADR
treatments O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
whom O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
frequently O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
neurological O-ADR O-ADR
impairment O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
observed O-ADR O-ADR
, O-ADR O-ADR
treat O-ADR O-ADR
urgently O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
these O-ADR O-ADR
infections B-ADR B-ADR
were O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressants O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
methotrexate O-ADR O-ADR
or O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
cutaneous B-ADR B-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
cutaneous O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
Have O-ADR O-ADR
anaphylactic O-ADR O-ADR
and O-ADR O-ADR
hypersensitivity O-ADR O-ADR
treatment O-ADR O-ADR
measures O-ADR O-ADR
available O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Congestive O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
Many O-ADR O-ADR
commonly O-ADR O-ADR
used O-ADR O-ADR
cardiovascular O-ADR O-ADR
, O-ADR O-ADR
pulmonary O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
neuropsychiatric O-ADR O-ADR
medications O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
AdreView O-ADR O-ADR
imaging O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
above O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
CIMZIA O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
MTX O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
ACR20 O-ADR O-ADR
response O-ADR O-ADR
was O-ADR O-ADR
lower O-ADR O-ADR
among O-ADR O-ADR
antibody O-ADR O-ADR
positive O-ADR O-ADR
patients O-ADR O-ADR
than O-ADR O-ADR
among O-ADR O-ADR
antibody O-ADR O-ADR
- O-ADR O-ADR
negative O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
, O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
Study O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
59 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
EYLEA O-ADR O-ADR
were O-ADR O-ADR
conjunctival B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
cataract B-ADR B-ADR
, O-ADR O-ADR
vitreous B-ADR B-ADR
floaters I-ADR I-ADR
, O-ADR O-ADR
intraocular B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vitreous B-ADR B-ADR
detachment I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Withdrawal O-ADR O-ADR
: O-ADR O-ADR
Symptoms O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
rapid O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
pooled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
agranulocytosis B-ADR B-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Concurrent O-ADR O-ADR
Administration O-ADR O-ADR
with O-ADR O-ADR
Vemurafenib O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
finding O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
transaminases I-ADR I-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
concomitant O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
total I-ADR I-ADR
bilirubin I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
concurrent O-ADR O-ADR
YERVOY O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
vemurafenib O-ADR O-ADR
( O-ADR O-ADR
960 O-ADR O-ADR
mg O-ADR O-ADR
BID O-ADR O-ADR
or O-ADR O-ADR
720 O-ADR O-ADR
mg O-ADR O-ADR
BID O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Agranulocytosis O-ADR O-ADR
/ O-ADR O-ADR
Neutropenia O-ADR O-ADR
Fatal B-ADR B-ADR
agranulocytosis B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
Ferriprox O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
a O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
MBE B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
pneumonias B-ADR B-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
hospitalization O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
Beleodaq O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Regeneron O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
855 O-ADR O-ADR
- O-ADR O-ADR
395 O-ADR O-ADR
- O-ADR O-ADR
3248 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
caution O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
adrenocortical O-ADR O-ADR
insufficiency O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
if O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
withdrawn O-ADR O-ADR
from O-ADR O-ADR
prednisone O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
prednisone O-ADR O-ADR
dose O-ADR O-ADR
reductions O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
experience O-ADR O-ADR
unusual O-ADR O-ADR
stress O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
concurrent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
liver O-ADR O-ADR
toxicity O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Adrenocortical B-ADR B-ADR
insufficiency I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
adrenocortical O-ADR O-ADR
insufficiency O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
general O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
was O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
primarily O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
week O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
infrequent O-ADR O-ADR
after O-ADR O-ADR
Week O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
dermatitis I-ADR I-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
weeks O-ADR O-ADR
and O-ADR O-ADR
ranged O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
additional O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
moderate O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
manifested O-ADR O-ADR
by O-ADR O-ADR
liver B-ADR B-ADR
function I-ADR I-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
( O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
of O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
total B-ADR O-ADR
bilirubin I-ADR O-ADR
elevation I-ADR O-ADR
of O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
; O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
neutropenia O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Instruct O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
to O-ADR O-ADR
immediately O-ADR O-ADR
discontinue O-ADR O-ADR
Ferriprox O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
neutropenia O-ADR B-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
for O-ADR O-ADR
nephrotic O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Dysphagia O-ADR O-ADR
Esophageal B-ADR B-ADR
dysmotility I-ADR I-ADR
and O-ADR O-ADR
aspiration B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Symptomatic B-ADR B-ADR
hypotension I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
FARXIGA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
elderly O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
loop O-ADR O-ADR
diuretics O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Palmar O-ADR O-ADR
- O-ADR O-ADR
Plantar O-ADR O-ADR
Erythrodysesthesia O-ADR O-ADR
Syndrome O-ADR O-ADR
Palmar B-ADR B-ADR
- O-ADR O-ADR
plantar O-ADR O-ADR
erythrodysesthesia I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PPES B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
COMETRIQ O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
severe O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
arm O-ADR O-ADR
through O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Drugs O-ADR O-ADR
with O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
blocking O-ADR O-ADR
effects O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
induce O-ADR O-ADR
priapism B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
KALYDECO O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
three O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
353 O-ADR O-ADR
patients O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
with O-ADR O-ADR
CF O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
G551D O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
( O-ADR O-ADR
Trials O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
were O-ADR O-ADR
homozygous O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
F508del O-ADR O-ADR
mutation O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
persists O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
dose O-ADR O-ADR
modification O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
preservative O-ADR O-ADR
in O-ADR O-ADR
BEPREVE O-ADR O-ADR
, O-ADR O-ADR
benzalkonium O-ADR O-ADR
chloride O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
absorbed O-ADR O-ADR
by O-ADR O-ADR
soft O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
. O-ADR O-ADR
New O-ADR O-ADR
malignancies B-ADR B-ADR
related I-ADR I-ADR
to I-ADR I-ADR
the I-ADR I-ADR
breast I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Immunizations O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
may O-ADR O-ADR
receive O-ADR O-ADR
vaccinations O-ADR O-ADR
, O-ADR O-ADR
except O-ADR O-ADR
for O-ADR O-ADR
live O-ADR O-ADR
or O-ADR O-ADR
live O-ADR O-ADR
attenuated O-ADR O-ADR
vaccines O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
infection B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
creatinine I-ADR I-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
multi B-ADR B-ADR
- O-ADR O-ADR
organ O-ADR O-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
56 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
any O-ADR O-ADR
bleeding O-ADR O-ADR
requires O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
, O-ADR O-ADR
temporarily O-ADR O-ADR
interrupt O-ADR O-ADR
the O-ADR O-ADR
INLYTA O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
11 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
of O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
In O-ADR O-ADR
Any O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
Dose O-ADR O-ADR
Group O-ADR O-ADR
and O-ADR O-ADR
Which O-ADR O-ADR
Occurred O-ADR O-ADR
at O-ADR O-ADR
Greater O-ADR O-ADR
Incidence O-ADR O-ADR
Than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Placebo O-ADR O-ADR
Group O-ADR O-ADR
at O-ADR O-ADR
3 O-ADR O-ADR
Weeks O-ADR O-ADR
in O-ADR O-ADR
Adjunctive O-ADR O-ADR
Bipolar O-ADR O-ADR
Mania O-ADR O-ADR
Trials O-ADR O-ADR
* O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
flexible O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
. O-ADR O-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
and O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Immune B-ADR B-ADR
reconstitution I-ADR I-ADR
syndrome I-ADR I-ADR
: O-ADR O-ADR
May O-ADR O-ADR
necessitate O-ADR O-ADR
further O-ADR O-ADR
evaluation O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
ATHENA O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
was O-ADR O-ADR
30 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Study O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Advanced O-ADR O-ADR
Hormone O-ADR O-ADR
Receptor O-ADR O-ADR
- O-ADR O-ADR
Positive O-ADR O-ADR
, O-ADR O-ADR
HER2 O-ADR O-ADR
- O-ADR O-ADR
Negative O-ADR O-ADR
Breast O-ADR O-ADR
Cancer O-ADR O-ADR
The O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
485 O-ADR O-ADR
) O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
239 O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
or O-ADR O-ADR
metastatic O-ADR O-ADR
hormone O-ADR O-ADR
receptor O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
, O-ADR O-ADR
HER2 O-ADR O-ADR
- O-ADR O-ADR
negative O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
POTENTIAL O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
MYOCARDIAL B-ADR B-ADR
INFARCTION I-ADR I-ADR
WITH O-ADR O-ADR
LONG O-ADR B-ADR
- O-ADR O-ADR
TERM O-ADR O-ADR
USE O-ADR I-ADR
: O-ADR O-ADR
FOR O-ADR O-ADR
SHORT O-ADR B-ADR
- O-ADR O-ADR
TERM O-ADR O-ADR
HOSPITAL O-ADR I-ADR
USE O-ADR I-ADR
ONLY O-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
ADRs O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
intensity O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
in O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
SINGLE O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
provided O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
( O-ADR O-ADR
52 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
adult O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
primarily O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
prolactin I-ADR I-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
26 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Keratitis B-ADR B-ADR
: O-ADR O-ADR
Occurs O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Decreased O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Motility O-ADR O-ADR
Toviaz O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
antimuscarinic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
decreased O-ADR O-ADR
gastrointestinal O-ADR O-ADR
motility O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
constipation O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
586 O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
59 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
46 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
) O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Interruption O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
, O-ADR O-ADR
pending O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
/ O-ADR O-ADR
benefit O-ADR O-ADR
assessment O-ADR O-ADR
, O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
individual O-ADR O-ADR
basis O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
in O-ADR O-ADR
children O-ADR O-ADR
, O-ADR O-ADR
adolescents O-ADR O-ADR
and O-ADR O-ADR
young O-ADR O-ADR
adults O-ADR O-ADR
taking O-ADR O-ADR
antidepressants O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
GRANIX O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Allergic B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
angioneurotic B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
allergic I-ADR I-ADR
, O-ADR O-ADR
drug B-ADR B-ADR
hypersensitivity I-ADR I-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pruritic B-ADR B-ADR
rash I-ADR I-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
) O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Sickle B-ADR B-ADR
cell I-ADR I-ADR
crisis I-ADR I-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
crisis O-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
secondary O-ADR O-ADR
to O-ADR O-ADR
membranous B-ADR B-ADR
glomerulonephritis I-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
persistently O-ADR O-ADR
positive B-ADR O-ADR
anti I-ADR O-ADR
- O-ADR O-ADR
rhGAA O-ADR O-ADR
IgG I-ADR O-ADR
antibody I-ADR O-ADR
titers I-ADR O-ADR
. O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
congenital O-ADR O-ADR
prolongation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
condition O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
symptomatic O-ADR O-ADR
cardiac O-ADR O-ADR
arrhythmias O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
clinically O-ADR O-ADR
relevant O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
cardiac O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
CABP O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
51 O-ADR O-ADR
/ O-ADR O-ADR
520 O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Teflaro O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
/ O-ADR O-ADR
534 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
ceftriaxone O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
seroconverted B-ADR O-ADR
from I-ADR O-ADR
a I-ADR O-ADR
negative I-ADR O-ADR
to I-ADR O-ADR
a I-ADR O-ADR
positive I-ADR O-ADR
direct I-ADR O-ADR
Coombs I-ADR O-ADR
' I-ADR O-ADR
test I-ADR O-ADR
result I-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
clinical O-ADR O-ADR
context O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
abnormal O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
( O-ADR O-ADR
ALT O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reference O-ADR O-ADR
range O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ULORIC O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
interrupted O-ADR O-ADR
and O-ADR O-ADR
investigation O-ADR O-ADR
done O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
the O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
from O-ADR O-ADR
Extension O-ADR O-ADR
Trial O-ADR O-ADR
in O-ADR O-ADR
Adults O-ADR O-ADR
with O-ADR O-ADR
Chronic O-ADR O-ADR
Immune O-ADR O-ADR
( O-ADR O-ADR
Idiopathic O-ADR O-ADR
) O-ADR O-ADR
Thrombocytopenia O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
PROMACTA O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
299 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
10 O-ADR O-ADR
Hyperbilirubinemia B-ADR B-ADR
6 O-ADR O-ADR
ALT B-ADR B-ADR
increased I-ADR I-ADR
6 O-ADR O-ADR
Cataract B-ADR B-ADR
5 O-ADR O-ADR
AST B-ADR B-ADR
increased I-ADR I-ADR
4 O-ADR O-ADR
Fatigue B-ADR B-ADR
4 O-ADR O-ADR
Nausea B-ADR B-ADR
4 O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
three O-ADR O-ADR
controlled O-ADR O-ADR
chronic O-ADR O-ADR
ITP O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
serum B-ADR B-ADR
liver I-ADR I-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
( O-ADR O-ADR
predominantly O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
such O-ADR O-ADR
combinations O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
decision O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
made O-ADR O-ADR
to O-ADR O-ADR
discontinue O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
medication O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
tapered O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
rapidly O-ADR O-ADR
as O-ADR O-ADR
is O-ADR O-ADR
feasible O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
with O-ADR O-ADR
recognition O-ADR O-ADR
that O-ADR O-ADR
abrupt O-ADR O-ADR
discontinuation O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
certain O-ADR O-ADR
symptoms O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
description O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
uncertain O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
HSTCL O-ADR O-ADR
is O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
other O-ADR O-ADR
immunosuppressants O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
highest O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
EOVIST O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
allow O-ADR O-ADR
a O-ADR O-ADR
sufficient O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
cuSCC B-ADR B-ADR
was O-ADR O-ADR
136 O-ADR O-ADR
to197 O-ADR O-ADR
days O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
to O-ADR O-ADR
197 O-ADR O-ADR
days O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
arm O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Imaging O-ADR O-ADR
Errors O-ADR O-ADR
Imaging O-ADR O-ADR
errors O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
11 O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
choline O-ADR O-ADR
PET O-ADR O-ADR
and O-ADR O-ADR
PET O-ADR O-ADR
/ O-ADR O-ADR
CT O-ADR O-ADR
imaging O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
GRANIX O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Capillary B-ADR B-ADR
Leak I-ADR I-ADR
Syndrome I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
if O-ADR O-ADR
symptoms O-ADR O-ADR
develop O-ADR O-ADR
and O-ADR O-ADR
administer O-ADR O-ADR
standard O-ADR O-ADR
symptomatic O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Splenic O-ADR O-ADR
Rupture O-ADR O-ADR
Splenic B-ADR B-ADR
rupture I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
human O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
suspected O-ADR O-ADR
of O-ADR O-ADR
having O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
ONJ O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
Prolia O-ADR O-ADR
should O-ADR O-ADR
receive O-ADR O-ADR
care O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
dentist O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
oral O-ADR O-ADR
surgeon O-ADR O-ADR
. O-ADR O-ADR
Anti O-ADR O-ADR
- O-ADR O-ADR
ecallantide O-ADR O-ADR
IgE O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
tested O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
P O-ADR O-ADR
. O-ADR O-ADR
pastoris O-ADR O-ADR
IgE O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
detected O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
20 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
PRES O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
GILENYA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
involving O-ADR I-ADR
the O-ADR I-ADR
liver O-ADR O-ADR
allograft O-ADR I-ADR
( O-ADR O-ADR
one O-ADR O-ADR
fatal B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
fatal B-ADR B-ADR
case O-ADR O-ADR
of O-ADR O-ADR
PML B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
the O-ADR O-ADR
147 O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
NULOJIX O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
over O-ADR O-ADR
7800 O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
postmenopausal O-ADR O-ADR
osteoporosis O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Hematologic O-ADR O-ADR
Parameters O-ADR O-ADR
Decreased B-ADR B-ADR
hemoglobin I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
AFINITOR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
present O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
leucovorin O-ADR O-ADR
within O-ADR O-ADR
2 O-ADR O-ADR
hours O-ADR O-ADR
before O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
postmarketing O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
[ O-ADR O-ADR
seeBoxed O-ADR O-ADR
WarningandWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
bilirubin I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
no O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
postmenopausal O-ADR O-ADR
osteoporosis O-ADR O-ADR
are O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Leading O-ADR O-ADR
to O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
: O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
/ O-ADR O-ADR
104 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
101 O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Venous O-ADR O-ADR
Thromboembolic O-ADR O-ADR
Events O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
deaths B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Image O-ADR O-ADR
interpretation O-ADR O-ADR
errors O-ADR O-ADR
( O-ADR O-ADR
especially O-ADR O-ADR
false O-ADR O-ADR
negatives O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
XEOMIN O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
22 O-ADR O-ADR
to O-ADR O-ADR
79 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
62 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
predominantly O-ADR O-ADR
female O-ADR O-ADR
( O-ADR O-ADR
65 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
79 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
time O-ADR O-ADR
since O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
995 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
999 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
977 O-ADR O-ADR
) O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
symptomatic O-ADR O-ADR
bradycardia O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
hold O-ADR O-ADR
XALKORI O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
asymptomatic O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
60 O-ADR O-ADR
bpm O-ADR O-ADR
or O-ADR O-ADR
above O-ADR O-ADR
, O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
evaluate O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
adjust O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
administer O-ADR O-ADR
antihistamines O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
antipyretics O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Medications O-ADR O-ADR
Known O-ADR O-ADR
to O-ADR O-ADR
Cause O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
Insulin O-ADR O-ADR
and O-ADR O-ADR
insulin O-ADR O-ADR
secretagogues O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
sulfonylureas O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
hypoglycemia O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
immune O-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR I-ADR
initially O-ADR O-ADR
manifested O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
minority O-ADR O-ADR
occurred O-ADR O-ADR
weeks O-ADR O-ADR
to O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
COC O-ADR O-ADR
Use O-ADR O-ADR
Before O-ADR O-ADR
or O-ADR O-ADR
During O-ADR O-ADR
Early O-ADR O-ADR
Pregnancy O-ADR O-ADR
Extensive O-ADR O-ADR
epidemiological O-ADR O-ADR
studies O-ADR O-ADR
have O-ADR O-ADR
revealed O-ADR O-ADR
no O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
birth B-ADR B-ADR
defects I-ADR I-ADR
in O-ADR O-ADR
women O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
used O-ADR O-ADR
oral O-ADR O-ADR
contraceptives O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
pregnancy O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
invasive O-ADR O-ADR
dental O-ADR O-ADR
procedures O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
COMETRIQ O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
28 O-ADR O-ADR
days O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
scheduled O-ADR O-ADR
surgery O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
on O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
increased O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
because O-ADR O-ADR
serum O-ADR O-ADR
concentrations O-ADR O-ADR
of O-ADR O-ADR
thyroid B-ADR O-ADR
- O-ADR O-ADR
binding O-ADR O-ADR
globulin I-ADR O-ADR
increase I-ADR O-ADR
with O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
COCs O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
contraceptive O-ADR O-ADR
methods O-ADR O-ADR
are O-ADR O-ADR
being O-ADR O-ADR
considered O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
reported O-ADR O-ADR
retinopathy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Carcinoma O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Breasts O-ADR O-ADR
and O-ADR O-ADR
Reproductive O-ADR O-ADR
Organs O-ADR O-ADR
Women O-ADR O-ADR
who O-ADR O-ADR
currently O-ADR O-ADR
have O-ADR O-ADR
or O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
Natazia O-ADR O-ADR
because O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
hormonally O-ADR O-ADR
- O-ADR O-ADR
sensitive O-ADR O-ADR
tumor O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Increased O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
indicated O-ADR O-ADR
before O-ADR O-ADR
, O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
stressful O-ADR O-ADR
situations O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Nutritional O-ADR O-ADR
Management O-ADR O-ADR
Since O-ADR O-ADR
hyperammonemia O-ADR O-ADR
is O-ADR O-ADR
the O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
protein O-ADR O-ADR
catabolism O-ADR O-ADR
, O-ADR O-ADR
complete O-ADR O-ADR
protein O-ADR O-ADR
restriction O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
maintained O-ADR O-ADR
for O-ADR O-ADR
24 O-ADR O-ADR
to O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
and O-ADR O-ADR
caloric O-ADR O-ADR
supplementation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
maximized O-ADR O-ADR
to O-ADR O-ADR
reverse O-ADR O-ADR
catabolism O-ADR O-ADR
and O-ADR O-ADR
nitrogen O-ADR O-ADR
turnover O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
pregnant O-ADR O-ADR
and O-ADR O-ADR
use O-ADR O-ADR
Natazia O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
experience O-ADR O-ADR
amenorrhea B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
plasma O-ADR O-ADR
zinc O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
supplement O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
deficiency O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
using O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
another O-ADR O-ADR
medicine O-ADR O-ADR
containing O-ADR O-ADR
a O-ADR O-ADR
LABA O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
salmeterol O-ADR O-ADR
, O-ADR O-ADR
formoterol O-ADR O-ADR
fumarate O-ADR O-ADR
, O-ADR O-ADR
arformoterol O-ADR O-ADR
tartrate O-ADR O-ADR
, O-ADR O-ADR
indacaterol O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
reason O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Reversible B-ADR B-ADR
posterior I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
RPLS B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
. O-ADR O-ADR
Documented O-ADR O-ADR
symptomatic B-ADR B-ADR
hypoglycemia I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
when O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
sulfonylurea O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
coagulation O-ADR O-ADR
disorders O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
concomitant O-ADR O-ADR
anticoagulants O-ADR O-ADR
( O-ADR O-ADR
except O-ADR O-ADR
for O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
aspirin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Reversal O-ADR O-ADR
of O-ADR O-ADR
Anticoagulant O-ADR O-ADR
Effect O-ADR O-ADR
: O-ADR O-ADR
A O-ADR O-ADR
specific O-ADR O-ADR
reversal O-ADR O-ADR
agent O-ADR O-ADR
for O-ADR O-ADR
dabigatran O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
shares O-ADR O-ADR
this O-ADR O-ADR
pharmacologic O-ADR O-ADR
activity O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Increased B-ADR B-ADR
LDL I-ADR I-ADR
- O-ADR O-ADR
C O-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
per O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
, O-ADR O-ADR
Including O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
mild O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
pruritus B-ADR B-ADR
) O-ADR O-ADR
after O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
following O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
Transplant O-ADR O-ADR
Lymphoproliferative O-ADR O-ADR
Disorder O-ADR O-ADR
Reported O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
post B-ADR B-ADR
- O-ADR O-ADR
transplant O-ADR O-ADR
lymphoproliferative I-ADR I-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
PTLD B-ADR B-ADR
) O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
36 O-ADR O-ADR
months O-ADR O-ADR
post O-ADR O-ADR
transplant O-ADR O-ADR
were O-ADR O-ADR
obtained O-ADR O-ADR
for O-ADR O-ADR
NULOJIX O-ADR O-ADR
by O-ADR O-ADR
pooling O-ADR O-ADR
both O-ADR O-ADR
dosage O-ADR O-ADR
regimens O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
804 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
third O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
kidney O-ADR O-ADR
transplantation O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
145 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
which O-ADR O-ADR
evaluated O-ADR O-ADR
two O-ADR O-ADR
NULOJIX O-ADR O-ADR
dosage O-ADR O-ADR
regimens O-ADR O-ADR
similar O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
slightly O-ADR O-ADR
different O-ADR O-ADR
, O-ADR O-ADR
from O-ADR O-ADR
those O-ADR O-ADR
of O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
IMMUNE B-ADR B-ADR
- O-ADR O-ADR
MEDIATED O-ADR O-ADR
ADVERSE I-ADR I-ADR
REACTIONS I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
IMMUNE B-ADR B-ADR
- O-ADR O-ADR
MEDIATED O-ADR O-ADR
ADVERSE I-ADR I-ADR
REACTIONS I-ADR I-ADR
YERVOY O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
activation O-ADR O-ADR
and O-ADR O-ADR
proliferation O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
FARXIGA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
characteristics O-ADR O-ADR
, O-ADR O-ADR
volume O-ADR O-ADR
status O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
and O-ADR O-ADR
corrected O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
arrhythmic O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
palpitations O-ADR O-ADR
, O-ADR O-ADR
lightheadedness O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
new O-ADR O-ADR
onset O-ADR O-ADR
dyspnea O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
an O-ADR O-ADR
ECG O-ADR O-ADR
performed O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reporting O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
oxcarbazepine O-ADR O-ADR
use O-ADR O-ADR
exceeds O-ADR O-ADR
the O-ADR O-ADR
background O-ADR O-ADR
incidence O-ADR O-ADR
rate O-ADR O-ADR
estimates O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
factor O-ADR O-ADR
of O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
adequate O-ADR O-ADR
and O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
using O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
clinical O-ADR O-ADR
monitoring O-ADR O-ADR
for O-ADR O-ADR
SIRTURO O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
signs O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
elevated B-ADR B-ADR
creatine I-ADR I-ADR
phosphokinase I-ADR I-ADR
, O-ADR O-ADR
myoglobinuria B-ADR B-ADR
( O-ADR O-ADR
rhabdomyolysis B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Record O-ADR O-ADR
the O-ADR O-ADR
date O-ADR O-ADR
you O-ADR O-ADR
open O-ADR O-ADR
the O-ADR O-ADR
foil O-ADR O-ADR
pouch O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
space O-ADR O-ADR
provided O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
blister O-ADR O-ADR
package O-ADR O-ADR
label O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
XEOMIN O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
XEOMIN O-ADR O-ADR
( O-ADR O-ADR
120 O-ADR O-ADR
Units O-ADR O-ADR
or O-ADR O-ADR
240 O-ADR O-ADR
Units O-ADR O-ADR
) O-ADR O-ADR
included O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
neck B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
Hemoglobin O-ADR O-ADR
/ O-ADR O-ADR
Hematocrit O-ADR O-ADR
Low B-ADR B-ADR
hemoglobin I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Edarbi O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
ADCETRIS O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
in O-ADR O-ADR
327 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
Hodgkin O-ADR O-ADR
lymphoma O-ADR O-ADR
( O-ADR O-ADR
HL O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
systemic O-ADR O-ADR
anaplastic O-ADR O-ADR
large O-ADR O-ADR
cell O-ADR O-ADR
lymphoma O-ADR O-ADR
( O-ADR O-ADR
sALCL O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
160 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
uncontrolled O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
167 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
consisted O-ADR O-ADR
mainly O-ADR O-ADR
of O-ADR O-ADR
dyspnea B-ADR B-ADR
. O-ADR O-ADR
No O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
secondary O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
from O-ADR O-ADR
persons O-ADR O-ADR
receiving O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
on O-ADR O-ADR
new O-ADR O-ADR
immunizations O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
in O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
Bipolar O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
SAPHRIS O-ADR O-ADR
dose O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
acute O-ADR O-ADR
therapy O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
have O-ADR O-ADR
unusual O-ADR O-ADR
vaginal O-ADR B-ADR
bleeding O-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
resolved O-ADR O-ADR
over O-ADR O-ADR
several O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
) O-ADR O-ADR
Program O-ADR O-ADR
. O-ADR O-ADR
Through O-ADR O-ADR
96 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
treatment O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
HORIZANT O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
persisted O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
about O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weight B-ADR B-ADR
increased I-ADR I-ADR
were O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
as O-ADR O-ADR
common O-ADR O-ADR
on O-ADR O-ADR
20 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
as O-ADR O-ADR
on O-ADR O-ADR
10 O-ADR O-ADR
to O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
Infections B-ADR B-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
death B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
458 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
675 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
for O-ADR O-ADR
keratitis O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
Following O-ADR O-ADR
resolution O-ADR O-ADR
of O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
resuming O-ADR O-ADR
KALYDECO O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
, O-ADR O-ADR
HYPERSENSITIVITY B-ADR B-ADR
AND O-ADR O-ADR
IMMUNE B-ADR B-ADR
- O-ADR O-ADR
MEDIATED O-ADR O-ADR
REACTIONS I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
CARDIORESPIRATORY B-ADR B-ADR
FAILURE I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
See O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
potentially O-ADR O-ADR
significant O-ADR O-ADR
drug O-ADR O-ADR
interactions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
dose O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
when O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
/ O-ADR O-ADR
PgP O-ADR O-ADR
inducer O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
39 O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
75 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
94 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
52 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
Administration O-ADR O-ADR
of O-ADR O-ADR
ILARIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
and O-ADR O-ADR
Discontinuation O-ADR O-ADR
- O-ADR O-ADR
Perioperative O-ADR O-ADR
Hypertension O-ADR O-ADR
Studies O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
perioperative O-ADR O-ADR
hypertension O-ADR O-ADR
receiving O-ADR O-ADR
Cleviprex O-ADR O-ADR
was O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
active O-ADR O-ADR
comparators O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Continue O-ADR O-ADR
hydration O-ADR O-ADR
and O-ADR O-ADR
alkalinization O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
urine O-ADR O-ADR
as O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Episodes O-ADR O-ADR
vary O-ADR O-ADR
in O-ADR O-ADR
frequency O-ADR O-ADR
, O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
if O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
delayed O-ADR O-ADR
. O-ADR O-ADR
Healthcare O-ADR O-ADR
professionals O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
aware O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
similarity O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
between O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
hereditary O-ADR O-ADR
angioedema O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
Spinal O-ADR O-ADR
/ O-ADR O-ADR
epidural O-ADR O-ADR
anesthesia O-ADR O-ADR
or O-ADR O-ADR
puncture O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
bleeding B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Worsening B-ADR B-ADR
Renal I-ADR I-ADR
Impairment I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
portions O-ADR O-ADR
through O-ADR O-ADR
approximately O-ADR O-ADR
92 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
lymphoma B-ADR B-ADR
and O-ADR O-ADR
NMSC B-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
31 O-ADR O-ADR
( O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
06 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
92 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
NMSC B-ADR B-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
00 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
vitro O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
human O-ADR O-ADR
platelets O-ADR O-ADR
indicate O-ADR O-ADR
that O-ADR O-ADR
STENDRA O-ADR O-ADR
potentiates B-ADR O-ADR
the I-ADR O-ADR
anti I-ADR O-ADR
- O-ADR O-ADR
aggregatory O-ADR O-ADR
effect I-ADR O-ADR
of I-ADR O-ADR
sodium I-ADR O-ADR
nitroprusside I-ADR O-ADR
( O-ADR O-ADR
a O-ADR O-ADR
nitric O-ADR O-ADR
oxide O-ADR O-ADR
[ O-ADR O-ADR
NO O-ADR O-ADR
] O-ADR O-ADR
donor O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Prolongation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
Interval O-ADR O-ADR
Some O-ADR O-ADR
antimalarials O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
halofantrine O-ADR O-ADR
, O-ADR O-ADR
quinine O-ADR O-ADR
, O-ADR O-ADR
quinidine O-ADR O-ADR
) O-ADR O-ADR
including O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
prolongation B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
QT I-ADR I-ADR
interval I-ADR I-ADR
on O-ADR I-ADR
the O-ADR I-ADR
electrocardiogram O-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity O-ADR B-ADR
reactions O-ADR I-ADR
: O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
bullous B-ADR B-ADR
eruption I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
small O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
limits O-ADR O-ADR
the O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
draw O-ADR O-ADR
definitive O-ADR O-ADR
conclusions O-ADR O-ADR
regarding O-ADR O-ADR
the O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
golimumab O-ADR O-ADR
and O-ADR O-ADR
clinical O-ADR O-ADR
efficacy O-ADR O-ADR
or O-ADR O-ADR
safety O-ADR O-ADR
measures O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Liver O-ADR O-ADR
Injury O-ADR O-ADR
* O-ADR O-ADR
Hepatocellular B-ADR B-ADR
liver I-ADR I-ADR
injury I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
acute B-ADR B-ADR
liver I-ADR I-ADR
failure I-ADR I-ADR
requiring O-ADR O-ADR
transplant O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
above O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
test O-ADR O-ADR
results O-ADR O-ADR
were O-ADR O-ADR
considered O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
ELISA O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Risk O-ADR O-ADR
for O-ADR O-ADR
Image O-ADR O-ADR
Misinterpretation O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Errors O-ADR O-ADR
Errors O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
while O-ADR O-ADR
using O-ADR O-ADR
Vizamyl O-ADR O-ADR
PET O-ADR O-ADR
images O-ADR O-ADR
to O-ADR O-ADR
estimate O-ADR O-ADR
brain O-ADR O-ADR
neuritic O-ADR O-ADR
plaque O-ADR O-ADR
density O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Administration O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
infusions O-ADR O-ADR
were O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
infusion B-ADR B-ADR
reaction I-ADR I-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
infusions O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
medication O-ADR O-ADR
pending O-ADR O-ADR
examination O-ADR O-ADR
if O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
sudden O-ADR O-ADR
partial O-ADR O-ADR
or O-ADR O-ADR
complete O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
sudden O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
proptosis O-ADR O-ADR
, O-ADR O-ADR
diplopia O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
migraine O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
receiving O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
metabolized O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
cytochrome O-ADR O-ADR
enzyme O-ADR O-ADR
CYP2D6 O-ADR O-ADR
which O-ADR O-ADR
also O-ADR O-ADR
have O-ADR O-ADR
cardiac O-ADR O-ADR
effects O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
flecainide O-ADR O-ADR
, O-ADR O-ADR
imipramine O-ADR O-ADR
, O-ADR O-ADR
amitriptyline O-ADR O-ADR
, O-ADR O-ADR
clomipramine O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Postmarketing O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
hepatosplenic B-ADR B-ADR
T I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
lymphoma I-ADR I-ADR
( O-ADR O-ADR
HSTCL B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
rare O-ADR O-ADR
type O-ADR O-ADR
of O-ADR O-ADR
T O-ADR B-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
lymphoma O-ADR I-ADR
that O-ADR O-ADR
has O-ADR O-ADR
a O-ADR O-ADR
very O-ADR O-ADR
aggressive O-ADR O-ADR
disease O-ADR O-ADR
course O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
usually O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
data O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
using O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
towards O-ADR O-ADR
another O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
; O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
caution O-ADR O-ADR
is O-ADR O-ADR
needed O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Teflaro O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
reported O-ADR O-ADR
included O-ADR O-ADR
sudden O-ADR B-ADR
onset O-ADR I-ADR
of O-ADR I-ADR
severe O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
altered B-ADR B-ADR
mental I-ADR I-ADR
status I-ADR I-ADR
, O-ADR O-ADR
visual B-ADR B-ADR
disturbances I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
seizure B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
hyperglycemia B-ADR B-ADR
based O-ADR O-ADR
on O-ADR O-ADR
laboratory O-ADR O-ADR
values O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
/ O-ADR O-ADR
187 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
dacarbazine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Serious O-ADR O-ADR
Allergic O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEUTROPENIA B-ADR B-ADR
AND O-ADR O-ADR
HYPERSENSITIVITY B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEUTROPENIA B-ADR B-ADR
AND O-ADR O-ADR
HYPERSENSITIVITY B-ADR B-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEUTROPENIA B-ADR B-ADR
AND O-ADR O-ADR
HYPERSENSITIVITY B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Neuropathies O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
fatal B-ADR B-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
( O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
place O-ADR O-ADR
DUAVEE O-ADR O-ADR
in O-ADR O-ADR
pill O-ADR O-ADR
boxes O-ADR O-ADR
or O-ADR O-ADR
pill O-ADR O-ADR
organizers O-ADR O-ADR
. O-ADR O-ADR
Extrapyramidal O-ADR O-ADR
Symptoms O-ADR O-ADR
( O-ADR O-ADR
EPS O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
provided O-ADR O-ADR
information O-ADR O-ADR
regarding O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
EPS B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
SEGA O-ADR O-ADR
with O-ADR O-ADR
TSC O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
stomatitis B-ADR B-ADR
and O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
below O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
upon O-ADR O-ADR
two O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
48 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Trials O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
213 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CF O-ADR O-ADR
ages O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
53 O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
G551D O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
and O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALYDECO O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
corticosteroid O-ADR O-ADR
eye O-ADR O-ADR
drops O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
uveitis O-ADR O-ADR
, O-ADR O-ADR
iritis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
episcleritis O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
endocrinopathy I-ADR I-ADR
was O-ADR O-ADR
11 O-ADR O-ADR
weeks O-ADR O-ADR
and O-ADR O-ADR
ranged O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
19 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
help O-ADR O-ADR
reduce O-ADR O-ADR
your O-ADR O-ADR
chances O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
osteoporosis O-ADR O-ADR
( O-ADR O-ADR
thin O-ADR O-ADR
, O-ADR O-ADR
weak O-ADR O-ADR
bones O-ADR O-ADR
) O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
use O-ADR O-ADR
DUAVEE O-ADR O-ADR
only O-ADR O-ADR
to O-ADR O-ADR
prevent O-ADR O-ADR
osteoporosis O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
menopause O-ADR O-ADR
, O-ADR O-ADR
talk O-ADR O-ADR
with O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
about O-ADR O-ADR
whether O-ADR O-ADR
a O-ADR O-ADR
different O-ADR O-ADR
treatment O-ADR O-ADR
or O-ADR O-ADR
medicine O-ADR O-ADR
without O-ADR O-ADR
estrogens O-ADR O-ADR
might O-ADR O-ADR
be O-ADR O-ADR
better O-ADR O-ADR
for O-ADR O-ADR
you O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
shortest O-ADR O-ADR
time O-ADR O-ADR
possible O-ADR O-ADR
and O-ADR O-ADR
only O-ADR O-ADR
for O-ADR O-ADR
as O-ADR O-ADR
long O-ADR O-ADR
as O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
from O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
one O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
three O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Immunization O-ADR O-ADR
Live O-ADR O-ADR
vaccines O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
for O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
before O-ADR O-ADR
or O-ADR O-ADR
concurrently O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
as O-ADR O-ADR
clinical O-ADR O-ADR
safety O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
is O-ADR O-ADR
probably O-ADR O-ADR
greatest O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
spasticity O-ADR O-ADR
but O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
also O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
spasticity O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
would O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
of O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
severity O-ADR O-ADR
. O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
acutely O-ADR O-ADR
deteriorating O-ADR O-ADR
COPD O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
eight O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
pancreatitis B-ADR B-ADR
( I-ADR O-ADR
acute I-ADR B-ADR
) O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
comparator O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Obtain O-ADR O-ADR
serum O-ADR O-ADR
potassium O-ADR O-ADR
, O-ADR O-ADR
calcium O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
magnesium O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
correct O-ADR O-ADR
if O-ADR O-ADR
abnormal O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
A O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
involving O-ADR O-ADR
69 O-ADR O-ADR
patients O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
ages O-ADR O-ADR
of O-ADR O-ADR
6 O-ADR O-ADR
and O-ADR O-ADR
68 O-ADR O-ADR
years O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
R117H O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
discontinuation O-ADR O-ADR
rate O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
for O-ADR O-ADR
PRISTIQ O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
YERVOY O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
activation O-ADR O-ADR
and O-ADR O-ADR
proliferation O-ADR O-ADR
. O-ADR O-ADR
Information O-ADR O-ADR
on O-ADR O-ADR
selected O-ADR O-ADR
significant O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
is O-ADR O-ADR
summarized O-ADR O-ADR
below O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
oral O-ADR O-ADR
contraceptives O-ADR O-ADR
to O-ADR O-ADR
induce O-ADR O-ADR
withdrawal O-ADR O-ADR
bleeding O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
test O-ADR O-ADR
for O-ADR O-ADR
pregnancy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
pruritus B-ADR B-ADR
increased O-ADR O-ADR
after O-ADR O-ADR
more O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infections O-ADR B-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
exposure O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Conduct O-ADR O-ADR
periodic O-ADR O-ADR
monitoring O-ADR O-ADR
with O-ADR O-ADR
electrocardiograms O-ADR O-ADR
( O-ADR O-ADR
ECGs O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
electrolytes O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
bradyarrhythmias O-ADR O-ADR
, O-ADR O-ADR
electrolyte O-ADR O-ADR
abnormalities O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Confidence O-ADR O-ADR
interval O-ADR O-ADR
Patients O-ADR O-ADR
Major O-ADR O-ADR
bleeding B-ADR B-ADR
event O-ADR O-ADR
a O-ADR O-ADR
Bleeding B-ADR B-ADR
sites O-ADR O-ADR
for O-ADR O-ADR
MBE B-ADR B-ADR
b O-ADR O-ADR
Clinically O-ADR O-ADR
relevant O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
Any O-ADR O-ADR
bleeding B-ADR B-ADR
In O-ADR O-ADR
the O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
MEDY O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
gastrointestinal B-ADR B-ADR
bleeds I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
warfarin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
insufficient O-ADR O-ADR
numbers O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
biopsy O-ADR O-ADR
- O-ADR O-ADR
proven O-ADR O-ADR
hepatitis O-ADR O-ADR
to O-ADR O-ADR
characterize O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
event O-ADR O-ADR
. O-ADR O-ADR
Increased O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
indicated O-ADR O-ADR
before O-ADR O-ADR
, O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
stressful O-ADR O-ADR
situations O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
hyperuricemia O-ADR O-ADR
and O-ADR O-ADR
bulky O-ADR O-ADR
disease O-ADR O-ADR
experienced O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
cycle O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
died B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
multi B-ADR B-ADR
- O-ADR O-ADR
organ O-ADR O-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
frequently O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
neurological O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
unknown O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
HALAVEN O-ADR O-ADR
were O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
some O-ADR O-ADR
past O-ADR O-ADR
studies O-ADR O-ADR
have O-ADR O-ADR
suggested O-ADR O-ADR
that O-ADR O-ADR
COCs O-ADR O-ADR
might O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
breast B-ADR B-ADR
cancer I-ADR I-ADR
, O-ADR O-ADR
more O-ADR O-ADR
recent O-ADR O-ADR
studies O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
confirmed O-ADR O-ADR
such O-ADR O-ADR
findings O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
of O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
intensity O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
resume O-ADR O-ADR
Ferriprox O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
developed O-ADR O-ADR
agranulocytosis O-ADR O-ADR
unless O-ADR O-ADR
potential O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
potential O-ADR O-ADR
risks O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Exelixis O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
855 O-ADR O-ADR
- O-ADR O-ADR
500 O-ADR O-ADR
- O-ADR O-ADR
3935 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
seen O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
studies O-ADR O-ADR
included O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
malaise B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weakness B-ADR B-ADR
; O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
; O-ADR O-ADR
somnolence B-ADR B-ADR
; O-ADR O-ADR
cough B-ADR B-ADR
; O-ADR O-ADR
constipation B-ADR B-ADR
; O-ADR O-ADR
headache B-ADR B-ADR
; O-ADR O-ADR
mucosal B-ADR B-ADR
inflammation I-ADR I-ADR
and O-ADR O-ADR
stomatitis B-ADR B-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1669 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
49 O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
ILD B-ADR B-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
ILD B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
fatal B-ADR B-ADR
ILD B-ADR B-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
total O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
394 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
; O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
116 O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
PRISTIQ O-ADR O-ADR
for O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
658 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
421 O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
for O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
416 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
Prolongation I-ADR I-ADR
: O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
QT I-ADR I-ADR
interval I-ADR I-ADR
; O-ADR O-ADR
avoid O-ADR O-ADR
use O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
also O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
prolonged O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Immediate O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Immediate O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
Exposure O-ADR O-ADR
in O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
LY O-ADR O-ADR
PRADAXA O-ADR O-ADR
110 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
Warfarin O-ADR O-ADR
Total O-ADR O-ADR
number O-ADR O-ADR
treated O-ADR O-ADR
5983 O-ADR O-ADR
6059 O-ADR O-ADR
5998 O-ADR O-ADR
Exposure O-ADR O-ADR
> O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
4936 O-ADR O-ADR
4939 O-ADR O-ADR
5193 O-ADR O-ADR
> O-ADR O-ADR
24 O-ADR O-ADR
months O-ADR O-ADR
2387 O-ADR O-ADR
2405 O-ADR O-ADR
2470 O-ADR O-ADR
Mean O-ADR O-ADR
exposure O-ADR O-ADR
( O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
20 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
20 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
21 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Total O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
242 O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
261 O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
659 O-ADR O-ADR
Drug O-ADR O-ADR
Discontinuation O-ADR O-ADR
in O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
LY O-ADR O-ADR
The O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
warfarin O-ADR O-ADR
. O-ADR O-ADR
as O-ADR O-ADR
rescue O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
bronchospasm O-ADR O-ADR
. O-ADR O-ADR
Only O-ADR O-ADR
use O-ADR O-ADR
SIRTURO O-ADR O-ADR
when O-ADR O-ADR
an O-ADR O-ADR
effective O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
otherwise O-ADR O-ADR
be O-ADR O-ADR
provided O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
When O-ADR O-ADR
discontinuing O-ADR O-ADR
HORIZANT O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RLS O-ADR O-ADR
receiving O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
can O-ADR O-ADR
discontinue O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
without O-ADR O-ADR
tapering O-ADR O-ADR
. O-ADR O-ADR
DRESS B-ADR B-ADR
typically O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
not O-ADR O-ADR
exclusively O-ADR O-ADR
, O-ADR O-ADR
presents O-ADR O-ADR
with O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
lymphadenopathy B-ADR B-ADR
, O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
organ O-ADR O-ADR
system O-ADR O-ADR
involvement O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
hepatitis B-ADR B-ADR
, O-ADR O-ADR
nephritis B-ADR B-ADR
, O-ADR O-ADR
hematological B-ADR B-ADR
abnormalities I-ADR I-ADR
, O-ADR O-ADR
myocarditis B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
myositis B-ADR B-ADR
sometimes O-ADR O-ADR
resembling O-ADR O-ADR
an O-ADR O-ADR
acute O-ADR O-ADR
viral O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
assessed O-ADR O-ADR
as O-ADR O-ADR
unrelated O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
their O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
experience O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
depression O-ADR O-ADR
, O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
mood O-ADR O-ADR
changes O-ADR O-ADR
. O-ADR O-ADR
Report O-ADR O-ADR
any O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
NSF O-ADR O-ADR
following O-ADR O-ADR
DOTAREM O-ADR O-ADR
administration O-ADR O-ADR
to O-ADR O-ADR
Guerbet O-ADR O-ADR
LLC O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
729 O-ADR O-ADR
- O-ADR O-ADR
6679 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
On O-ADR O-ADR
Day O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
decline B-ADR B-ADR
in I-ADR I-ADR
heart I-ADR I-ADR
rate I-ADR I-ADR
generally O-ADR O-ADR
occurs O-ADR O-ADR
within O-ADR O-ADR
6 O-ADR O-ADR
hours O-ADR O-ADR
and O-ADR O-ADR
recovers O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
levels O-ADR O-ADR
, O-ADR O-ADR
by O-ADR O-ADR
8 O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
hours O-ADR O-ADR
postdose O-ADR O-ADR
. O-ADR O-ADR
Falls B-ADR B-ADR
were O-ADR O-ADR
not O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
loss B-ADR B-ADR
of I-ADR I-ADR
consciousness I-ADR I-ADR
or O-ADR O-ADR
seizure B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
anaphylactic O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
serious O-ADR O-ADR
allergic O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Liver B-ADR B-ADR
injury I-ADR I-ADR
: O-ADR O-ADR
liver O-ADR O-ADR
enzyme O-ADR O-ADR
results O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
available O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Thyroid O-ADR O-ADR
Dysfunction O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
hypothyroidism B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
69 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
29 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
bradycardia B-ADR B-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypotension B-ADR B-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
US O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
compared O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
LABA O-ADR O-ADR
( O-ADR O-ADR
salmeterol O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
usual O-ADR O-ADR
asthma O-ADR O-ADR
therapy O-ADR O-ADR
showed O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
salmeterol O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
reinitiating O-ADR O-ADR
INLYTA O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
previously O-ADR O-ADR
experiencing O-ADR O-ADR
RPLS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Cardiac O-ADR O-ADR
Disorders O-ADR O-ADR
Palpitations B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
appropriate O-ADR O-ADR
, O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
therapy O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
warranted O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
with O-ADR O-ADR
alvimopan O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
CrCl O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
50mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
) O-ADR O-ADR
would O-ADR O-ADR
require O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
strength O-ADR O-ADR
smaller O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
, O-ADR O-ADR
AMPYRA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Consultation O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
specialist O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
neurologist O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
infectious O-ADR O-ADR
disease O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
suspected O-ADR O-ADR
or O-ADR O-ADR
confirmed O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
events O-ADR O-ADR
were O-ADR O-ADR
counted O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
or O-ADR O-ADR
within O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
stopping O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
wound O-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
complications O-ADR I-ADR
may O-ADR O-ADR
require O-ADR O-ADR
surgical O-ADR O-ADR
intervention O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
a O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
standing O-ADR O-ADR
concern O-ADR O-ADR
, O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
that O-ADR O-ADR
antidepressants O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
role O-ADR O-ADR
in O-ADR O-ADR
inducing O-ADR O-ADR
worsening B-ADR B-ADR
of I-ADR I-ADR
depression I-ADR I-ADR
and O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidality B-ADR B-ADR
in O-ADR O-ADR
certain O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
early O-ADR O-ADR
phases O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Complete O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infections O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Venous B-ADR B-ADR
Thromboembolism I-ADR I-ADR
: O-ADR O-ADR
Deep B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
types O-ADR O-ADR
of O-ADR O-ADR
AR O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
withdrawal O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
varied O-ADR O-ADR
considerably O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
cutaneous B-ADR B-ADR
squamous I-ADR I-ADR
cell I-ADR I-ADR
carcinomas I-ADR I-ADR
and O-ADR O-ADR
keratoacanthomas B-ADR B-ADR
( O-ADR O-ADR
cuSCC B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
187 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
dacarbazine O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
had O-ADR O-ADR
platelet B-ADR B-ADR
counts I-ADR I-ADR
of I-ADR I-ADR
less I-ADR I-ADR
than I-ADR I-ADR
50 I-ADR I-ADR
* I-ADR O-ADR
10 I-ADR I-ADR
9 I-ADR I-ADR
per I-ADR I-ADR
L I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Classical O-ADR O-ADR
HL O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
auto O-ADR O-ADR
- O-ADR O-ADR
HSCT O-ADR O-ADR
Consolidation O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
ADCETRIS O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
329 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
at O-ADR O-ADR
high O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
relapse O-ADR O-ADR
or O-ADR O-ADR
progression O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
auto O-ADR O-ADR
- O-ADR O-ADR
HSCT O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
starting O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
schedule O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
administered O-ADR O-ADR
intravenously O-ADR O-ADR
over O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
16 O-ADR O-ADR
cycles O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
surveillance O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
women O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
Antibodies O-ADR O-ADR
to O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
golimumab O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
following O-ADR O-ADR
IV O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
MTX O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Direct B-ADR B-ADR
Coombs I-ADR I-ADR
' I-ADR I-ADR
test I-ADR I-ADR
seroconversion I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
Teflaro O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
size O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
limited O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
studies O-ADR O-ADR
precludes O-ADR O-ADR
the O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
draw O-ADR O-ADR
firm O-ADR O-ADR
conclusions O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
, O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
medication O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
resolved O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Macrophage O-ADR O-ADR
Activation O-ADR O-ADR
Syndrome O-ADR O-ADR
Macrophage O-ADR B-ADR
activation O-ADR I-ADR
syndrome O-ADR I-ADR
( O-ADR O-ADR
MAS O-ADR B-ADR
) O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
disorder O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
develop O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
rheumatic O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
particular O-ADR O-ADR
SJIA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
aggressively O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
fluid O-ADR O-ADR
and O-ADR O-ADR
electrolyte O-ADR O-ADR
management O-ADR O-ADR
, O-ADR O-ADR
protein O-ADR O-ADR
supplementation O-ADR O-ADR
, O-ADR O-ADR
antibiotic O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
surgical O-ADR O-ADR
evaluation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instituted O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Post O-ADR O-ADR
Marketing O-ADR O-ADR
Experience O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
rarely O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
BEPREVE O-ADR O-ADR
. O-ADR O-ADR
Test O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
HBV O-ADR O-ADR
infection O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
end O-ADR O-ADR
- O-ADR O-ADR
stage O-ADR O-ADR
renal O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
hepatic O-ADR O-ADR
contrast O-ADR O-ADR
was O-ADR O-ADR
markedly O-ADR O-ADR
reduced O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
elevated O-ADR B-ADR
serum O-ADR I-ADR
ferritin O-ADR I-ADR
levels O-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
disturbances O-ADR O-ADR
of O-ADR O-ADR
electrolyte O-ADR O-ADR
balance O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
hypokalemia O-ADR O-ADR
or O-ADR O-ADR
hypomagnesemia O-ADR O-ADR
. O-ADR O-ADR
Percentages O-ADR O-ADR
calculated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
male O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
group O-ADR O-ADR
as O-ADR O-ADR
denominator O-ADR O-ADR
: O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
514 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
556 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
557 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
ANC B-ADR O-ADR
less I-ADR O-ADR
than I-ADR O-ADR
0 I-ADR O-ADR
. O-ADR O-ADR
5x10 O-ADR O-ADR
9 I-ADR O-ADR
/ I-ADR O-ADR
L O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ILARIS O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Elevations O-ADR B-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
GILENYA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Contracture O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
BENLYSTA O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
673 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
111 O-ADR O-ADR
; O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
only O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
674 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
675 O-ADR O-ADR
) O-ADR O-ADR
intravenously O-ADR O-ADR
over O-ADR O-ADR
a O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
hour O-ADR O-ADR
period O-ADR O-ADR
on O-ADR O-ADR
Days O-ADR O-ADR
0 O-ADR O-ADR
, O-ADR O-ADR
14 O-ADR O-ADR
, O-ADR O-ADR
28 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
every O-ADR O-ADR
28 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
that O-ADR O-ADR
reduced O-ADR O-ADR
immunosuppression O-ADR O-ADR
represents O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
functioning O-ADR O-ADR
allograft O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
pooled O-ADR O-ADR
mean O-ADR O-ADR
maximum O-ADR O-ADR
dose O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
hour O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
hours O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
initial O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
fever B-ADR B-ADR
was O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
19 O-ADR O-ADR
days O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
fever B-ADR B-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
days O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
4 O-ADR O-ADR
days O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
AMPYRA O-ADR O-ADR
is O-ADR O-ADR
eliminated O-ADR O-ADR
through O-ADR O-ADR
the O-ADR O-ADR
kidneys O-ADR O-ADR
primarily O-ADR O-ADR
as O-ADR O-ADR
unchanged O-ADR O-ADR
drug O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
cautiously O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
seizure O-ADR O-ADR
disorder O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
between O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
one O-ADR O-ADR
death B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
on O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Hepatic O-ADR O-ADR
function O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
closely O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
YERVOY O-ADR O-ADR
dosing O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
compromised O-ADR O-ADR
cardiac O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
acute B-ADR B-ADR
exacerbation I-ADR I-ADR
of I-ADR I-ADR
their I-ADR I-ADR
cardiac I-ADR I-ADR
or I-ADR I-ADR
respiratory I-ADR I-ADR
compromise I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
fluid B-ADR B-ADR
overload I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
additional O-ADR O-ADR
monitoring O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
chosen O-ADR O-ADR
for O-ADR O-ADR
inclusion O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
either O-ADR O-ADR
their O-ADR O-ADR
seriousness O-ADR O-ADR
, O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
reporting O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
causal O-ADR O-ADR
connection O-ADR O-ADR
to O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
HORIZANT O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
the O-ADR O-ADR
somnolence B-ADR B-ADR
persisted O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
about O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Proteinuria O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
proteinuria B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
26 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypokalemia B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
each O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
KALYDECO O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
, O-ADR O-ADR
all O-ADR O-ADR
> O-ADR O-ADR
8 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
reductions O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
59 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
pregnancy O-ADR O-ADR
is O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Edarbi O-ADR O-ADR
as O-ADR O-ADR
soon O-ADR O-ADR
as O-ADR O-ADR
possible O-ADR O-ADR
[ O-ADR O-ADR
seeUse O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
DISTANT B-ADR B-ADR
SPREAD I-ADR I-ADR
OF I-ADR I-ADR
TOXIN I-ADR I-ADR
EFFECT I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
DISTANT B-ADR B-ADR
SPREAD I-ADR I-ADR
OF I-ADR I-ADR
TOXIN I-ADR I-ADR
EFFECT I-ADR I-ADR
Postmarketing O-ADR O-ADR
reports O-ADR O-ADR
indicate O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
spread B-ADR B-ADR
from I-ADR I-ADR
the I-ADR I-ADR
area I-ADR I-ADR
of I-ADR I-ADR
injection I-ADR I-ADR
to O-ADR O-ADR
produce O-ADR I-ADR
symptoms O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR I-ADR
botulinum O-ADR I-ADR
toxin B-ADR I-ADR
effects I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Decrease B-ADR B-ADR
in I-ADR I-ADR
pulmonary I-ADR I-ADR
function I-ADR I-ADR
tests I-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Obtain O-ADR O-ADR
PFT O-ADR O-ADR
when O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Less O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
included O-ADR O-ADR
dysphagia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
gait B-ADR B-ADR
disturbance I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
hypertonia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sensation B-ADR B-ADR
of I-ADR I-ADR
heaviness I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anaphylaxis O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
immediately O-ADR O-ADR
discontinue O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
than O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
most O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
became O-ADR O-ADR
noticeable O-ADR O-ADR
about O-ADR O-ADR
one O-ADR O-ADR
week O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
lasted O-ADR O-ADR
several O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
glucose O-ADR O-ADR
levels O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
hemoglobin O-ADR O-ADR
A1c O-ADR O-ADR
( O-ADR O-ADR
HbA1c O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
or O-ADR O-ADR
refractory O-ADR O-ADR
PTCL O-ADR O-ADR
. O-ADR O-ADR
Tables O-ADR O-ADR
5 O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
summarize O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
in O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
low O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
WBC O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
their O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
CBC O-ADR O-ADR
) O-ADR O-ADR
monitored O-ADR O-ADR
frequently O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
few O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
decline O-ADR O-ADR
in O-ADR O-ADR
WBC O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
causative O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
seeUse O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
signs O-ADR O-ADR
suggesting O-ADR O-ADR
allergic O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
in O-ADR O-ADR
particular O-ADR O-ADR
, O-ADR O-ADR
difficulties O-ADR O-ADR
in O-ADR O-ADR
breathing O-ADR O-ADR
or O-ADR O-ADR
swallowing O-ADR O-ADR
, O-ADR O-ADR
swelling O-ADR O-ADR
of O-ADR O-ADR
tongue O-ADR O-ADR
, O-ADR O-ADR
lips O-ADR O-ADR
and O-ADR O-ADR
face O-ADR O-ADR
, O-ADR O-ADR
urticaria O-ADR O-ADR
, O-ADR O-ADR
skin O-ADR O-ADR
rash O-ADR O-ADR
) O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
and O-ADR O-ADR
alternative O-ADR O-ADR
therapy O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
Withholding O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
serious O-ADR O-ADR
infections O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
infection O-ADR O-ADR
( O-ADR O-ADR
s O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
resolved O-ADR O-ADR
. O-ADR O-ADR
Events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
dizziness B-ADR B-ADR
and O-ADR O-ADR
disturbance B-ADR B-ADR
in I-ADR I-ADR
gait I-ADR I-ADR
were O-ADR O-ADR
more O-ADR O-ADR
often O-ADR O-ADR
serious O-ADR O-ADR
in O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
often O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
withdrawal O-ADR O-ADR
in O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Management O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reaction O-ADR O-ADR
and O-ADR O-ADR
include O-ADR O-ADR
slowing O-ADR O-ADR
or O-ADR O-ADR
temporary O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
additional O-ADR O-ADR
antihistamines O-ADR O-ADR
, O-ADR O-ADR
antipyretics O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
corticosteroids O-ADR O-ADR
for O-ADR O-ADR
mild O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
thigh O-ADR O-ADR
or O-ADR O-ADR
groin O-ADR O-ADR
pain O-ADR O-ADR
to O-ADR O-ADR
rule O-ADR O-ADR
out O-ADR O-ADR
a O-ADR O-ADR
femoral O-ADR O-ADR
fracture O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
including O-ADR O-ADR
skin B-ADR B-ADR
infections I-ADR I-ADR
: O-ADR O-ADR
May O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
those O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
BEPREVE O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
contact O-ADR O-ADR
lens O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
irritation O-ADR O-ADR
. O-ADR O-ADR
d O-ADR O-ADR
Includes O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
malaise B-ADR B-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
PRADAXA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
pathological O-ADR O-ADR
bleeding O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Increase O-ADR O-ADR
in O-ADR O-ADR
Serum O-ADR O-ADR
Inorganic O-ADR O-ADR
Phosphorus O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
13 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
increases B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
mean I-ADR I-ADR
serum I-ADR I-ADR
phosphorus I-ADR I-ADR
levels I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
in O-ADR O-ADR
FARXIGA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
increase O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
versus O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
04 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Institute O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
Prescribers O-ADR O-ADR
should O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
somnolence O-ADR O-ADR
and O-ADR O-ADR
sedation O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
depressants O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
HALAVEN O-ADR O-ADR
was O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
substantial O-ADR O-ADR
evidence O-ADR O-ADR
that O-ADR O-ADR
COCs O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
breast B-ADR B-ADR
cancer I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
pneumonitis O-ADR O-ADR
thought O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
Zydelig O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Deterioration O-ADR O-ADR
of O-ADR O-ADR
Disease O-ADR O-ADR
and O-ADR O-ADR
Acute O-ADR O-ADR
Episodes O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
rapidly O-ADR O-ADR
deteriorating O-ADR O-ADR
or O-ADR O-ADR
potentially O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Assess O-ADR O-ADR
for O-ADR O-ADR
decrease O-ADR O-ADR
in O-ADR O-ADR
bone O-ADR O-ADR
mineral O-ADR O-ADR
density O-ADR O-ADR
initially O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
neurological O-ADR O-ADR
compromise O-ADR O-ADR
is O-ADR O-ADR
noted O-ADR O-ADR
, O-ADR O-ADR
urgent O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
necessary O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
before O-ADR O-ADR
neuraxial O-ADR O-ADR
intervention O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
anticoagulated O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
anticoagulated O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Therapeutic O-ADR O-ADR
Monitoring O-ADR O-ADR
Plasma O-ADR O-ADR
ammonia O-ADR O-ADR
levels O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
maintained O-ADR O-ADR
within O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
for O-ADR O-ADR
age O-ADR O-ADR
via O-ADR O-ADR
individual O-ADR O-ADR
dose O-ADR O-ADR
adjustment O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Confidence O-ADR O-ADR
interval O-ADR O-ADR
Patients O-ADR O-ADR
Major O-ADR O-ADR
bleeding B-ADR B-ADR
event O-ADR O-ADR
a O-ADR O-ADR
Clinically O-ADR O-ADR
relevant O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
Any O-ADR O-ADR
bleeding B-ADR B-ADR
In O-ADR O-ADR
the O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
SONATE O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
gastrointestinal B-ADR B-ADR
bleeds I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Factors O-ADR O-ADR
that O-ADR O-ADR
can O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
epidural O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
hematomas O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
indwelling O-ADR O-ADR
epidural O-ADR O-ADR
catheters O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
affect O-ADR O-ADR
hemostasis O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
steroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
NSAIDs O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
platelet O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
anticoagulants O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
traumatic O-ADR O-ADR
or O-ADR O-ADR
repeated O-ADR O-ADR
epidural O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
punctures O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
spinal O-ADR O-ADR
deformity O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
surgery O-ADR O-ADR
optimal O-ADR O-ADR
timing O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
and O-ADR O-ADR
neuraxial O-ADR O-ADR
procedures O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
ZYKADIA O-ADR O-ADR
until O-ADR O-ADR
hyperglycemia O-ADR O-ADR
is O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
resume O-ADR O-ADR
ZYKADIA O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
permanently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
intestinal O-ADR O-ADR
perforation O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
taking O-ADR O-ADR
Zydelig O-ADR O-ADR
who O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
pulmonary O-ADR O-ADR
symptoms O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
cough O-ADR O-ADR
, O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
hypoxia O-ADR O-ADR
, O-ADR O-ADR
interstitial O-ADR O-ADR
infiltrates O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
radiologic O-ADR O-ADR
exam O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
decline O-ADR O-ADR
by O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
oxygen O-ADR O-ADR
saturation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
pneumonitis O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
sera O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
screening O-ADR O-ADR
immunoassay O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
biological O-ADR O-ADR
assay O-ADR O-ADR
was O-ADR O-ADR
performed O-ADR O-ADR
to O-ADR O-ADR
detect O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
28 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
79 O-ADR O-ADR
% O-ADR O-ADR
experienced O-ADR O-ADR
complete O-ADR O-ADR
resolution O-ADR O-ADR
, O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
improved O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
improve O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
blinatumomab O-ADR O-ADR
antibody O-ADR O-ADR
formation O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
reported O-ADR O-ADR
retinopathy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Neurological O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Dizziness O-ADR O-ADR
and O-ADR O-ADR
Disturbance O-ADR O-ADR
in O-ADR O-ADR
Gait O-ADR O-ADR
and O-ADR O-ADR
Coordination O-ADR O-ADR
APTIOM O-ADR O-ADR
causes O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
dizziness B-ADR B-ADR
and O-ADR O-ADR
disturbance B-ADR B-ADR
in I-ADR I-ADR
gait I-ADR I-ADR
( O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
ataxia B-ADR B-ADR
, O-ADR O-ADR
vertigo B-ADR B-ADR
, O-ADR O-ADR
balance B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
gait B-ADR B-ADR
disturbance I-ADR I-ADR
, O-ADR O-ADR
nystagmus B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
abnormal B-ADR B-ADR
coordination I-ADR I-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hemorrhage O-ADR O-ADR
Fatal B-ADR B-ADR
bleeding B-ADR B-ADR
events I-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Spinal O-ADR O-ADR
or O-ADR O-ADR
Cervical O-ADR O-ADR
Cord O-ADR O-ADR
Compression O-ADR O-ADR
Spinal O-ADR O-ADR
or O-ADR O-ADR
cervical O-ADR O-ADR
cord O-ADR O-ADR
compression O-ADR O-ADR
( O-ADR O-ADR
SCC O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
complication O-ADR O-ADR
of O-ADR O-ADR
MPS O-ADR O-ADR
IVA O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
as O-ADR O-ADR
part O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
natural O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
38 O-ADR O-ADR
weeks O-ADR O-ADR
with O-ADR O-ADR
1832 O-ADR O-ADR
individuals O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
50 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
men O-ADR O-ADR
were O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1000 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
800 O-ADR O-ADR
IU O-ADR O-ADR
of O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
supplementation O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
if O-ADR O-ADR
DUAVEE O-ADR O-ADR
passes O-ADR O-ADR
into O-ADR O-ADR
your O-ADR O-ADR
breast O-ADR O-ADR
milk O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
describes O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
arm O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
that O-ADR O-ADR
therapeutic O-ADR O-ADR
infectious O-ADR O-ADR
agents O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
concurrently O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cardiovascular O-ADR O-ADR
disorders O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
stimulation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Blood O-ADR B-ADR
pressure O-ADR I-ADR
( O-ADR I-ADR
BP O-ADR I-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
BP O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Infections O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
died B-ADR B-ADR
from O-ADR O-ADR
infections B-ADR B-ADR
or O-ADR O-ADR
sepsis B-ADR B-ADR
. O-ADR O-ADR
Testing O-ADR O-ADR
was O-ADR O-ADR
performed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
hypersensitivity B-ADR O-ADR
reactions I-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
mast O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
activation O-ADR O-ADR
was O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Weight O-ADR O-ADR
Decrease O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
psoriatic O-ADR O-ADR
arthritis O-ADR O-ADR
( O-ADR O-ADR
PsA O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decrease I-ADR I-ADR
between O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
- O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
body O-ADR O-ADR
weight O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
49 O-ADR O-ADR
/ O-ADR O-ADR
497 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
/ O-ADR O-ADR
495 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
LACTIC B-ADR B-ADR
ACIDOSIS O-ADR O-ADR
/ O-ADR O-ADR
SEVERE O-ADR O-ADR
HEPATOMEGALY B-ADR B-ADR
WITH O-ADR O-ADR
STEATOSIS B-ADR B-ADR
and O-ADR O-ADR
POST O-ADR O-ADR
TREATMENT O-ADR O-ADR
ACUTE B-ADR B-ADR
EXACERBATION I-ADR I-ADR
OF I-ADR I-ADR
HEPATITIS I-ADR I-ADR
B I-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
prednisone O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
fracture O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
Serum O-ADR O-ADR
follicle O-ADR O-ADR
stimulating O-ADR O-ADR
hormone O-ADR O-ADR
( O-ADR O-ADR
FSH O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
estradiol O-ADR O-ADR
levels O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
useful O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
vasomotor O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
aspiration O-ADR O-ADR
pneumonia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
also O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
notable O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
seriousness O-ADR O-ADR
, O-ADR O-ADR
severity O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
increased O-ADR O-ADR
frequency O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
only O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
MAOI O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
additional O-ADR O-ADR
estrogens O-ADR O-ADR
as O-ADR O-ADR
this O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
endometrial O-ADR O-ADR
hyperplasia O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
erection O-ADR O-ADR
that O-ADR O-ADR
persists O-ADR O-ADR
longer O-ADR O-ADR
than O-ADR O-ADR
4 O-ADR O-ADR
hours O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
assistance O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
evidence O-ADR O-ADR
to O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
high O-ADR O-ADR
and O-ADR O-ADR
sustained O-ADR O-ADR
IgG O-ADR O-ADR
antibody O-ADR O-ADR
titers O-ADR O-ADR
may O-ADR O-ADR
experience O-ADR O-ADR
reduced B-ADR O-ADR
clinical I-ADR O-ADR
efficacy I-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
loss B-ADR B-ADR
of I-ADR I-ADR
motor I-ADR I-ADR
function I-ADR I-ADR
, O-ADR O-ADR
ventilator O-ADR O-ADR
dependence O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
because O-ADR O-ADR
ILARIS O-ADR O-ADR
may O-ADR O-ADR
interfere B-ADR O-ADR
with I-ADR O-ADR
normal I-ADR O-ADR
immune I-ADR O-ADR
response I-ADR O-ADR
to O-ADR O-ADR
new O-ADR O-ADR
antigens O-ADR O-ADR
, O-ADR O-ADR
vaccinations O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
effective O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
Subgroup O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
women O-ADR O-ADR
50 O-ADR O-ADR
to O-ADR O-ADR
59 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
suggest O-ADR O-ADR
a O-ADR O-ADR
statistically O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
significant O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
CHD B-ADR B-ADR
events O-ADR I-ADR
( O-ADR O-ADR
CE O-ADR O-ADR
[ O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
625 O-ADR O-ADR
mg O-ADR O-ADR
] O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
years O-ADR O-ADR
since O-ADR O-ADR
menopause O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
versus O-ADR O-ADR
16 O-ADR O-ADR
per O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
women O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
for O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
investigational O-ADR O-ADR
uses O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
among O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
657 O-ADR O-ADR
Cimzia O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
Hodgkin B-ADR B-ADR
' I-ADR I-ADR
s O-ADR O-ADR
lymphoma I-ADR I-ADR
among O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
319 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Coronary O-ADR O-ADR
Heart O-ADR O-ADR
Disease O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
WHI O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
substudy O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
overall O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
coronary B-ADR B-ADR
heart I-ADR I-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
CHD B-ADR B-ADR
) O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
nonfatal O-ADR B-ADR
myocardial B-ADR I-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
silent B-ADR B-ADR
myocardial I-ADR I-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
CHD B-ADR B-ADR
death I-ADR I-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
receiving O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
attentive O-ADR O-ADR
to O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
SJIA O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
these O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
triggers O-ADR O-ADR
for O-ADR O-ADR
MAS O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
serotonergic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
triptans O-ADR O-ADR
, O-ADR O-ADR
tricyclic O-ADR O-ADR
antidepressants O-ADR O-ADR
, O-ADR O-ADR
fentanyl O-ADR O-ADR
, O-ADR O-ADR
lithium O-ADR O-ADR
, O-ADR O-ADR
tramadol O-ADR O-ADR
, O-ADR O-ADR
buspirone O-ADR O-ADR
, O-ADR O-ADR
tryptophan O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
St O-ADR O-ADR
. O-ADR O-ADR
John O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Wort O-ADR O-ADR
is O-ADR O-ADR
clinically O-ADR O-ADR
warranted O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
aware O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
serotonin O-ADR O-ADR
syndrome O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
and O-ADR O-ADR
dose O-ADR O-ADR
increases O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
with O-ADR O-ADR
bleomycin O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
28 O-ADR O-ADR
women O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
19 O-ADR O-ADR
women O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
diagnosed O-ADR O-ADR
with O-ADR O-ADR
probable O-ADR O-ADR
dementia B-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
DIFICID O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
tablets O-ADR O-ADR
taken O-ADR O-ADR
twice O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
for O-ADR O-ADR
10 O-ADR O-ADR
days O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
564 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CDAD O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
comparator O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
86 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
a O-ADR O-ADR
full O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
show O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidality B-ADR B-ADR
with O-ADR O-ADR
antidepressants O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
beyond O-ADR O-ADR
age O-ADR O-ADR
24 O-ADR O-ADR
; O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
antidepressants O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
aged O-ADR O-ADR
65 O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
290 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
trials O-ADR O-ADR
enrolling O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
markedly O-ADR O-ADR
delayed O-ADR O-ADR
methotrexate O-ADR O-ADR
clearance O-ADR O-ADR
secondary O-ADR O-ADR
to O-ADR O-ADR
renal O-ADR O-ADR
dysfunction O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
term O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
other O-ADR O-ADR
types O-ADR O-ADR
of O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
also O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
: O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hematoma I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
erythema I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
rash I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hypersensitivity I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hemorrhage I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunosuppression O-ADR O-ADR
The O-ADR O-ADR
impact O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
interleukin O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
IL O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
therapy O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
malignancies O-ADR B-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GlaxoSmithKline O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
825 O-ADR O-ADR
- O-ADR O-ADR
5249 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
ENTEREG O-ADR O-ADR
REMS O-ADR O-ADR
Program O-ADR O-ADR
that O-ADR O-ADR
restricts O-ADR O-ADR
use O-ADR O-ADR
to O-ADR O-ADR
enrolled O-ADR O-ADR
hospitals O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ENTEREG O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
miss O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
, O-ADR O-ADR
take O-ADR O-ADR
it O-ADR O-ADR
as O-ADR O-ADR
soon O-ADR O-ADR
as O-ADR O-ADR
you O-ADR O-ADR
remember O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
YERVOY O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
neuropathy O-ADR O-ADR
( O-ADR O-ADR
interfering O-ADR O-ADR
with O-ADR O-ADR
daily O-ADR O-ADR
activities O-ADR O-ADR
) O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Guillain O-ADR O-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
- O-ADR O-ADR
like O-ADR O-ADR
syndromes O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
ADRs O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
FLAMINGO O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
those O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
SINGLE O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
laboratory O-ADR O-ADR
and O-ADR O-ADR
ECG O-ADR O-ADR
effects O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
separately O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
64 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
GILOTRIF O-ADR O-ADR
and O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
pemetrexed O-ADR O-ADR
/ O-ADR O-ADR
cisplatin O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
safe O-ADR O-ADR
handling O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
workers O-ADR O-ADR
from O-ADR O-ADR
unintentional O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
some O-ADR O-ADR
basis O-ADR O-ADR
to O-ADR O-ADR
believe O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
. O-ADR O-ADR
INLYTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
untreated O-ADR O-ADR
brain O-ADR O-ADR
metastasis O-ADR O-ADR
or O-ADR O-ADR
recent O-ADR O-ADR
active O-ADR O-ADR
gastrointestinal O-ADR O-ADR
bleeding O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GlaxoSmithKline O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
825 O-ADR O-ADR
- O-ADR O-ADR
5249 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
fluid O-ADR O-ADR
volume O-ADR O-ADR
overload O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
insulin O-ADR O-ADR
therapy O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hyperglycemia O-ADR O-ADR
. O-ADR O-ADR
HORIZANT O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
prodrug O-ADR O-ADR
of O-ADR O-ADR
gabapentin O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
was O-ADR O-ADR
generally O-ADR O-ADR
consistent O-ADR O-ADR
among O-ADR O-ADR
drugs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
data O-ADR O-ADR
analyzed O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
any O-ADR O-ADR
AED O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
, O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
unusual O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
mood O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
. O-ADR O-ADR
Obtain O-ADR O-ADR
an O-ADR O-ADR
ECG O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
the O-ADR O-ADR
consequence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
surgical O-ADR O-ADR
procedure O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Paradoxical O-ADR O-ADR
Bronchospasm O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
inhaled O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
may O-ADR O-ADR
produce O-ADR O-ADR
paradoxical B-ADR B-ADR
bronchospasm I-ADR I-ADR
that O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
dermatologic O-ADR O-ADR
reaction O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
APTIOM O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
unless O-ADR O-ADR
the O-ADR O-ADR
reaction O-ADR O-ADR
is O-ADR O-ADR
clearly O-ADR O-ADR
not O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
867 O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
clinical O-ADR O-ADR
phase O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
28 O-ADR O-ADR
cycles O-ADR O-ADR
with O-ADR O-ADR
Natazia O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
oral O-ADR O-ADR
contraceptive O-ADR O-ADR
and O-ADR O-ADR
264 O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
cycles O-ADR O-ADR
evaluating O-ADR O-ADR
Natazia O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
heavy O-ADR O-ADR
, O-ADR O-ADR
prolonged O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
frequent O-ADR O-ADR
menstrual O-ADR O-ADR
bleeding O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
without O-ADR O-ADR
organic O-ADR O-ADR
pathology O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
include O-ADR O-ADR
itching B-ADR B-ADR
, O-ADR O-ADR
body B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
swelling B-ADR B-ADR
of I-ADR I-ADR
lips I-ADR I-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
possible O-ADR O-ADR
cause O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
joint O-ADR O-ADR
pain O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
drug O-ADR O-ADR
if O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressants O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
not O-ADR O-ADR
taking O-ADR O-ADR
immunosuppressants O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
immunogenicity O-ADR O-ADR
of O-ADR O-ADR
BLINCYTO O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
using O-ADR O-ADR
either O-ADR O-ADR
an O-ADR O-ADR
electrochemiluminescence O-ADR O-ADR
detection O-ADR O-ADR
technology O-ADR O-ADR
( O-ADR O-ADR
ECL O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
enzyme O-ADR O-ADR
- O-ADR O-ADR
linked O-ADR O-ADR
immunosorbent O-ADR O-ADR
assay O-ADR O-ADR
( O-ADR O-ADR
ELISA O-ADR O-ADR
) O-ADR O-ADR
screening O-ADR O-ADR
immunoassay O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
binding O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
blinatumomab O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
systemic B-ADR B-ADR
hypersensitivity I-ADR I-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
transaminases B-ADR B-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
, O-ADR O-ADR
local B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
thrombosis B-ADR B-ADR
, O-ADR O-ADR
hyperbilirubinemia B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
shows O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
Neuropathy B-ADR B-ADR
lasting O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
associated O-ADR I-ADR
with O-ADR I-ADR
the O-ADR I-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
( I-ADR O-ADR
1 I-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% I-ADR O-ADR
) I-ADR O-ADR
, I-ADR O-ADR
problems I-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
suggest O-ADR O-ADR
SJS O-ADR O-ADR
/ O-ADR O-ADR
TEN O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
resumed O-ADR O-ADR
and O-ADR O-ADR
alternative O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
Zydelig O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
ALT O-ADR O-ADR
or O-ADR O-ADR
AST O-ADR O-ADR
is O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
continue O-ADR O-ADR
to O-ADR O-ADR
monitor O-ADR O-ADR
AST O-ADR O-ADR
, O-ADR O-ADR
ALT O-ADR O-ADR
and O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
weekly O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
abnormality O-ADR O-ADR
is O-ADR O-ADR
resolved O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
COC O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
cholestasis B-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
the O-ADR O-ADR
condition O-ADR O-ADR
recur O-ADR O-ADR
with O-ADR O-ADR
subsequent O-ADR O-ADR
COC O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Withdrawal O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
convulsions O-ADR B-ADR
, O-ADR O-ADR
psychosis O-ADR B-ADR
, O-ADR O-ADR
hallucinations O-ADR B-ADR
, O-ADR O-ADR
behavioral O-ADR B-ADR
disorder O-ADR I-ADR
, O-ADR O-ADR
tremor O-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anxiety O-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
abrupt O-ADR O-ADR
discontinuance O-ADR O-ADR
of O-ADR O-ADR
benzodiazepines O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
uncommonly O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
AdreView O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
completed O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
completed O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
with O-ADR O-ADR
hypertriglyceridemia O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
thereof O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
pancreatitis B-ADR B-ADR
when O-ADR O-ADR
using O-ADR O-ADR
COCs O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
hypertension B-ADR B-ADR
increases O-ADR O-ADR
with O-ADR O-ADR
increasing O-ADR O-ADR
concentration O-ADR O-ADR
of O-ADR O-ADR
progestin O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
genital O-ADR O-ADR
mycotic O-ADR O-ADR
infections O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infection I-ADR I-ADR
during O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
than O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
prior O-ADR O-ADR
history O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
23 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
25 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
FARXIGA O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
were O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
melanoma O-ADR O-ADR
skin I-ADR I-ADR
cancer I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
401 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
/ O-ADR O-ADR
405 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
cyclosporine O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
at O-ADR O-ADR
each O-ADR O-ADR
visit O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
endocrinopathy O-ADR O-ADR
. O-ADR O-ADR
POTIGA O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
weight B-ADR B-ADR
gain I-ADR I-ADR
, O-ADR O-ADR
with O-ADR O-ADR
mean O-ADR O-ADR
weight B-ADR B-ADR
increasing I-ADR I-ADR
by O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
kg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
900 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Cytopenias O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
cytopenias B-ADR B-ADR
including O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
19 O-ADR O-ADR
to O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anemia B-ADR B-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hepatic O-ADR O-ADR
Effects O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
fatal B-ADR B-ADR
and O-ADR O-ADR
nonfatal O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
NESINA O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
some O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reports O-ADR O-ADR
contain O-ADR O-ADR
insufficient O-ADR O-ADR
information O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
the O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
QTc O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
500 O-ADR O-ADR
ms O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
60 O-ADR O-ADR
ms O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
with O-ADR O-ADR
Torsade O-ADR O-ADR
de O-ADR O-ADR
pointes O-ADR O-ADR
or O-ADR O-ADR
polymorphic O-ADR O-ADR
ventricular O-ADR O-ADR
tachycardia O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
/ O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
arrhythmia O-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ophthalmic O-ADR O-ADR
steroids O-ADR O-ADR
include O-ADR O-ADR
elevated B-ADR B-ADR
intraocular I-ADR I-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
optic B-ADR B-ADR
nerve I-ADR I-ADR
damage I-ADR I-ADR
, O-ADR O-ADR
visual B-ADR B-ADR
acuity I-ADR I-ADR
and I-ADR O-ADR
field I-ADR B-ADR
defects I-ADR I-ADR
, O-ADR O-ADR
posterior B-ADR B-ADR
subcapsular I-ADR I-ADR
cataract I-ADR I-ADR
formation I-ADR O-ADR
; O-ADR O-ADR
secondary B-ADR B-ADR
ocular I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
perforation B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
globe I-ADR I-ADR
where O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
thinning O-ADR B-ADR
of O-ADR I-ADR
the O-ADR I-ADR
cornea O-ADR I-ADR
or O-ADR O-ADR
sclera O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
ECG B-ADR B-ADR
changes I-ADR I-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
flattening B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
T I-ADR I-ADR
wave I-ADR I-ADR
, O-ADR O-ADR
prolongation B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
QTc I-ADR I-ADR
interval I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ST B-ADR B-ADR
segment I-ADR I-ADR
depression I-ADR I-ADR
, O-ADR O-ADR
although O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
findings O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
PRADAXA O-ADR O-ADR
were O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
bleeding B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
emtricitabine O-ADR O-ADR
and O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
components O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
are O-ADR O-ADR
primarily O-ADR O-ADR
excreted O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
kidney O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
medical O-ADR O-ADR
support O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cardiopulmonary O-ADR O-ADR
resuscitation O-ADR O-ADR
equipment O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
readily O-ADR O-ADR
available O-ADR O-ADR
when O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
onset O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
hypertension B-ADR B-ADR
( O-ADR O-ADR
systolic B-ADR O-ADR
blood I-ADR O-ADR
pressure I-ADR O-ADR
> I-ADR O-ADR
150 I-ADR O-ADR
mmHg I-ADR O-ADR
or O-ADR O-ADR
diastolic B-ADR O-ADR
blood I-ADR O-ADR
pressure I-ADR O-ADR
> I-ADR O-ADR
100 I-ADR O-ADR
mmHg I-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
INLYTA O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
increases I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
4 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Peripheral B-ADR B-ADR
neuropathies I-ADR I-ADR
NEC I-ADR I-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
under O-ADR O-ADR
HLT O-ADR B-ADR
peripheral B-ADR I-ADR
neuropathies I-ADR I-ADR
NEC I-ADR I-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
acute B-ADR O-ADR
exacerbations I-ADR O-ADR
of I-ADR O-ADR
hepatitis I-ADR O-ADR
B I-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
coinfected O-ADR O-ADR
with O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
human O-ADR O-ADR
immunodeficiency O-ADR O-ADR
virus O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
discontinued O-ADR O-ADR
EMTRIVA O-ADR O-ADR
or O-ADR O-ADR
VIREAD O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
are O-ADR O-ADR
components O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
Causes O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
on O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
arm O-ADR O-ADR
included O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
each O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
death B-ADR B-ADR
( O-ADR O-ADR
cause O-ADR O-ADR
unknown O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Angioedema O-ADR O-ADR
Angioedema B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
face I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
fesoterodine O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
could O-ADR O-ADR
cross O-ADR O-ADR
over O-ADR O-ADR
to O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
AFINITOR O-ADR O-ADR
upon O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
YERVOY O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Stevens O-ADR O-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome O-ADR O-ADR
, O-ADR O-ADR
toxic O-ADR O-ADR
epidermal O-ADR O-ADR
necrolysis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
rash O-ADR O-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
full O-ADR O-ADR
thickness O-ADR O-ADR
dermal O-ADR O-ADR
ulceration O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
necrotic O-ADR O-ADR
, O-ADR O-ADR
bullous O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
hemorrhagic O-ADR O-ADR
manifestations O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
26 O-ADR O-ADR
weeks O-ADR O-ADR
duration O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
conducted O-ADR O-ADR
: O-ADR O-ADR
with O-ADR O-ADR
metformin O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
sulfonylurea O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
thiazolidinedione O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
Chronic O-ADR O-ADR
Lymphocytic O-ADR O-ADR
Leukemia O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
TREANDA O-ADR O-ADR
in O-ADR O-ADR
153 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CLL O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Adequate O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
or O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
carriers O-ADR O-ADR
of O-ADR O-ADR
HBV O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
viral O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
prevent O-ADR O-ADR
HBV O-ADR O-ADR
reactivation O-ADR B-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
reported O-ADR O-ADR
peripheral O-ADR O-ADR
neuropathy O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
reported O-ADR O-ADR
retinopathy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
epileptiform O-ADR O-ADR
activity O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
EEG O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
substantially O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
that O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
AMPYRA O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Biological O-ADR O-ADR
Disease O-ADR O-ADR
- O-ADR O-ADR
Modifying O-ADR O-ADR
Antirheumatic O-ADR O-ADR
Drugs O-ADR O-ADR
( O-ADR O-ADR
Biological O-ADR O-ADR
DMARDs O-ADR O-ADR
) O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
were O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
concurrent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
anakinra O-ADR O-ADR
( O-ADR O-ADR
an O-ADR O-ADR
interleukin O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
antagonist O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
another O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
, O-ADR O-ADR
etanercept O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
added O-ADR O-ADR
benefit O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
etanercept O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
its O-ADR O-ADR
development O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
adjunctive O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
LGS O-ADR O-ADR
, O-ADR O-ADR
ONFI O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
333 O-ADR O-ADR
healthy O-ADR O-ADR
volunteers O-ADR O-ADR
and O-ADR O-ADR
300 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
current O-ADR O-ADR
or O-ADR O-ADR
prior O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
LGS O-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
197 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
mean O-ADR O-ADR
baseline O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
levels O-ADR O-ADR
was O-ADR O-ADR
90 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
90 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
across O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
Each O-ADR O-ADR
ECLIPSE O-ADR O-ADR
study O-ADR O-ADR
compared O-ADR O-ADR
Cleviprex O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
752 O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
comparator O-ADR O-ADR
: O-ADR O-ADR
nitroglycerin O-ADR O-ADR
( O-ADR O-ADR
NTG O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
278 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
sodium O-ADR O-ADR
nitroprusside O-ADR O-ADR
( O-ADR O-ADR
SNP O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
283 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
nicardipine O-ADR O-ADR
( O-ADR O-ADR
NIC O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
193 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Continuation O-ADR O-ADR
and O-ADR O-ADR
Timing O-ADR O-ADR
of O-ADR O-ADR
Leucovorin O-ADR O-ADR
Rescue O-ADR O-ADR
Continue O-ADR O-ADR
to O-ADR O-ADR
administer O-ADR O-ADR
leucovorin O-ADR O-ADR
after O-ADR O-ADR
VORAXAZE O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
factors O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
hematuria B-ADR B-ADR
were O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
balanced O-ADR O-ADR
between O-ADR O-ADR
arms O-ADR O-ADR
and O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
account O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
increased O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
hematuria B-ADR B-ADR
on O-ADR O-ADR
the O-ADR O-ADR
JEVTANA O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
greatest O-ADR O-ADR
risk O-ADR O-ADR
appears O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
prolonged O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
increased O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
15 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
for O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
occasionally O-ADR O-ADR
fatal B-ADR B-ADR
anaphylactic B-ADR B-ADR
) I-ADR I-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
Dysgeusia B-ADR B-ADR
( O-ADR O-ADR
alteration B-ADR B-ADR
of I-ADR I-ADR
taste I-ADR I-ADR
) O-ADR O-ADR
was O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
frequency O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
alone O-ADR O-ADR
( O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
noted O-ADR O-ADR
that O-ADR O-ADR
PRISTIQ O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
treating O-ADR O-ADR
bipolar O-ADR O-ADR
depression O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
Infected O-ADR O-ADR
Subjects O-ADR O-ADR
With O-ADR O-ADR
No O-ADR O-ADR
Antiretroviral O-ADR O-ADR
Treatment O-ADR O-ADR
History O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
Week O-ADR O-ADR
144 O-ADR O-ADR
pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
1408 O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
Study O-ADR O-ADR
102 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
103 O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
infected O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
anaphylactic B-ADR B-ADR
) I-ADR I-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Teflaro O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
In O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
already O-ADR O-ADR
taking O-ADR O-ADR
an O-ADR O-ADR
optimized O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitor O-ADR O-ADR
, O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
lowest O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cardiomyopathy B-ADR B-ADR
: O-ADR O-ADR
Assess O-ADR O-ADR
LVEF O-ADR O-ADR
before O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
after O-ADR O-ADR
one O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
every O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
unknown O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Glucose B-ADR B-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
Phosphate O-ADR O-ADR
Dehydrogenase I-ADR I-ADR
Deficiency I-ADR I-ADR
: O-ADR O-ADR
Closely O-ADR O-ADR
monitor O-ADR O-ADR
for O-ADR O-ADR
hemolytic O-ADR O-ADR
anemia O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
recognized O-ADR O-ADR
that O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
. O-ADR O-ADR
Individuals O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
already O-ADR O-ADR
experienced O-ADR O-ADR
NAION O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
NAION O-ADR O-ADR
recurrence O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
reduced O-ADR O-ADR
clinical O-ADR O-ADR
response O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
inhibitory O-ADR O-ADR
antibody O-ADR O-ADR
activity O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
risk O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
persist O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
8 O-ADR O-ADR
to O-ADR O-ADR
15 O-ADR O-ADR
years O-ADR O-ADR
after O-ADR O-ADR
estrogen O-ADR O-ADR
therapy O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
329 O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
327 O-ADR O-ADR
( O-ADR O-ADR
167 O-ADR O-ADR
brentuximab O-ADR O-ADR
vedotin O-ADR O-ADR
, O-ADR O-ADR
160 O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
PML O-ADR O-ADR
is O-ADR O-ADR
diagnosed O-ADR O-ADR
, O-ADR O-ADR
consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
withdrawal O-ADR O-ADR
of O-ADR O-ADR
immunosuppression O-ADR O-ADR
taking O-ADR O-ADR
into O-ADR O-ADR
account O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
allograft O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
on O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressant O-ADR O-ADR
agents O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
immune O-ADR O-ADR
systems O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
tuberculosis O-ADR O-ADR
and O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
NULOJIX O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
TAFINLAR O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
if O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
intolerable O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
skin O-ADR O-ADR
toxicity O-ADR O-ADR
. O-ADR O-ADR
Established O-ADR O-ADR
microvascular O-ADR O-ADR
complications O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
included O-ADR O-ADR
diabetic O-ADR B-ADR
nephropathy O-ADR I-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
retinopathy O-ADR B-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
neuropathy O-ADR B-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Suicide O-ADR B-ADR
is O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR B-ADR
and O-ADR O-ADR
certain O-ADR O-ADR
other O-ADR O-ADR
psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
these O-ADR O-ADR
disorders O-ADR O-ADR
themselves O-ADR O-ADR
are O-ADR O-ADR
the O-ADR O-ADR
strongest O-ADR O-ADR
predictors O-ADR O-ADR
of O-ADR O-ADR
suicide O-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Impaired O-ADR O-ADR
Wound O-ADR O-ADR
Healing O-ADR O-ADR
Everolimus O-ADR O-ADR
delays B-ADR B-ADR
wound I-ADR I-ADR
healing I-ADR I-ADR
and O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
wound B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
complications I-ADR I-ADR
like O-ADR O-ADR
wound B-ADR B-ADR
dehiscence I-ADR I-ADR
, O-ADR O-ADR
wound B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
incisional B-ADR B-ADR
hernia I-ADR I-ADR
, O-ADR O-ADR
lymphocele B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
seroma B-ADR B-ADR
. O-ADR O-ADR
Bone B-ADR B-ADR
pain I-ADR I-ADR
was O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GRANIX O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
numerically O-ADR O-ADR
two O-ADR O-ADR
times O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
drive O-ADR O-ADR
or O-ADR O-ADR
operate O-ADR O-ADR
heavy O-ADR O-ADR
machinery O-ADR O-ADR
until O-ADR O-ADR
they O-ADR O-ADR
know O-ADR O-ADR
how O-ADR O-ADR
Toviaz O-ADR O-ADR
affects O-ADR O-ADR
them O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Toviaz O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
myasthenia O-ADR O-ADR
gravis O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
disease O-ADR O-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
decreased O-ADR B-ADR
cholinergic O-ADR I-ADR
activity O-ADR I-ADR
at O-ADR I-ADR
the O-ADR I-ADR
neuromuscular O-ADR I-ADR
junction O-ADR I-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
and O-ADR O-ADR
26 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
duration O-ADR O-ADR
were O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Myositis B-ADR B-ADR
. O-ADR O-ADR
All O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
maximum O-ADR O-ADR
AST B-ADR O-ADR
levels I-ADR O-ADR
> I-ADR O-ADR
8 I-ADR O-ADR
* I-ADR O-ADR
ULN I-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
returned O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
levels O-ADR O-ADR
following O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
KALYDECO O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
among O-ADR O-ADR
FANAPT O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
and O-ADR O-ADR
More O-ADR O-ADR
Frequent O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
enumerates O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
spontaneously O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
listing O-ADR O-ADR
those O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
FANAPT O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
dose O-ADR O-ADR
group O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
unexplained O-ADR O-ADR
or O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
weight O-ADR O-ADR
loss O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
weight O-ADR O-ADR
loss O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
OTEZLA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR B-ADR
, O-ADR O-ADR
epinephrine O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
Dystonic B-ADR B-ADR
symptoms I-ADR I-ADR
include O-ADR O-ADR
: O-ADR O-ADR
spasm B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
neck I-ADR I-ADR
muscles I-ADR I-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
progressing O-ADR O-ADR
to O-ADR O-ADR
tightness B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
throat I-ADR I-ADR
, O-ADR O-ADR
swallowing B-ADR B-ADR
difficulty I-ADR I-ADR
, O-ADR O-ADR
difficulty B-ADR B-ADR
breathing I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
protrusion B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
tongue I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
gastrointestinal B-ADR B-ADR
perforation I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
715 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
withdrawal O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
POTIGA O-ADR O-ADR
were O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
confusional B-ADR B-ADR
state I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
somnolence B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
Bone O-ADR O-ADR
Loss O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Receiving O-ADR O-ADR
Androgen O-ADR O-ADR
Deprivation O-ADR O-ADR
Therapy O-ADR O-ADR
for O-ADR O-ADR
Prostate O-ADR O-ADR
Cancer O-ADR O-ADR
or O-ADR O-ADR
Adjuvant O-ADR O-ADR
Aromatase O-ADR O-ADR
Inhibitor O-ADR O-ADR
Therapy O-ADR O-ADR
for O-ADR O-ADR
Breast O-ADR O-ADR
Cancer O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
bone O-ADR O-ADR
loss O-ADR B-ADR
in O-ADR O-ADR
men O-ADR O-ADR
with O-ADR O-ADR
nonmetastatic O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
receiving O-ADR O-ADR
androgen O-ADR O-ADR
deprivation O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
ADT O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
multinational O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
1468 O-ADR O-ADR
men O-ADR O-ADR
aged O-ADR O-ADR
48 O-ADR O-ADR
to O-ADR O-ADR
97 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
120 O-ADR O-ADR
women O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
129 O-ADR O-ADR
women O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
Prolia O-ADR O-ADR
administered O-ADR O-ADR
once O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
60 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneous O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
randomized O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
ALT B-ADR B-ADR
) I-ADR I-ADR
elevations I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
alogliptin O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Hyponatremia O-ADR O-ADR
Clinically O-ADR O-ADR
significant O-ADR O-ADR
hyponatremia B-ADR B-ADR
( O-ADR O-ADR
sodium O-ADR O-ADR
< O-ADR O-ADR
125 O-ADR O-ADR
mEq O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
can O-ADR O-ADR
develop O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Contamination O-ADR O-ADR
of O-ADR O-ADR
Tip O-ADR O-ADR
and O-ADR O-ADR
Solution O-ADR O-ADR
To O-ADR O-ADR
minimize O-ADR O-ADR
contaminating O-ADR O-ADR
the O-ADR O-ADR
dropper O-ADR O-ADR
tip O-ADR O-ADR
and O-ADR O-ADR
solution O-ADR O-ADR
, O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
touch O-ADR O-ADR
the O-ADR O-ADR
eyelids O-ADR O-ADR
or O-ADR O-ADR
surrounding O-ADR O-ADR
areas O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
dropper O-ADR O-ADR
tip O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
bottle O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
and O-ADR O-ADR
infections O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
promptly O-ADR O-ADR
. O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
endocrinopathies I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
and O-ADR O-ADR
clinical O-ADR O-ADR
chemistries O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Malignancies O-ADR O-ADR
Malignancies B-ADR B-ADR
, O-ADR O-ADR
excluding O-ADR O-ADR
non B-ADR O-ADR
- O-ADR O-ADR
melanoma O-ADR O-ADR
skin I-ADR O-ADR
cancer I-ADR O-ADR
and O-ADR O-ADR
PTLD B-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
401 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
/ O-ADR O-ADR
405 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
Mammary B-ADR B-ADR
gland I-ADR I-ADR
proliferative I-ADR I-ADR
changes I-ADR I-ADR
and O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
prolactin I-ADR I-ADR
were O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
mice O-ADR O-ADR
and O-ADR O-ADR
rats O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Rare O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
FARXIGA O-ADR O-ADR
can O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
when O-ADR O-ADR
combined O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
penile O-ADR O-ADR
modeling O-ADR O-ADR
procedure O-ADR O-ADR
was O-ADR O-ADR
performed O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
site O-ADR O-ADR
on O-ADR O-ADR
patients O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
cycle O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anticoagulation O-ADR O-ADR
with O-ADR O-ADR
PRADAXA O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
reason O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
pathological O-ADR O-ADR
bleeding O-ADR O-ADR
or O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
coverage O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
anticoagulant O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Pheochromocytoma O-ADR O-ADR
and O-ADR O-ADR
Neuroblastoma O-ADR O-ADR
Drugs O-ADR O-ADR
which O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
norepinephrine O-ADR O-ADR
uptake O-ADR O-ADR
in O-ADR O-ADR
neuroendocrine O-ADR O-ADR
tumors O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
false O-ADR O-ADR
negative O-ADR O-ADR
imaging O-ADR O-ADR
results O-ADR O-ADR
. O-ADR O-ADR
Over O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
adverse B-ADR B-ADR
reaction I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
injected I-ADR I-ADR
extremity I-ADR I-ADR
after O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
Beleodaq O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fatal B-ADR B-ADR
hepatotoxicity B-ADR B-ADR
and O-ADR O-ADR
liver B-ADR B-ADR
function I-ADR I-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
estimate O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
attributable O-ADR O-ADR
risk O-ADR O-ADR
is O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
cases O-ADR O-ADR
/ O-ADR O-ADR
100 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
COC O-ADR O-ADR
users O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Drugs O-ADR O-ADR
which O-ADR O-ADR
block O-ADR O-ADR
norepinephrine O-ADR O-ADR
uptake O-ADR O-ADR
or O-ADR O-ADR
deplete O-ADR O-ADR
norepinephrine O-ADR O-ADR
stores O-ADR O-ADR
may O-ADR O-ADR
decrease O-ADR O-ADR
AdreView O-ADR O-ADR
uptake O-ADR O-ADR
. O-ADR O-ADR
Discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Twenty O-ADR O-ADR
- O-ADR O-ADR
five O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Beleodaq O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
hematomas B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
permanent B-ADR B-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
rechallenge O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
neutropenia O-ADR O-ADR
with O-ADR O-ADR
Ferriprox O-ADR O-ADR
unless O-ADR O-ADR
potential O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
potential O-ADR O-ADR
risks O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
ZYKADIA O-ADR O-ADR
with O-ADR O-ADR
resumption O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Potentiation O-ADR O-ADR
of O-ADR O-ADR
Sedation O-ADR O-ADR
from O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Central O-ADR O-ADR
Nervous O-ADR O-ADR
System O-ADR O-ADR
Depressants O-ADR O-ADR
Since O-ADR O-ADR
ONFI O-ADR O-ADR
has O-ADR O-ADR
a O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
( O-ADR O-ADR
CNS O-ADR O-ADR
) O-ADR O-ADR
depressant O-ADR O-ADR
effect O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
or O-ADR O-ADR
their O-ADR O-ADR
caregivers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
cautioned O-ADR O-ADR
against O-ADR O-ADR
simultaneous O-ADR O-ADR
use O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
CNS O-ADR O-ADR
depressant O-ADR O-ADR
drugs O-ADR O-ADR
or O-ADR O-ADR
alcohol O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cautioned O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
CNS O-ADR O-ADR
depressant O-ADR O-ADR
drugs O-ADR O-ADR
or O-ADR O-ADR
alcohol O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
potentiated O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
insufficient O-ADR O-ADR
data O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
FARXIGA O-ADR O-ADR
has O-ADR O-ADR
an O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
bladder O-ADR B-ADR
tumors O-ADR O-ADR
. O-ADR O-ADR
Rash B-ADR B-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
IMMUNE B-ADR B-ADR
- O-ADR O-ADR
MEDIATED O-ADR O-ADR
ADVERSE I-ADR I-ADR
REACTIONS I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
XEOMIN O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
79 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
53 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
female O-ADR O-ADR
( O-ADR O-ADR
66 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
91 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
turn O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
inhibit B-ADR B-ADR
reproductive I-ADR I-ADR
function I-ADR I-ADR
by O-ADR O-ADR
impairing B-ADR B-ADR
gonadalsteroidogenesis I-ADR I-ADR
in O-ADR O-ADR
both O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
from O-ADR O-ADR
study O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
genital B-ADR B-ADR
infection I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Eli O-ADR O-ADR
Lilly O-ADR O-ADR
and O-ADR O-ADR
Company O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
LillyRx O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
545 O-ADR O-ADR
- O-ADR O-ADR
5979 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administering O-ADR O-ADR
Vimizim O-ADR O-ADR
following O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Contact O-ADR O-ADR
Lens O-ADR O-ADR
Use O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
wear O-ADR O-ADR
a O-ADR O-ADR
contact O-ADR O-ADR
lens O-ADR O-ADR
if O-ADR O-ADR
their O-ADR O-ADR
eye O-ADR O-ADR
is O-ADR O-ADR
red O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
higher O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
sodium I-ADR I-ADR
values I-ADR I-ADR
of O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
mEq O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
18 O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
26 O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
during O-ADR O-ADR
infusion O-ADR O-ADR
with O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
including O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
gastrointestinal B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
retching B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
urticaria B-ADR B-ADR
. O-ADR O-ADR
Exclude O-ADR O-ADR
other O-ADR O-ADR
potential O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
diagnosed O-ADR O-ADR
with O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
findings O-ADR O-ADR
in O-ADR O-ADR
animals O-ADR O-ADR
, O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
postmarketing O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
. O-ADR O-ADR
Alcohol O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
hepatotoxic O-ADR O-ADR
drugs O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
SIRTURO O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
hepatic O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
if O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
Transaminase B-ADR B-ADR
elevations I-ADR I-ADR
generally O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
Phase O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
2 O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
546 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CML O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
prior O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
fluid B-ADR B-ADR
retention I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
eGFR O-ADR O-ADR
88 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
usefulness O-ADR O-ADR
of O-ADR O-ADR
hemodialysis O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
prevention O-ADR O-ADR
of O-ADR O-ADR
NSF O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
, O-ADR O-ADR
their O-ADR O-ADR
caregivers O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
families O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
informed O-ADR O-ADR
that O-ADR O-ADR
HORIZANT O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
and O-ADR O-ADR
behavior O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
alert O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
, O-ADR O-ADR
any O-ADR O-ADR
unusual O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
mood O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
, O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
thoughts O-ADR O-ADR
about O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
harm O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
mild O-ADR O-ADR
pancreatitis O-ADR O-ADR
, O-ADR O-ADR
hold O-ADR O-ADR
ERWINAZE O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
subside O-ADR O-ADR
and O-ADR O-ADR
amylase O-ADR O-ADR
levels O-ADR O-ADR
return O-ADR O-ADR
to O-ADR O-ADR
normal O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
Transaminase O-ADR O-ADR
elevations O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
enroll O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Transaminase O-ADR O-ADR
( O-ADR O-ADR
ALT O-ADR O-ADR
or O-ADR O-ADR
AST O-ADR O-ADR
) O-ADR O-ADR
Elevations O-ADR O-ADR
Elevated B-ADR B-ADR
transaminases I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CF O-ADR O-ADR
receiving O-ADR O-ADR
KALYDECO O-ADR O-ADR
. O-ADR O-ADR
Alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
in O-ADR O-ADR
motor O-ADR O-ADR
function O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
inhibitory O-ADR O-ADR
antibodies O-ADR O-ADR
that O-ADR O-ADR
neutralize O-ADR O-ADR
enzyme O-ADR O-ADR
uptake O-ADR O-ADR
or O-ADR O-ADR
activity O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Antifungal O-ADR O-ADR
agents O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
unless O-ADR O-ADR
fungal O-ADR O-ADR
infection O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
diagnosed O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
: O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
experienced O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
38 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
reaction O-ADR O-ADR
judged O-ADR O-ADR
by O-ADR O-ADR
investigators O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
moderate O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
or O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
severe O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
( O-ADR O-ADR
27 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
required O-ADR O-ADR
local O-ADR O-ADR
or O-ADR O-ADR
systemic O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
36 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Lipid O-ADR O-ADR
Intake O-ADR O-ADR
Cleviprex O-ADR O-ADR
contains O-ADR O-ADR
approximately O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
g O-ADR O-ADR
of O-ADR O-ADR
lipid O-ADR O-ADR
per O-ADR O-ADR
mL O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
kcal O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
suicidality B-ADR B-ADR
risk O-ADR O-ADR
extends O-ADR O-ADR
to O-ADR O-ADR
longer O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
beyond O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Prophylaxis O-ADR O-ADR
for O-ADR O-ADR
PJP O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
when O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
immunosuppressive O-ADR O-ADR
agents O-ADR O-ADR
are O-ADR O-ADR
required O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
at O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
Higher O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
Placebo O-ADR O-ADR
Controlled O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
HAE O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
KALBITOR O-ADR O-ADR
a O-ADR O-ADR
Patients O-ADR O-ADR
experiencing O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
event O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
preferred O-ADR O-ADR
term O-ADR O-ADR
are O-ADR O-ADR
counted O-ADR O-ADR
only O-ADR O-ADR
once O-ADR O-ADR
for O-ADR O-ADR
that O-ADR O-ADR
preferred O-ADR O-ADR
term O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
infections B-ADR B-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
serious O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
outcomes O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Polyoma O-ADR O-ADR
Virus O-ADR O-ADR
Nephropathy O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
JC B-ADR B-ADR
virus O-ADR I-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
PML B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
polyoma B-ADR B-ADR
virus I-ADR I-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
nephropathy I-ADR I-ADR
( O-ADR O-ADR
PVAN B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
mostly O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
BK B-ADR B-ADR
virus I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
They O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
bilateral O-ADR O-ADR
and O-ADR O-ADR
many O-ADR O-ADR
patients O-ADR O-ADR
report O-ADR O-ADR
prodromal O-ADR O-ADR
pain O-ADR B-ADR
in O-ADR I-ADR
the O-ADR I-ADR
affected O-ADR I-ADR
area O-ADR O-ADR
, O-ADR O-ADR
usually O-ADR O-ADR
presenting O-ADR O-ADR
as O-ADR O-ADR
dull O-ADR O-ADR
, O-ADR O-ADR
aching O-ADR O-ADR
thigh B-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
weeks O-ADR O-ADR
to O-ADR O-ADR
months O-ADR O-ADR
before O-ADR O-ADR
a O-ADR O-ADR
complete O-ADR O-ADR
fracture O-ADR B-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
CIMZIA O-ADR O-ADR
RA O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
open O-ADR O-ADR
label O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
three O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
367 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Individuals O-ADR O-ADR
with O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
crowded O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
optic O-ADR O-ADR
disc O-ADR O-ADR
are O-ADR O-ADR
also O-ADR O-ADR
considered O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NAION O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
, O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
evidence O-ADR O-ADR
is O-ADR O-ADR
insufficient O-ADR O-ADR
to O-ADR O-ADR
support O-ADR O-ADR
screening O-ADR O-ADR
of O-ADR O-ADR
prospective O-ADR O-ADR
users O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
this O-ADR O-ADR
uncommon O-ADR O-ADR
condition O-ADR O-ADR
. O-ADR O-ADR
Hypertoxin O-ADR O-ADR
- O-ADR O-ADR
producing O-ADR O-ADR
strains O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
cause O-ADR O-ADR
increased O-ADR O-ADR
morbidity O-ADR O-ADR
and O-ADR O-ADR
mortality O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
these O-ADR O-ADR
infections O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
refractory O-ADR O-ADR
to O-ADR O-ADR
antimicrobial O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
colectomy O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
component O-ADR O-ADR
reduces O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
endometrial O-ADR B-ADR
hyperplasia O-ADR I-ADR
that O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
component O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
are O-ADR O-ADR
coadministered O-ADR O-ADR
with O-ADR O-ADR
inducers O-ADR O-ADR
of O-ADR O-ADR
CYP3A4 O-ADR O-ADR
it O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
decreased O-ADR O-ADR
concentrations O-ADR O-ADR
of O-ADR O-ADR
artemether O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
lumefantrine O-ADR O-ADR
and O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
antimalarial O-ADR O-ADR
efficacy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
TB B-ADR B-ADR
included O-ADR O-ADR
extrapulmonary B-ADR B-ADR
TB I-ADR I-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
recent O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
or O-ADR O-ADR
unstable O-ADR O-ADR
heart O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Hepatic O-ADR O-ADR
: O-ADR O-ADR
Liver B-ADR B-ADR
Injury I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Respiratory O-ADR O-ADR
: O-ADR O-ADR
Interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
including O-ADR O-ADR
pneumonitis B-ADR B-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Immune O-ADR O-ADR
: O-ADR O-ADR
Anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
angioedema B-ADR B-ADR
Vascular O-ADR O-ADR
: O-ADR O-ADR
Vasculitis B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
leukocytoclastic B-ADR B-ADR
vasculitis I-ADR I-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
DEATH B-ADR B-ADR
, O-ADR O-ADR
STROKE B-ADR B-ADR
AND O-ADR O-ADR
HEART B-ADR B-ADR
FAILURE I-ADR I-ADR
IN O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DECOMPENSATED O-ADR O-ADR
HEART O-ADR B-ADR
FAILURE O-ADR I-ADR
OR O-ADR O-ADR
PERMANENT O-ADR O-ADR
ATRIAL O-ADR B-ADR
FIBRILLATION O-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
DEATH B-ADR B-ADR
, O-ADR O-ADR
STROKE B-ADR B-ADR
AND O-ADR O-ADR
HEART B-ADR B-ADR
FAILURE I-ADR I-ADR
IN O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DECOMPENSATED O-ADR O-ADR
HEART O-ADR O-ADR
FAILURE O-ADR O-ADR
OR O-ADR O-ADR
PERMANENT O-ADR O-ADR
ATRIAL O-ADR O-ADR
FIBRILLATION O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
symptomatic O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
and O-ADR O-ADR
recent O-ADR O-ADR
decompensation O-ADR O-ADR
requiring O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
NYHA O-ADR O-ADR
Class O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
; O-ADR O-ADR
MULTAQ O-ADR O-ADR
doubles O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
diagnoses O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
from O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
cancer B-ADR B-ADR
. O-ADR O-ADR
TAFINLAR O-ADR O-ADR
may O-ADR O-ADR
render O-ADR O-ADR
hormonal O-ADR O-ADR
contraceptives O-ADR O-ADR
less O-ADR O-ADR
effective O-ADR O-ADR
and O-ADR O-ADR
an O-ADR O-ADR
alternative O-ADR O-ADR
method O-ADR O-ADR
of O-ADR O-ADR
contraception O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
, O-ADR O-ADR
ILARIS O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
MAS B-ADR B-ADR
in O-ADR O-ADR
SJIA O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
no O-ADR O-ADR
definitive O-ADR O-ADR
conclusion O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
immunosuppressants O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ILARIS O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
. O-ADR O-ADR
Liver O-ADR O-ADR
enzymes O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
symptoms O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
hepatic O-ADR O-ADR
dysfunction O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
unexplained O-ADR O-ADR
nausea O-ADR O-ADR
, O-ADR O-ADR
vomiting O-ADR O-ADR
, O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
anorexia O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
jaundice O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
dark O-ADR O-ADR
urine O-ADR O-ADR
. O-ADR O-ADR
PVAN B-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
serious O-ADR O-ADR
outcomes O-ADR O-ADR
; O-ADR O-ADR
including O-ADR O-ADR
deteriorating B-ADR B-ADR
renal I-ADR I-ADR
function I-ADR I-ADR
and O-ADR O-ADR
kidney B-ADR B-ADR
graft I-ADR I-ADR
loss I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
accelerated O-ADR O-ADR
vaccination O-ADR O-ADR
schedule O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
initial O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
fever B-ADR B-ADR
( O-ADR O-ADR
any O-ADR O-ADR
severity O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
11 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
202 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
fever B-ADR B-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
129 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
ILARIS O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
requiring O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
specific O-ADR O-ADR
IgE O-ADR O-ADR
antibodies O-ADR O-ADR
experienced O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
[ O-ADR O-ADR
seeBoxed O-ADR O-ADR
WarningandWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Observational O-ADR O-ADR
studies O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
conventional O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR B-ADR
mortality O-ADR I-ADR
. O-ADR O-ADR
STRIBILD O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
chronic O-ADR O-ADR
HBV O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
coinfected O-ADR O-ADR
with O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
serum O-ADR O-ADR
phosphorus O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
included O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
seriousness O-ADR O-ADR
and O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
. O-ADR O-ADR
Program O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
authorized O-ADR O-ADR
hospital O-ADR O-ADR
representative O-ADR O-ADR
must O-ADR O-ADR
acknowledge O-ADR O-ADR
that O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
hospital O-ADR O-ADR
staff O-ADR O-ADR
who O-ADR O-ADR
prescribe O-ADR O-ADR
, O-ADR O-ADR
dispense O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
administer O-ADR O-ADR
ENTEREG O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
provided O-ADR O-ADR
the O-ADR O-ADR
educational O-ADR O-ADR
materials O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
limit O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ENTEREG O-ADR O-ADR
to O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
inpatient O-ADR O-ADR
use O-ADR O-ADR
; O-ADR O-ADR
* O-ADR O-ADR
patients O-ADR O-ADR
will O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
15 O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
ENTEREG O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
* O-ADR O-ADR
ENTEREG O-ADR O-ADR
will O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
dispensed O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
after O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
discharged O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
hospital O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
dermatitis O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
rash O-ADR O-ADR
and O-ADR O-ADR
pruritus O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
pancreatitis O-ADR B-ADR
is O-ADR O-ADR
a O-ADR O-ADR
contraindication O-ADR O-ADR
to O-ADR O-ADR
additional O-ADR O-ADR
asparaginase O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
experienced O-ADR O-ADR
disturbance B-ADR B-ADR
in I-ADR I-ADR
attention I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
feeling B-ADR B-ADR
abnormal I-ADR I-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
experienced O-ADR O-ADR
dysphagia B-ADR B-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
INLYTA O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hypertension B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
neuropathies I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Macular B-ADR B-ADR
edema I-ADR I-ADR
: O-ADR O-ADR
Perform O-ADR O-ADR
an O-ADR O-ADR
examination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
fundus O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
macula O-ADR O-ADR
before O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
reflects O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
398 O-ADR O-ADR
patients O-ADR O-ADR
19 O-ADR O-ADR
to O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
that O-ADR O-ADR
assessed O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
temporary O-ADR O-ADR
improvement O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
appearance O-ADR O-ADR
of O-ADR O-ADR
glabellar O-ADR O-ADR
lines O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
think O-ADR O-ADR
you O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
pregnant O-ADR O-ADR
, O-ADR O-ADR
you O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
pregnancy O-ADR O-ADR
test O-ADR O-ADR
and O-ADR O-ADR
know O-ADR O-ADR
the O-ADR O-ADR
results O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Drugs O-ADR O-ADR
that O-ADR O-ADR
act O-ADR O-ADR
directly O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
system O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
death B-ADR B-ADR
to I-ADR I-ADR
the I-ADR I-ADR
developing I-ADR I-ADR
fetus I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
intensity O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
titration O-ADR O-ADR
phase O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
A O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
Vimizim O-ADR O-ADR
was O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
176 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MPS O-ADR O-ADR
IVA O-ADR O-ADR
, O-ADR O-ADR
ages O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
57 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
vary O-ADR O-ADR
substantially O-ADR O-ADR
by O-ADR O-ADR
age O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
100 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
analyzed O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
predisposed O-ADR O-ADR
to O-ADR O-ADR
hypocalcemia O-ADR O-ADR
and O-ADR O-ADR
disturbances O-ADR O-ADR
of O-ADR O-ADR
mineral O-ADR O-ADR
metabolism O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
QT O-ADR O-ADR
Interval O-ADR O-ADR
Prolongation O-ADR O-ADR
QTc B-ADR B-ADR
prolongation I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
presented O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
information O-ADR O-ADR
collected O-ADR O-ADR
from O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
, O-ADR O-ADR
multi O-ADR O-ADR
- O-ADR O-ADR
center O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
clinical O-ADR O-ADR
pharmacology O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
intramuscular O-ADR O-ADR
administration O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
ERWINAZE O-ADR O-ADR
Master O-ADR O-ADR
Treatment O-ADR O-ADR
Protocol O-ADR O-ADR
( O-ADR O-ADR
EMTP O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
expanded O-ADR O-ADR
access O-ADR O-ADR
program O-ADR O-ADR
( O-ADR O-ADR
both O-ADR O-ADR
intramuscular O-ADR O-ADR
, O-ADR O-ADR
intravenous O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
or O-ADR O-ADR
unknown O-ADR O-ADR
administration O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
, O-ADR O-ADR
multi O-ADR O-ADR
- O-ADR O-ADR
center O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
pharmacokinetic O-ADR O-ADR
( O-ADR O-ADR
PK O-ADR O-ADR
) O-ADR O-ADR
study O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
intravenous O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ERWINAZE O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
enrolled O-ADR O-ADR
58 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
on O-ADR O-ADR
National O-ADR O-ADR
Cancer O-ADR O-ADR
Institute O-ADR O-ADR
( O-ADR O-ADR
NCI O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
sponsored O-ADR O-ADR
cooperative O-ADR O-ADR
group O-ADR O-ADR
ALL O-ADR O-ADR
protocols O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
unable O-ADR O-ADR
to O-ADR O-ADR
continue O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
pegaspargase O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hypersensitivity O-ADR B-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Neither O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
nor O-ADR O-ADR
epidemiologic O-ADR O-ADR
studies O-ADR O-ADR
conducted O-ADR O-ADR
to O-ADR O-ADR
date O-ADR O-ADR
have O-ADR O-ADR
shown O-ADR O-ADR
an O-ADR O-ADR
association O-ADR O-ADR
between O-ADR O-ADR
chronic O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
class O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
tumorigenesis O-ADR B-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
available O-ADR O-ADR
evidence O-ADR O-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
too O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
conclusive O-ADR O-ADR
at O-ADR O-ADR
this O-ADR O-ADR
time O-ADR O-ADR
. O-ADR O-ADR
Hyperprolactinemia B-ADR B-ADR
may O-ADR O-ADR
suppress B-ADR B-ADR
hypothalamic I-ADR I-ADR
GnRH I-ADR I-ADR
, O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
reduced B-ADR B-ADR
pituitary I-ADR I-ADR
gonadotropin I-ADR I-ADR
secretion I-ADR I-ADR
. O-ADR O-ADR
No O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PML B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
) O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
developed O-ADR O-ADR
IgE O-ADR O-ADR
- O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
antibodies O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
proportions O-ADR O-ADR
and O-ADR O-ADR
higher O-ADR O-ADR
titers O-ADR O-ADR
with O-ADR O-ADR
successive O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
genotoxicity B-ADR O-ADR
in O-ADR O-ADR
animal O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
Ferriprox O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
LABA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
vilanterol O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredients O-ADR O-ADR
in O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
tuberculosis B-ADR B-ADR
have I-ADR O-ADR
frequently I-ADR O-ADR
presented I-ADR O-ADR
with I-ADR O-ADR
disseminated I-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
4 O-ADR O-ADR
pivotal O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
drug O-ADR B-ADR
hypersensitivity B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pruritus B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
allergic B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PRADAXA O-ADR O-ADR
. O-ADR O-ADR
Consequently O-ADR O-ADR
, O-ADR O-ADR
FARXIGA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
bladder O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
Prescribers O-ADR O-ADR
should O-ADR O-ADR
caution O-ADR O-ADR
patients O-ADR O-ADR
against O-ADR O-ADR
engaging O-ADR O-ADR
in O-ADR O-ADR
hazardous O-ADR O-ADR
activities O-ADR O-ADR
requiring O-ADR O-ADR
mental O-ADR O-ADR
alertness O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
operating O-ADR O-ADR
dangerous O-ADR O-ADR
machinery O-ADR O-ADR
or O-ADR O-ADR
motor O-ADR O-ADR
vehicles O-ADR O-ADR
, O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
ONFI O-ADR O-ADR
is O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
per O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
FARXIGA O-ADR O-ADR
. O-ADR O-ADR
Have O-ADR O-ADR
anaphylactic O-ADR O-ADR
and O-ADR O-ADR
hypersensitivity O-ADR O-ADR
treatment O-ADR O-ADR
measures O-ADR O-ADR
available O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Rupture B-ADR B-ADR
of I-ADR I-ADR
hepatic I-ADR I-ADR
adenomas I-ADR I-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
death B-ADR B-ADR
through O-ADR O-ADR
intra B-ADR B-ADR
- O-ADR O-ADR
abdominal O-ADR O-ADR
hemorrhage I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
QT O-ADR O-ADR
Prolongation O-ADR O-ADR
In O-ADR O-ADR
an O-ADR O-ADR
uncontrolled O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
ECG O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
26 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
on O-ADR O-ADR
Day O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
independent O-ADR O-ADR
of O-ADR O-ADR
eribulin O-ADR O-ADR
concentration O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
observed O-ADR O-ADR
on O-ADR O-ADR
Day O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
whose O-ADR O-ADR
baseline O-ADR O-ADR
ALT O-ADR O-ADR
or O-ADR O-ADR
AST O-ADR O-ADR
were O-ADR O-ADR
elevated O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
experience O-ADR O-ADR
liver B-ADR B-ADR
test I-ADR I-ADR
elevation I-ADR I-ADR
than O-ADR O-ADR
those O-ADR O-ADR
beginning O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
values O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CIGARETTE O-ADR O-ADR
SMOKING O-ADR O-ADR
AND O-ADR O-ADR
SERIOUS O-ADR O-ADR
CARDIOVASCULAR B-ADR B-ADR
EVENTS I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
desired O-ADR O-ADR
therapeutic O-ADR O-ADR
response O-ADR O-ADR
was O-ADR O-ADR
achieved O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
hour O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
nadir O-ADR O-ADR
was O-ADR O-ADR
13 O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
recovery O-ADR O-ADR
from O-ADR O-ADR
severe O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
< O-ADR O-ADR
500 O-ADR O-ADR
/ O-ADR O-ADR
mm O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Bacterial O-ADR O-ADR
Infections O-ADR O-ADR
Prolonged O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
suppress B-ADR B-ADR
the I-ADR I-ADR
host I-ADR I-ADR
response I-ADR I-ADR
and O-ADR O-ADR
thus O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
hazard O-ADR O-ADR
of O-ADR O-ADR
secondary B-ADR B-ADR
ocular I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
New O-ADR O-ADR
- O-ADR O-ADR
Onset O-ADR O-ADR
Diabetes O-ADR O-ADR
After O-ADR O-ADR
Transplantation O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
new B-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
diabetes I-ADR O-ADR
after I-ADR O-ADR
transplantation I-ADR O-ADR
( O-ADR O-ADR
NODAT B-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
defined O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
as O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
antidiabetic O-ADR O-ADR
agent O-ADR O-ADR
for O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
or O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
fasting O-ADR O-ADR
plasma O-ADR O-ADR
glucose O-ADR O-ADR
values O-ADR O-ADR
> O-ADR O-ADR
= O-ADR I-ADR
126 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
mmol O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
transplantation O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
ophthalmologic O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
POTIGA O-ADR O-ADR
should O-ADR O-ADR
only O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
responded O-ADR O-ADR
inadequately O-ADR O-ADR
to O-ADR O-ADR
several O-ADR O-ADR
alternative O-ADR O-ADR
treatments O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
whom O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
retinal O-ADR B-ADR
abnormalities O-ADR I-ADR
and O-ADR O-ADR
potential O-ADR O-ADR
vision O-ADR B-ADR
loss O-ADR I-ADR
. O-ADR O-ADR
Causality O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Adjunctive O-ADR O-ADR
Therapy O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
Study O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
discontinuation O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
Angioedema O-ADR O-ADR
TECFIDERA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
or O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
Diarrhea B-ADR B-ADR
37 O-ADR O-ADR
0 O-ADR O-ADR
Nausea B-ADR B-ADR
21 O-ADR O-ADR
0 O-ADR O-ADR
Stomatitis B-ADR B-ADR
16 O-ADR O-ADR
0 O-ADR O-ADR
Gastroesophageal B-ADR B-ADR
reflux I-ADR I-ADR
disease I-ADR I-ADR
13 O-ADR O-ADR
0 O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
Rash B-ADR B-ADR
22 O-ADR O-ADR
0 O-ADR O-ADR
Bruising B-ADR B-ADR
16 O-ADR O-ADR
0 O-ADR O-ADR
Pruritus B-ADR B-ADR
11 O-ADR O-ADR
0 O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administrative O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
Fatigue B-ADR B-ADR
21 O-ADR O-ADR
0 O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
connective O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
Muscle B-ADR B-ADR
spasms I-ADR I-ADR
21 O-ADR O-ADR
0 O-ADR O-ADR
Arthropathy B-ADR B-ADR
13 O-ADR O-ADR
0 O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
Upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
19 O-ADR O-ADR
0 O-ADR O-ADR
Sinusitis B-ADR B-ADR
19 O-ADR O-ADR
0 O-ADR O-ADR
Pneumonia B-ADR B-ADR
14 O-ADR O-ADR
6 O-ADR O-ADR
Skin B-ADR B-ADR
infection I-ADR I-ADR
14 O-ADR O-ADR
2 O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
thoracic O-ADR O-ADR
and O-ADR O-ADR
mediastinal O-ADR O-ADR
disorders O-ADR O-ADR
Epistaxis B-ADR B-ADR
19 O-ADR O-ADR
0 O-ADR O-ADR
Cough B-ADR B-ADR
13 O-ADR O-ADR
0 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Dizziness B-ADR B-ADR
14 O-ADR O-ADR
0 O-ADR O-ADR
Headache B-ADR B-ADR
13 O-ADR O-ADR
0 O-ADR O-ADR
Neoplasms O-ADR B-ADR
benign O-ADR O-ADR
, O-ADR O-ADR
malignant O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
unspecified O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
cysts O-ADR O-ADR
and O-ADR O-ADR
polyps O-ADR O-ADR
) O-ADR O-ADR
Skin B-ADR B-ADR
cancer I-ADR I-ADR
11 O-ADR O-ADR
0 O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
: O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
EmergentBased O-ADR O-ADR
on O-ADR O-ADR
laboratory O-ADR O-ADR
measurements O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
INLYTA O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
715 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
monotherapy O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
included O-ADR O-ADR
537 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
RCC O-ADR O-ADR
. O-ADR O-ADR
Renal B-ADR B-ADR
function I-ADR I-ADR
abnormalities I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
QT O-ADR O-ADR
Prolongation O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
Antipsychotic O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
itself O-ADR O-ADR
, O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
suppress O-ADR O-ADR
( O-ADR O-ADR
or O-ADR O-ADR
partially O-ADR O-ADR
suppress O-ADR O-ADR
) O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
and O-ADR O-ADR
thereby O-ADR O-ADR
may O-ADR O-ADR
possibly O-ADR O-ADR
mask O-ADR O-ADR
the O-ADR O-ADR
underlying O-ADR O-ADR
process O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
rare B-ADR O-ADR
type I-ADR O-ADR
of I-ADR O-ADR
T I-ADR B-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
lymphoma I-ADR I-ADR
has O-ADR O-ADR
a O-ADR O-ADR
very O-ADR O-ADR
aggressive O-ADR O-ADR
disease O-ADR O-ADR
course O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
usually O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
most O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
develop O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
ADA O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
ERWINAZE O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
treatment O-ADR O-ADR
by O-ADR O-ADR
intramuscular O-ADR O-ADR
administration O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
of O-ADR O-ADR
56 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
ERWINAZE O-ADR O-ADR
. O-ADR O-ADR
Merkel B-ADR B-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
syncope B-ADR B-ADR
were O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
events O-ADR O-ADR
: O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
sedation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypersomnia B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hypertension O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Embryofetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
, O-ADR O-ADR
GILOTRIF O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
HORIZANT O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
interchangeable O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
gabapentin O-ADR O-ADR
products O-ADR O-ADR
. O-ADR O-ADR
Inform O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
and O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
infusion O-ADR O-ADR
reaction O-ADR O-ADR
occur O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Patient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
FD O-ADR O-ADR
& O-ADR O-ADR
C O-ADR O-ADR
Yellow O-ADR O-ADR
No O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
DOTAREM O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
2813 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
2672 O-ADR O-ADR
adults O-ADR O-ADR
and O-ADR O-ADR
141 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
committed O-ADR O-ADR
suicide B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
OTEZLA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
neuromuscular O-ADR O-ADR
disorders O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
effects O-ADR O-ADR
including O-ADR O-ADR
severe O-ADR O-ADR
dysphagia B-ADR B-ADR
and O-ADR O-ADR
respiratory B-ADR B-ADR
compromise I-ADR I-ADR
from O-ADR O-ADR
typical O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
residual O-ADR B-ADR
visual B-ADR I-ADR
acuity I-ADR I-ADR
loss I-ADR I-ADR
even O-ADR O-ADR
after O-ADR O-ADR
resolution O-ADR O-ADR
of O-ADR O-ADR
macular B-ADR O-ADR
edema I-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
multiple O-ADR O-ADR
sclerosis O-ADR O-ADR
, O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
visual B-ADR B-ADR
symptoms I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
799 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
fingolimod O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
783 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
773 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Infections B-ADR B-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pneumonitis B-ADR B-ADR
were O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reasons O-ADR O-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
delay O-ADR O-ADR
or O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
. O-ADR O-ADR
Mean O-ADR O-ADR
percentage O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
BMD I-ADR I-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
to O-ADR O-ADR
Week O-ADR O-ADR
144 O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
STRIBILD O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
group O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
lumbar O-ADR O-ADR
spine O-ADR I-ADR
( O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
68 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
hip O-ADR O-ADR
( O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
83 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
77 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Local O-ADR O-ADR
Skin O-ADR O-ADR
Reactions O-ADR O-ADR
Severe O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
in I-ADR I-ADR
the I-ADR I-ADR
treated I-ADR O-ADR
area I-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
topical O-ADR O-ADR
application O-ADR O-ADR
of O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
SJIA O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
201 O-ADR O-ADR
SJIA O-ADR O-ADR
patients O-ADR O-ADR
aged O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
20 O-ADR O-ADR
years O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
ILARIS O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
SJIA O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
See O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
listing O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
contraindicated O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
potentially O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
significant O-ADR O-ADR
drug O-ADR O-ADR
interactions O-ADR O-ADR
or O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
virologic O-ADR O-ADR
activity O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
several O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
or O-ADR O-ADR
recurrent O-ADR O-ADR
infection O-ADR O-ADR
; O-ADR O-ADR
* O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
tuberculosis O-ADR O-ADR
; O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
opportunistic O-ADR O-ADR
infection O-ADR O-ADR
; O-ADR O-ADR
* O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
resided O-ADR O-ADR
or O-ADR O-ADR
traveled O-ADR O-ADR
in O-ADR O-ADR
areas O-ADR O-ADR
of O-ADR O-ADR
endemic O-ADR O-ADR
tuberculosis O-ADR O-ADR
or O-ADR O-ADR
endemic O-ADR O-ADR
mycoses O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
histoplasmosis O-ADR O-ADR
, O-ADR O-ADR
coccidioidomycosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
blastomycosis O-ADR O-ADR
; O-ADR O-ADR
or O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
three O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
extension O-ADR O-ADR
study O-ADR O-ADR
lasting O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Increase O-ADR O-ADR
in O-ADR O-ADR
Intraocular O-ADR O-ADR
Pressure O-ADR O-ADR
Acute B-ADR B-ADR
increases I-ADR B-ADR
in I-ADR I-ADR
intraocular I-ADR I-ADR
pressure I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
seen O-ADR O-ADR
within O-ADR O-ADR
60 O-ADR O-ADR
minutes O-ADR O-ADR
of O-ADR O-ADR
intravitreal O-ADR O-ADR
injection O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
MTC B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
liraglutide O-ADR O-ADR
, O-ADR O-ADR
another O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
receptor O-ADR O-ADR
agonist O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
period O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
reports O-ADR O-ADR
are O-ADR O-ADR
insufficient O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
or O-ADR O-ADR
exclude O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
MTC B-ADR O-ADR
and O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
receptor O-ADR O-ADR
agonist O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
. O-ADR O-ADR
With O-ADR O-ADR
the O-ADR O-ADR
interventions O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
anemia O-ADR O-ADR
management O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
average O-ADR O-ADR
additional O-ADR O-ADR
decrease O-ADR B-ADR
of O-ADR I-ADR
hemoglobin O-ADR I-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
g O-ADR I-ADR
per O-ADR I-ADR
dL O-ADR I-ADR
. O-ADR O-ADR
Hemodialysis O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
substantial O-ADR O-ADR
impact O-ADR O-ADR
on O-ADR O-ADR
apixaban O-ADR O-ADR
exposure O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
by O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
STENDRA O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Lasting O-ADR O-ADR
2 O-ADR O-ADR
Months O-ADR O-ADR
to O-ADR O-ADR
Determine O-ADR O-ADR
the O-ADR O-ADR
Time O-ADR O-ADR
to O-ADR O-ADR
Onset O-ADR O-ADR
of O-ADR O-ADR
Effect O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Placebon O-ADR O-ADR
= O-ADR O-ADR
143 O-ADR O-ADR
STENDRA O-ADR O-ADR
100 O-ADR O-ADR
mgn O-ADR O-ADR
= O-ADR O-ADR
146 O-ADR O-ADR
STENDRA O-ADR O-ADR
200 O-ADR O-ADR
mgn O-ADR O-ADR
= O-ADR O-ADR
146 O-ADR O-ADR
Headache B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
Nasal B-ADR B-ADR
congestion I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Gastroenteritis B-ADR B-ADR
viral I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Across O-ADR O-ADR
all O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
any O-ADR O-ADR
STENDRA O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
subject O-ADR O-ADR
reported O-ADR O-ADR
a O-ADR O-ADR
change B-ADR B-ADR
in I-ADR I-ADR
color I-ADR I-ADR
vision I-ADR I-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
8 O-ADR O-ADR
Phase O-ADR O-ADR
III O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
adjudicated O-ADR O-ADR
as O-ADR O-ADR
likely O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TANZEUM O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
365 O-ADR O-ADR
[ O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
of O-ADR O-ADR
468 O-ADR O-ADR
[ O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
active O-ADR O-ADR
comparators O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
065 O-ADR O-ADR
[ O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Tuberculosis O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
strongly O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
CIMZIA O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
previously O-ADR O-ADR
or O-ADR O-ADR
recently O-ADR O-ADR
traveled O-ADR O-ADR
to O-ADR O-ADR
countries O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
prevalence O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
close O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
person O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
tuberculosis O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postapproval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
would O-ADR O-ADR
like O-ADR O-ADR
more O-ADR O-ADR
information O-ADR O-ADR
, O-ADR O-ADR
talk O-ADR O-ADR
with O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
and O-ADR O-ADR
sALCL O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
were O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
brentuximab O-ADR O-ADR
vedotin O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
sensitive O-ADR O-ADR
electrochemiluminescent O-ADR O-ADR
immunoassay O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
studied O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
49 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
39 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
82 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
and O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
black O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
decline O-ADR O-ADR
in O-ADR O-ADR
WBC O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
causative O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Infections O-ADR O-ADR
: O-ADR O-ADR
PML B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
and O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
immunogenicity O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
test O-ADR O-ADR
results O-ADR O-ADR
were O-ADR O-ADR
considered O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
EYLEA O-ADR O-ADR
in O-ADR O-ADR
immunoassays O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
protocol O-ADR O-ADR
specified O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
continue O-ADR O-ADR
receiving O-ADR O-ADR
intravenous O-ADR O-ADR
hydration O-ADR O-ADR
, O-ADR O-ADR
urinary O-ADR O-ADR
alkalinization O-ADR O-ADR
and O-ADR O-ADR
leucovorin O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
that O-ADR O-ADR
leucovorin O-ADR O-ADR
administration O-ADR O-ADR
be O-ADR O-ADR
adjusted O-ADR O-ADR
to O-ADR O-ADR
ensure O-ADR O-ADR
that O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
administered O-ADR O-ADR
within O-ADR O-ADR
two O-ADR O-ADR
hours O-ADR O-ADR
before O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
VORAXAZE O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Vizamyl O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Other O-ADR O-ADR
malignancies B-ADR B-ADR
: O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
immunosuppressants O-ADR O-ADR
; O-ADR O-ADR
appears O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
intensity O-ADR O-ADR
and O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Thyroid O-ADR O-ADR
Accumulation O-ADR O-ADR
The O-ADR O-ADR
DaTscan O-ADR O-ADR
injection O-ADR O-ADR
may O-ADR O-ADR
contain O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
free O-ADR O-ADR
iodide O-ADR O-ADR
( O-ADR O-ADR
iodine O-ADR O-ADR
123 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
experiencing O-ADR O-ADR
Grade O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
diarrhea O-ADR O-ADR
, O-ADR O-ADR
dosage O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
modified O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
prophylaxis O-ADR O-ADR
of O-ADR O-ADR
thromboembolic O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
valvular O-ADR O-ADR
heart O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
bioprosthetic O-ADR O-ADR
heart O-ADR O-ADR
valve O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
CAPS O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
pattern O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
type O-ADR O-ADR
or O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
throughout O-ADR O-ADR
the O-ADR O-ADR
three O-ADR O-ADR
study O-ADR O-ADR
periods O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
taking O-ADR O-ADR
OTEZLA O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Studies O-ADR O-ADR
102 O-ADR O-ADR
and O-ADR O-ADR
103 O-ADR O-ADR
, O-ADR O-ADR
bone B-ADR B-ADR
fractures I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
27 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
STRIBILD O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ATRIPLA O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
19 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Infections B-ADR B-ADR
: O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
infections B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
immunosuppressive O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
lists O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
PHN O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
HORIZANT O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
and O-ADR O-ADR
numerically O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Stop O-ADR O-ADR
Kyprolis O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
dyspnea O-ADR O-ADR
until O-ADR O-ADR
resolved O-ADR O-ADR
or O-ADR O-ADR
returned O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
Wolff O-ADR O-ADR
- O-ADR O-ADR
Parkinson O-ADR O-ADR
- O-ADR O-ADR
White O-ADR O-ADR
syndrome O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
supraventricular B-ADR B-ADR
tachycardia I-ADR I-ADR
. O-ADR O-ADR
All O-ADR O-ADR
second B-ADR B-ADR
degree I-ADR I-ADR
AV I-ADR I-ADR
blocks I-ADR I-ADR
on I-ADR O-ADR
placebo I-ADR O-ADR
were I-ADR O-ADR
Mobitz I-ADR O-ADR
Type I-ADR O-ADR
I I-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
12 O-ADR O-ADR
hours O-ADR O-ADR
postdose O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
combination O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
immune O-ADR O-ADR
systems O-ADR O-ADR
respond O-ADR O-ADR
may O-ADR O-ADR
develop O-ADR O-ADR
an O-ADR O-ADR
inflammatory B-ADR B-ADR
response I-ADR O-ADR
to O-ADR O-ADR
indolent O-ADR O-ADR
or O-ADR O-ADR
residual B-ADR B-ADR
opportunistic I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Mycobacterium B-ADR B-ADR
avium I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
cytomegalovirus B-ADR B-ADR
, O-ADR O-ADR
Pneumocystis B-ADR B-ADR
jirovecii I-ADR I-ADR
pneumonia I-ADR I-ADR
[ O-ADR O-ADR
PCP B-ADR B-ADR
] O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
tuberculosis B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
necessitate O-ADR O-ADR
further O-ADR O-ADR
evaluation O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
indication O-ADR O-ADR
) O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZERBAXA O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hematologic O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
EMTP O-ADR O-ADR
trial O-ADR O-ADR
is O-ADR O-ADR
provided O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
98 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
completed O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
90 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
intended O-ADR O-ADR
patch O-ADR O-ADR
application O-ADR O-ADR
duration O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ILD B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
: O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
arrhythmia B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
, O-ADR O-ADR
ILD B-ADR B-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
experienced O-ADR O-ADR
prolonged O-ADR B-ADR
lymphopenia B-ADR I-ADR
( O-ADR O-ADR
lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
predominantly O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5x10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
for O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
TECFIDERA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
TECFIDERA O-ADR O-ADR
if O-ADR O-ADR
lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
persist O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GlaxoSmithKline O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
825 O-ADR O-ADR
- O-ADR O-ADR
5249 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
below O-ADR O-ADR
and O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Distant B-ADR B-ADR
Spread I-ADR I-ADR
of I-ADR I-ADR
Toxin I-ADR I-ADR
Effect I-ADR I-ADR
[ O-ADR O-ADR
seeBoxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Lack O-ADR O-ADR
of O-ADR O-ADR
Interchangeability O-ADR O-ADR
between O-ADR O-ADR
Botulinum O-ADR O-ADR
Toxin O-ADR O-ADR
Products O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Spread B-ADR B-ADR
of I-ADR I-ADR
Effects I-ADR I-ADR
from I-ADR I-ADR
Toxin I-ADR I-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Dysphagia B-ADR B-ADR
and O-ADR O-ADR
Breathing B-ADR B-ADR
Difficulties I-ADR I-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Facial O-ADR B-ADR
Anatomy O-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
Neuromuscular O-ADR O-ADR
Disorders O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Human O-ADR B-ADR
Albumin O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Intradermal B-ADR B-ADR
Immune I-ADR I-ADR
Reaction I-ADR I-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
hypertension O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
controlled O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
ocular O-ADR O-ADR
steroids O-ADR O-ADR
may O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
exacerbate B-ADR O-ADR
the I-ADR O-ADR
severity I-ADR O-ADR
of I-ADR O-ADR
many I-ADR O-ADR
viral I-ADR O-ADR
infections I-ADR O-ADR
of I-ADR O-ADR
the I-ADR O-ADR
eye I-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ocular B-ADR B-ADR
manifestations I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
tuberculosis B-ADR B-ADR
through O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
but O-ADR O-ADR
one O-ADR O-ADR
NULOJIX O-ADR O-ADR
patient O-ADR O-ADR
lived O-ADR O-ADR
in O-ADR O-ADR
countries O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
prevalence O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
29 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
required O-ADR O-ADR
catheterization O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
voiding O-ADR O-ADR
residuals O-ADR O-ADR
of O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
500 O-ADR O-ADR
mL O-ADR O-ADR
. O-ADR O-ADR
Neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
or O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XIAFLEX O-ADR O-ADR
. O-ADR O-ADR
Dyslipidemia O-ADR O-ADR
Mean O-ADR O-ADR
values O-ADR O-ADR
of O-ADR O-ADR
total O-ADR O-ADR
cholesterol O-ADR O-ADR
, O-ADR O-ADR
HDL O-ADR O-ADR
, O-ADR O-ADR
LDL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
triglycerides O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
possible O-ADR O-ADR
bacterial O-ADR O-ADR
, O-ADR O-ADR
fungal O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
viral O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
: O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
, O-ADR O-ADR
pneumothorax B-ADR B-ADR
, O-ADR O-ADR
gastric B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
general B-ADR B-ADR
physical I-ADR I-ADR
health I-ADR I-ADR
deterioration I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
tuberculosis I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
tamponade I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
each O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
milk O-ADR O-ADR
protein O-ADR O-ADR
allergy O-ADR O-ADR
after O-ADR O-ADR
inhalation O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
powder O-ADR O-ADR
medications O-ADR O-ADR
containing O-ADR O-ADR
lactose O-ADR O-ADR
; O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
milk O-ADR O-ADR
protein O-ADR O-ADR
allergy O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
Drug B-ADR B-ADR
Rash I-ADR I-ADR
with I-ADR O-ADR
Eosinophilia I-ADR O-ADR
and I-ADR O-ADR
Systemic I-ADR O-ADR
Symptoms I-ADR I-ADR
( O-ADR O-ADR
DRESS B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
constitutional O-ADR O-ADR
findings O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
organ B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
, O-ADR O-ADR
Including O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
such O-ADR O-ADR
as O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
closely O-ADR O-ADR
and O-ADR O-ADR
take O-ADR O-ADR
appropriate O-ADR O-ADR
measures O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
was O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
abiraterone O-ADR O-ADR
acetate O-ADR O-ADR
arm O-ADR O-ADR
were O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
joint B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
, O-ADR O-ADR
hot B-ADR B-ADR
flush I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
and O-ADR O-ADR
contusion B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reasons O-ADR O-ADR
for O-ADR O-ADR
dose O-ADR O-ADR
reductions O-ADR O-ADR
were O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
or O-ADR O-ADR
colitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
recurrent O-ADR O-ADR
contractures O-ADR O-ADR
with O-ADR O-ADR
XIAFLEX O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
similar O-ADR O-ADR
immunogenicity O-ADR O-ADR
results O-ADR O-ADR
as O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Viral O-ADR O-ADR
Infections O-ADR O-ADR
Employment O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
corticosteroid O-ADR O-ADR
medication O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
herpes O-ADR O-ADR
simplex O-ADR O-ADR
requires O-ADR O-ADR
great O-ADR O-ADR
caution O-ADR O-ADR
. O-ADR O-ADR
# O-ADR O-ADR
Most O-ADR O-ADR
herpes B-ADR B-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
59 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
and O-ADR O-ADR
any O-ADR O-ADR
concomitant O-ADR O-ADR
serotonergic O-ADR O-ADR
agents O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
above O-ADR O-ADR
events O-ADR O-ADR
occur O-ADR O-ADR
and O-ADR O-ADR
supportive O-ADR O-ADR
symptomatic O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
liver I-ADR I-ADR
enzymes I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
outside O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
CRS B-ADR O-ADR
and O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
and O-ADR O-ADR
individual O-ADR O-ADR
ADR O-ADR O-ADR
terms O-ADR O-ADR
are O-ADR O-ADR
sorted O-ADR O-ADR
in O-ADR O-ADR
descending O-ADR O-ADR
frequency O-ADR O-ADR
order O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Progressive B-ADR B-ADR
multifocal I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Withhold O-ADR O-ADR
TECFIDERA O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
or O-ADR O-ADR
symptom O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
Phase O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
2 O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
for O-ADR O-ADR
diarrhea O-ADR B-ADR
( O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
per O-ADR O-ADR
event O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
Inhalation O-ADR O-ADR
of O-ADR O-ADR
airborne O-ADR O-ADR
capsaicin O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
coughing B-ADR B-ADR
or O-ADR O-ADR
sneezing B-ADR B-ADR
. O-ADR O-ADR
Only O-ADR O-ADR
use O-ADR O-ADR
SIRTURO O-ADR O-ADR
when O-ADR O-ADR
an O-ADR O-ADR
effective O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
otherwise O-ADR O-ADR
be O-ADR O-ADR
provided O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
all O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
600 O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
Qutenza O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
malaria O-ADR O-ADR
between O-ADR O-ADR
ages O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
71 O-ADR O-ADR
years O-ADR O-ADR
: O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
332 O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
16 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
younger O-ADR O-ADR
and O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
647 O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
16 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
distant O-ADR O-ADR
effects O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
additional O-ADR O-ADR
respiratory O-ADR O-ADR
muscles O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
involved O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Spread O-ADR O-ADR
of O-ADR O-ADR
Toxin O-ADR O-ADR
Effect O-ADR O-ADR
Postmarketing O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
XEOMIN O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
approved O-ADR O-ADR
botulinum O-ADR O-ADR
toxins O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
botulinum O-ADR O-ADR
toxin B-ADR B-ADR
effects I-ADR I-ADR
may I-ADR I-ADR
, I-ADR I-ADR
in I-ADR I-ADR
some I-ADR I-ADR
cases I-ADR I-ADR
, I-ADR I-ADR
be I-ADR I-ADR
observed I-ADR I-ADR
beyond I-ADR I-ADR
the I-ADR I-ADR
site I-ADR I-ADR
of I-ADR I-ADR
local I-ADR I-ADR
injection I-ADR I-ADR
. O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
, O-ADR O-ADR
third B-ADR B-ADR
- O-ADR O-ADR
degree O-ADR O-ADR
AV I-ADR I-ADR
block I-ADR I-ADR
and O-ADR O-ADR
AV B-ADR B-ADR
block I-ADR I-ADR
with O-ADR O-ADR
junctional B-ADR B-ADR
escape I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
hour O-ADR O-ADR
observation O-ADR O-ADR
period O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
need O-ADR O-ADR
of O-ADR O-ADR
emergency O-ADR O-ADR
cardiorespiratory O-ADR O-ADR
support O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
an O-ADR O-ADR
exploratory O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
evaluating O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subcutaneous O-ADR O-ADR
formulation O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
persistent O-ADR O-ADR
asthma O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
golimumab O-ADR O-ADR
reported O-ADR O-ADR
malignancies B-ADR B-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Dyspnea O-ADR O-ADR
Dyspnea B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
28 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Careful O-ADR O-ADR
consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
this O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
conditions O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
supine O-ADR O-ADR
hypertension O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
managed O-ADR O-ADR
, O-ADR O-ADR
NORTHERA O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
cardiovascular O-ADR B-ADR
events O-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
Associated O-ADR O-ADR
With O-ADR O-ADR
Gabapentin O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
gabapentin O-ADR O-ADR
, O-ADR O-ADR
either O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
or O-ADR O-ADR
postmarketing O-ADR O-ADR
: O-ADR O-ADR
breast B-ADR B-ADR
enlargement I-ADR I-ADR
, O-ADR O-ADR
gynecomastia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
elevated B-ADR B-ADR
creatine I-ADR I-ADR
kinase I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
regularly O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
discontinued O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
monitoring O-ADR O-ADR
for O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
TIVICAY O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
hepatic O-ADR O-ADR
disease O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
accumulation B-ADR B-ADR
of I-ADR I-ADR
body I-ADR I-ADR
fat I-ADR I-ADR
and O-ADR O-ADR
immune B-ADR B-ADR
reconstitution I-ADR I-ADR
syndrome I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
combination O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
irrespective O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
) O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
pneumonitis B-ADR B-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Advanced O-ADR O-ADR
PNET O-ADR O-ADR
Grading O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
CTCAE O-ADR O-ADR
Version O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
aphthous B-ADR B-ADR
stomatitis I-ADR I-ADR
, O-ADR O-ADR
gingival B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
glossitis B-ADR B-ADR
, O-ADR O-ADR
glossodynia B-ADR B-ADR
, O-ADR O-ADR
lip B-ADR B-ADR
ulceration I-ADR I-ADR
, O-ADR O-ADR
mouth B-ADR B-ADR
ulceration I-ADR I-ADR
, O-ADR O-ADR
tongue B-ADR B-ADR
ulceration I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
mucosal B-ADR B-ADR
inflammation I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Corneal O-ADR O-ADR
Exposure O-ADR O-ADR
, O-ADR O-ADR
Corneal O-ADR O-ADR
Ulceration O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Ectropion O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
XEOMIN O-ADR O-ADR
for O-ADR O-ADR
Blepharospasm O-ADR O-ADR
Reduced B-ADR B-ADR
blinking I-ADR I-ADR
from O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
orbicularis O-ADR O-ADR
muscle O-ADR O-ADR
can O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
corneal B-ADR O-ADR
exposure I-ADR O-ADR
and O-ADR O-ADR
corneal B-ADR O-ADR
ulceration I-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
VII O-ADR O-ADR
nerve O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
and O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
is O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Exposure O-ADR O-ADR
to O-ADR O-ADR
sunlight O-ADR O-ADR
and O-ADR O-ADR
ultraviolet O-ADR O-ADR
( O-ADR O-ADR
UV O-ADR O-ADR
) O-ADR O-ADR
light O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
limited O-ADR O-ADR
by O-ADR O-ADR
wearing O-ADR O-ADR
protective O-ADR O-ADR
clothing O-ADR O-ADR
and O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
sunscreen O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
protection O-ADR O-ADR
factor O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
total O-ADR O-ADR
population O-ADR O-ADR
across O-ADR O-ADR
the O-ADR O-ADR
three O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
229 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
125 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
141 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
69 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
139 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
102 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
four O-ADR O-ADR
times O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
14 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
54 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
500 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
146 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
242 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
500 O-ADR O-ADR
mg O-ADR O-ADR
four O-ADR O-ADR
times O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
14 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Neonates O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Impaired B-ADR B-ADR
wound I-ADR I-ADR
healing I-ADR I-ADR
: O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
wound B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
complications I-ADR I-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
consider O-ADR O-ADR
PTLD O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
reporting O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
neurological O-ADR O-ADR
, O-ADR O-ADR
cognitive O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
behavioral O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
outcomes O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Progressive B-ADR B-ADR
multifocal I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
b O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
documented O-ADR O-ADR
symptomatic O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
hypoglycemia B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
TANZEUM O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
these O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
omitted O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
table O-ADR O-ADR
. O-ADR O-ADR
Bipolar O-ADR O-ADR
I O-ADR O-ADR
Disorder O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
SAPHRIS2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
SAPHRIS5 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
SAPHRIS10 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
kg O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
89 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
92 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
90 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
87 O-ADR O-ADR
) O-ADR O-ADR
Proportion O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Increase B-ADR B-ADR
in I-ADR I-ADR
Body I-ADR I-ADR
Weight I-ADR I-ADR
% O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
body I-ADR I-ADR
weight I-ADR I-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
morbid O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressants O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
all O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
underlying O-ADR O-ADR
anatomic O-ADR O-ADR
or O-ADR O-ADR
vascular O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
NAION O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
necessarily O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
: O-ADR O-ADR
low O-ADR O-ADR
cup O-ADR O-ADR
to O-ADR O-ADR
disc O-ADR O-ADR
ratio O-ADR O-ADR
( O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
crowded O-ADR O-ADR
disc O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
over O-ADR O-ADR
50 O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
coronary O-ADR O-ADR
artery O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
hyperlipidemia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
smoking O-ADR O-ADR
. O-ADR O-ADR
Reported O-ADR O-ADR
infections O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
, O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Active B-ADR B-ADR
tuberculosis I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
latent I-ADR I-ADR
tuberculosis I-ADR I-ADR
. O-ADR O-ADR
transfusion O-ADR O-ADR
) O-ADR O-ADR
if O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Rapid O-ADR O-ADR
intravenous O-ADR O-ADR
infusion B-ADR O-ADR
of I-ADR O-ADR
glycopeptide I-ADR O-ADR
antibacterial I-ADR O-ADR
agents I-ADR O-ADR
can I-ADR O-ADR
cause I-ADR O-ADR
reactions I-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
arrhythmias O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
circumstances O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
torsade O-ADR O-ADR
de O-ADR O-ADR
pointes O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
sudden O-ADR O-ADR
death O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
bradycardia O-ADR O-ADR
; O-ADR O-ADR
hypokalemia O-ADR O-ADR
or O-ADR O-ADR
hypomagnesemia O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
congenital O-ADR O-ADR
prolongation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
. O-ADR O-ADR
Certain O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
exertional B-ADR B-ADR
dyspnea I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
risk O-ADR O-ADR
was O-ADR O-ADR
demonstrated O-ADR O-ADR
in O-ADR O-ADR
year O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
persisted O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
discontinuation O-ADR O-ADR
rate O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
STENDRA O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
stopped O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
treatments O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
- O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
start O-ADR O-ADR
CIMZIA O-ADR O-ADR
during O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
SJIA O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ILARIS O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
43 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
41 O-ADR O-ADR
) O-ADR O-ADR
via O-ADR O-ADR
subcutaneous O-ADR O-ADR
injection O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
assessed O-ADR O-ADR
at O-ADR O-ADR
Day O-ADR O-ADR
15 O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
endpoints O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
safety O-ADR O-ADR
analysis O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
Day O-ADR O-ADR
29 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
pneumonitis B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
even O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
impairment I-ADR I-ADR
: O-ADR O-ADR
Reduce O-ADR O-ADR
the O-ADR O-ADR
JEVTANA O-ADR O-ADR
dose O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
mild O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
15 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
presenting O-ADR O-ADR
with O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
specific O-ADR O-ADR
respiratory O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
hypoxia O-ADR O-ADR
, O-ADR O-ADR
pleural O-ADR O-ADR
effusion O-ADR O-ADR
, O-ADR O-ADR
cough O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
infectious O-ADR O-ADR
, O-ADR O-ADR
neoplastic O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
causes O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
excluded O-ADR O-ADR
by O-ADR O-ADR
means O-ADR O-ADR
of O-ADR O-ADR
appropriate O-ADR O-ADR
investigations O-ADR O-ADR
. O-ADR O-ADR
Routine O-ADR O-ADR
ophthalmological O-ADR O-ADR
examination O-ADR O-ADR
detected O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
visual B-ADR O-ADR
symptoms I-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
NORTHERA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
supine B-ADR B-ADR
hypertension I-ADR I-ADR
and O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR B-ADR
cardiovascular B-ADR B-ADR
risk I-ADR I-ADR
if O-ADR O-ADR
supine B-ADR O-ADR
hypertension I-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
managed O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Careful O-ADR O-ADR
testing O-ADR O-ADR
of O-ADR O-ADR
corneal O-ADR O-ADR
sensation O-ADR O-ADR
in O-ADR O-ADR
eyes O-ADR O-ADR
previously O-ADR O-ADR
operated O-ADR O-ADR
upon O-ADR O-ADR
, O-ADR O-ADR
avoidance O-ADR O-ADR
of O-ADR O-ADR
injection O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
lower O-ADR O-ADR
lid O-ADR O-ADR
area O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
ectropion O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vigorous O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
epithelial O-ADR O-ADR
defect O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
employed O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
The O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
Grades O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
STRIBILD O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
102 O-ADR O-ADR
and O-ADR O-ADR
103 O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
an O-ADR O-ADR
examination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
fundus O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
macula O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
again O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
again O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
reports O-ADR O-ADR
visual O-ADR B-ADR
disturbances O-ADR I-ADR
while O-ADR O-ADR
on O-ADR O-ADR
GILENYA O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reported O-ADR O-ADR
frequency O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
group O-ADR O-ADR
receiving O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
may O-ADR O-ADR
underestimate O-ADR O-ADR
the O-ADR O-ADR
actual O-ADR O-ADR
frequency O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
lower O-ADR O-ADR
assay O-ADR O-ADR
sensitivity O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
high O-ADR O-ADR
drug O-ADR O-ADR
concentrations O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hyperpyrexia O-ADR O-ADR
and O-ADR O-ADR
Confusion O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
symptom O-ADR O-ADR
complex O-ADR O-ADR
resembling O-ADR O-ADR
neuroleptic B-ADR B-ADR
malignant I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
NMS B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
NORTHERA O-ADR O-ADR
use O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
surveillance O-ADR O-ADR
in O-ADR O-ADR
Japan O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
constitutional O-ADR O-ADR
findings O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
organ B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
liver B-ADR O-ADR
injury I-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Tardive B-ADR B-ADR
dyskinesia I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
if O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Allergic O-ADR O-ADR
Reactions O-ADR O-ADR
This O-ADR O-ADR
product O-ADR O-ADR
contains O-ADR O-ADR
FD O-ADR O-ADR
& O-ADR O-ADR
C O-ADR O-ADR
Yellow O-ADR O-ADR
No O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
AFINITOR O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
stomatitis B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
symptoms O-ADR O-ADR
are O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
of O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
generalized B-ADR B-ADR
muscle I-ADR I-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
ptosis B-ADR B-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
dysarthria B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
incontinence I-ADR I-ADR
and O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
withdrew O-ADR O-ADR
from O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
DUAVEE O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Liver B-ADR B-ADR
enzyme I-ADR I-ADR
elevation I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
the O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
( O-ADR O-ADR
366 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
613 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
394 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
treatment O-ADR O-ADR
application O-ADR O-ADR
and O-ADR O-ADR
274 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
followed O-ADR O-ADR
for O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
or O-ADR O-ADR
longer O-ADR O-ADR
. O-ADR O-ADR
Flush O-ADR O-ADR
eyes O-ADR O-ADR
and O-ADR O-ADR
mucous O-ADR O-ADR
membranes O-ADR O-ADR
with O-ADR O-ADR
cool O-ADR O-ADR
water O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ASTHMA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
DEATH B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ASTHMA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
DEATH B-ADR B-ADR
L O-ADR O-ADR
ong O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonist O-ADR O-ADR
s O-ADR O-ADR
( O-ADR O-ADR
LABA O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
TABLE O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Changes O-ADR O-ADR
in O-ADR O-ADR
Fasting O-ADR O-ADR
Glucose O-ADR O-ADR
in O-ADR O-ADR
Pediatric O-ADR O-ADR
Subjects O-ADR O-ADR
Bipolar O-ADR O-ADR
I O-ADR O-ADR
Disorder O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
SAPHRIS2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
SAPHRIS5 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
SAPHRIS10 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
Mean O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
in O-ADR O-ADR
Fasting O-ADR O-ADR
Glucose O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
( O-ADR O-ADR
56 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
( O-ADR O-ADR
51 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
45 O-ADR O-ADR
( O-ADR O-ADR
57 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
34 O-ADR O-ADR
( O-ADR O-ADR
52 O-ADR O-ADR
) O-ADR O-ADR
Proportion O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
with O-ADR O-ADR
Shifts O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
to O-ADR O-ADR
Endpoint O-ADR O-ADR
Normal O-ADR O-ADR
to O-ADR O-ADR
High O-ADR O-ADR
> O-ADR O-ADR
45 O-ADR O-ADR
& O-ADR O-ADR
< O-ADR O-ADR
100 O-ADR O-ADR
to O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
126 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
/ O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
56 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
51 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
57 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
52 O-ADR O-ADR
) O-ADR O-ADR
Dyslipidemia B-ADR O-ADR
Undesirable B-ADR O-ADR
alterations I-ADR B-ADR
in I-ADR I-ADR
lipids I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
. O-ADR O-ADR
Increases O-ADR O-ADR
in O-ADR O-ADR
Hemoglobin O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
mean O-ADR O-ADR
changes B-ADR B-ADR
( I-ADR I-ADR
percent I-ADR I-ADR
changes I-ADR I-ADR
) I-ADR I-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
were O-ADR O-ADR
- O-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
18 O-ADR O-ADR
g O-ADR I-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
- O-ADR I-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
47 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
51 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
antidepressants O-ADR O-ADR
, O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
or O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
mania O-ADR O-ADR
or O-ADR O-ADR
hypomania O-ADR O-ADR
. O-ADR O-ADR
Restless O-ADR O-ADR
Legs O-ADR O-ADR
Syndrome O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
HORIZANT O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
201 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RLS O-ADR O-ADR
included O-ADR O-ADR
613 O-ADR O-ADR
exposed O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
371 O-ADR O-ADR
exposed O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
TRULICITY O-ADR O-ADR
causes O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
medullary B-ADR B-ADR
thyroid I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
MTC B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
human O-ADR O-ADR
relevance O-ADR O-ADR
of O-ADR O-ADR
dulaglutide O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
rodent O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
determined O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Hyponatremia O-ADR O-ADR
Hyponatremia B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SSRIs O-ADR O-ADR
and O-ADR O-ADR
SNRIs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
fasting O-ADR O-ADR
blood O-ADR O-ADR
samples O-ADR O-ADR
were O-ADR O-ADR
drawn O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
one O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RA O-ADR O-ADR
receiving O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
by O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
epilepsy O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
23 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
and O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Ferriprox O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
agranulocytosis B-ADR B-ADR
that O-ADR O-ADR
can O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
and O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Long O-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative O-ADR I-ADR
radiation O-ADR I-ADR
exposure O-ADR I-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
cancer B-ADR B-ADR
. O-ADR O-ADR
Chromaturia B-ADR B-ADR
( O-ADR O-ADR
reddish O-ADR B-ADR
/ O-ADR O-ADR
brown O-ADR O-ADR
discoloration O-ADR I-ADR
of O-ADR I-ADR
the O-ADR I-ADR
urine O-ADR I-ADR
) O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
excretion O-ADR B-ADR
of O-ADR I-ADR
the O-ADR I-ADR
iron O-ADR I-ADR
in O-ADR I-ADR
the O-ADR I-ADR
urine O-ADR I-ADR
. O-ADR O-ADR
cDefined O-ADR O-ADR
as O-ADR O-ADR
bleeding B-ADR B-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
a O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
transfusion O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
packed O-ADR O-ADR
red O-ADR O-ADR
blood O-ADR O-ADR
cells O-ADR O-ADR
, O-ADR O-ADR
bleeding B-ADR B-ADR
at I-ADR I-ADR
a I-ADR I-ADR
critical I-ADR I-ADR
site I-ADR I-ADR
or O-ADR O-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
. O-ADR O-ADR
Immediately O-ADR O-ADR
discontinue O-ADR O-ADR
treatment O-ADR O-ADR
if O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
rash O-ADR O-ADR
or O-ADR O-ADR
rash O-ADR O-ADR
with O-ADR O-ADR
systemic O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
liver O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
develops O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
clinical O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
liver O-ADR O-ADR
transaminases O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Increased O-ADR O-ADR
Toxicity O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Presence O-ADR O-ADR
of O-ADR O-ADR
Severe O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
The O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
deaths B-ADR B-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
discontinue O-ADR O-ADR
TRULICITY O-ADR O-ADR
and O-ADR O-ADR
promptly O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
advice O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
not O-ADR O-ADR
applicable O-ADR O-ADR
; O-ADR O-ADR
( O-ADR O-ADR
grading O-ADR O-ADR
system O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
specify O-ADR O-ADR
> O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
for O-ADR O-ADR
alopecia B-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Hypertension O-ADR O-ADR
Blood O-ADR O-ADR
pressure O-ADR O-ADR
and O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
antihypertensive O-ADR O-ADR
medications O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Fat O-ADR O-ADR
Redistribution O-ADR O-ADR
buffalo B-ADR B-ADR
hump I-ADR I-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
wasting I-ADR I-ADR
, O-ADR O-ADR
breast B-ADR B-ADR
enlargement I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
cushingoid B-ADR B-ADR
appearance I-ADR I-ADR
' O-ADR O-ADR
' O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Major O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
within O-ADR O-ADR
each O-ADR O-ADR
subcategory O-ADR O-ADR
were O-ADR O-ADR
counted O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
contributed O-ADR O-ADR
events O-ADR O-ADR
to O-ADR O-ADR
multiple O-ADR O-ADR
subcategories O-ADR O-ADR
. O-ADR O-ADR
Premedication O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
acetaminophen O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
antihistamine O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
corticosteroid O-ADR O-ADR
. O-ADR O-ADR
Cardiac O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Pancreatitis B-ADR B-ADR
: O-ADR O-ADR
Has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
PHN O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
should O-ADR O-ADR
usually O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
Infusion O-ADR O-ADR
Reactions O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis B-ADR B-ADR
or O-ADR O-ADR
drug B-ADR B-ADR
hypersensitivity I-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NULOJIX O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
through O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patient O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
not O-ADR O-ADR
taking O-ADR O-ADR
any O-ADR O-ADR
immunosuppressive O-ADR O-ADR
or O-ADR O-ADR
immunomodulatory O-ADR O-ADR
medications O-ADR O-ADR
concomitantly O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
treating O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
weight O-ADR O-ADR
gain O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
and O-ADR O-ADR
assessed O-ADR O-ADR
against O-ADR O-ADR
that O-ADR O-ADR
expected O-ADR O-ADR
for O-ADR O-ADR
normal O-ADR O-ADR
growth O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
included O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
subdural B-ADR B-ADR
hematomas I-ADR I-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
Vimizim O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
such O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
promptly O-ADR O-ADR
discontinue O-ADR O-ADR
NESINA O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
potential O-ADR O-ADR
causes O-ADR O-ADR
, O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
monitoring O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
alternative O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
diabetes O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
as O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
was O-ADR O-ADR
TB O-ADR B-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
DALVANCE O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
53 O-ADR O-ADR
/ O-ADR O-ADR
1778 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
comparator O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
35 O-ADR O-ADR
/ O-ADR O-ADR
1224 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
XALKORI O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
chemotherapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Eye O-ADR O-ADR
and O-ADR O-ADR
Mucous O-ADR O-ADR
Membrane O-ADR O-ADR
Exposure O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
apply O-ADR O-ADR
Qutenza O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
face O-ADR O-ADR
or O-ADR O-ADR
scalp O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
eyes O-ADR O-ADR
or O-ADR O-ADR
mucous O-ADR O-ADR
membranes O-ADR O-ADR
. O-ADR O-ADR
Instruct O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infections O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
unapproved O-ADR O-ADR
uses O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
spasticity O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
approved O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
spread B-ADR B-ADR
of I-ADR I-ADR
toxin I-ADR I-ADR
effect I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
recommended O-ADR O-ADR
total O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
this O-ADR O-ADR
product O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
setting O-ADR O-ADR
with O-ADR O-ADR
resuscitation O-ADR O-ADR
equipment O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
agents O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
anaphylaxis O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Bipolar O-ADR B-ADR
Disorder O-ADR I-ADR
Adults O-ADR O-ADR
( O-ADR O-ADR
Adjunctive O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
asthenia B-ADR B-ADR
. O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
369 O-ADR O-ADR
subjects O-ADR O-ADR
and O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
956 O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Serum O-ADR O-ADR
Lipids O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
similar O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
ATRIPLA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
were O-ADR O-ADR
on O-ADR O-ADR
lipid O-ADR O-ADR
lowering O-ADR O-ADR
agents O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Ecchymosis O-ADR B-ADR
easily O-ADR O-ADR
occurs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
soft O-ADR O-ADR
tissues O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
eyelid O-ADR O-ADR
. O-ADR O-ADR
Continuation O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
macular B-ADR O-ADR
edema I-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
elevate O-ADR O-ADR
the O-ADR O-ADR
head O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
bed O-ADR O-ADR
when O-ADR O-ADR
resting O-ADR O-ADR
or O-ADR O-ADR
sleeping O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Decreased O-ADR O-ADR
Efficacy O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Baseline O-ADR O-ADR
Creatinine O-ADR O-ADR
Clearance O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
subgroup O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
cIAI O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
clinical O-ADR O-ADR
cure O-ADR O-ADR
rates O-ADR O-ADR
were O-ADR O-ADR
lower O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
( O-ADR O-ADR
CrCl O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
CrCl O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
( O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Renal O-ADR O-ADR
Angiomyolipoma O-ADR O-ADR
Grading O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
CTCAE O-ADR O-ADR
Version O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
aphthous B-ADR B-ADR
stomatitis I-ADR I-ADR
, O-ADR O-ADR
mouth B-ADR B-ADR
ulceration I-ADR I-ADR
, O-ADR O-ADR
gingival B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
glossitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
glossodynia B-ADR B-ADR
. O-ADR O-ADR
Thrombocytopenia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
DaTscan O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
- O-ADR O-ADR
Asthenia B-ADR B-ADR
. O-ADR O-ADR
More O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
group O-ADR O-ADR
receiving O-ADR O-ADR
TANZEUM O-ADR O-ADR
were O-ADR O-ADR
serious O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
TANZEUM O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
comparators O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
108 O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
face O-ADR O-ADR
/ O-ADR O-ADR
scalp O-ADR O-ADR
and O-ADR O-ADR
38 O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
trunk O-ADR O-ADR
/ O-ADR O-ADR
extremities O-ADR O-ADR
were O-ADR O-ADR
followed O-ADR O-ADR
for O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
decrease O-ADR O-ADR
thyroid O-ADR O-ADR
accumulation O-ADR O-ADR
of O-ADR O-ADR
iodine O-ADR O-ADR
123 O-ADR O-ADR
, O-ADR O-ADR
block O-ADR O-ADR
the O-ADR O-ADR
thyroid O-ADR O-ADR
gland O-ADR O-ADR
before O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
DaTscan O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
diagnosed O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
TAFINLAR O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
until O-ADR O-ADR
uveitis O-ADR O-ADR
/ O-ADR O-ADR
iritis O-ADR O-ADR
resolves O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
0 O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Ocular O-ADR O-ADR
Toxicities O-ADR O-ADR
Retinal O-ADR B-ADR
Pigment O-ADR I-ADR
Epithelial O-ADR I-ADR
Detachment O-ADR I-ADR
( O-ADR O-ADR
RPED O-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Retinal B-ADR B-ADR
pigment I-ADR I-ADR
epithelial I-ADR I-ADR
detachments I-ADR I-ADR
( O-ADR O-ADR
RPED B-ADR B-ADR
) O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
[ O-ADR O-ADR
refer O-ADR O-ADR
to O-ADR O-ADR
Full O-ADR O-ADR
Prescribing O-ADR O-ADR
Information O-ADR O-ADR
for O-ADR O-ADR
trametinib O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
stroke B-ADR B-ADR
and O-ADR O-ADR
DVT B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
an O-ADR O-ADR
ESA O-ADR O-ADR
was O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
if O-ADR O-ADR
diarrhea O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
negative O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Five O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
six O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
group O-ADR O-ADR
that O-ADR O-ADR
received O-ADR O-ADR
PROMACTA O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
thrombotic B-ADR B-ADR
complication I-ADR I-ADR
within O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
completing O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
platelet O-ADR O-ADR
count O-ADR O-ADR
above O-ADR O-ADR
200 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
presenting O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
STENDRA O-ADR O-ADR
has O-ADR O-ADR
systemic O-ADR O-ADR
vasodilatory O-ADR O-ADR
properties O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
augment O-ADR O-ADR
the O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
- O-ADR O-ADR
lowering O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
medications O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Orthostatic O-ADR O-ADR
Hypotension O-ADR O-ADR
, O-ADR O-ADR
Syncope O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Hemodynamic O-ADR O-ADR
Effects O-ADR O-ADR
SAPHRIS O-ADR O-ADR
may O-ADR O-ADR
induce O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
early O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
its O-ADR O-ADR
alpha1 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
antagonist O-ADR O-ADR
activity O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
involving O-ADR O-ADR
various O-ADR O-ADR
organ O-ADR O-ADR
systems O-ADR O-ADR
and O-ADR O-ADR
sites O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
primarily O-ADR O-ADR
derive O-ADR O-ADR
from O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
three O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
in O-ADR O-ADR
de O-ADR O-ADR
novo O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
were O-ADR O-ADR
reversible O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
dosing O-ADR O-ADR
or O-ADR O-ADR
repeated O-ADR O-ADR
dosing O-ADR O-ADR
appears O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity O-ADR B-ADR
: O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
with O-ADR O-ADR
cutaneous B-ADR B-ADR
manifestations I-ADR I-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
reactions O-ADR O-ADR
including O-ADR O-ADR
shock B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
or O-ADR O-ADR
ischemic O-ADR O-ADR
heart O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
or O-ADR O-ADR
conduction O-ADR O-ADR
abnormalities O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
cerebrovascular O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
conditions O-ADR O-ADR
which O-ADR O-ADR
would O-ADR O-ADR
predispose O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
hypotension O-ADR O-ADR
( O-ADR O-ADR
dehydration O-ADR O-ADR
, O-ADR O-ADR
hypovolemia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
antihypertensive O-ADR O-ADR
medications O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
elderly O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
trial O-ADR O-ADR
: O-ADR O-ADR
decreased B-ADR B-ADR
lymphocytes I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
absolute I-ADR I-ADR
neutrophil I-ADR I-ADR
count I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
phosphorus I-ADR I-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
total I-ADR I-ADR
white I-ADR I-ADR
blood I-ADR I-ADR
cell I-ADR I-ADR
count I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
platelets I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
spasm I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
hemoglobin I-ADR I-ADR
, O-ADR O-ADR
hypokalemia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
schizophrenia O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
572 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
378 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
promptly O-ADR O-ADR
discontinue O-ADR O-ADR
TANZEUM O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Macrovascular O-ADR B-ADR
Outcomes O-ADR I-ADR
: O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
of O-ADR O-ADR
PVT B-ADR B-ADR
included O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
During O-ADR O-ADR
adult O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
without O-ADR O-ADR
comparison O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
seizures B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
1953 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
Factors O-ADR O-ADR
that O-ADR O-ADR
can O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
spinal B-ADR B-ADR
hematomas I-ADR I-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
indwelling O-ADR O-ADR
epidural O-ADR O-ADR
catheters O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
affect O-ADR O-ADR
hemostasis O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
nonsteroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
NSAIDs O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
platelet O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
anticoagulants O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
traumatic O-ADR O-ADR
or O-ADR O-ADR
repeated O-ADR O-ADR
epidural O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
punctures O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
spinal O-ADR O-ADR
deformity O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
surgery O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
optimal O-ADR O-ADR
timing O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
and O-ADR O-ADR
neuraxial O-ADR O-ADR
procedures O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
frequently O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
neurological O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
flatulence B-ADR B-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
bilirubin I-ADR I-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Potassium O-ADR O-ADR
Iodide O-ADR O-ADR
Oral O-ADR O-ADR
Solution O-ADR O-ADR
or O-ADR O-ADR
Lugol O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Solution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
sensitive O-ADR O-ADR
to O-ADR O-ADR
such O-ADR O-ADR
products O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
of O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
weekly O-ADR O-ADR
basis O-ADR O-ADR
during O-ADR O-ADR
cycle O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
before O-ADR O-ADR
each O-ADR O-ADR
treatment O-ADR O-ADR
cycle O-ADR O-ADR
thereafter O-ADR O-ADR
so O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
adjusted O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
needed O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
generally O-ADR O-ADR
consisted O-ADR O-ADR
of O-ADR O-ADR
skin B-ADR B-ADR
erythema I-ADR I-ADR
and O-ADR O-ADR
pruritis B-ADR B-ADR
and O-ADR O-ADR
have O-ADR O-ADR
either O-ADR O-ADR
resolved O-ADR O-ADR
spontaneously O-ADR O-ADR
or O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
histamines O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hyperpyrexia B-ADR B-ADR
and O-ADR O-ADR
confusion B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
May O-ADR O-ADR
exacerbate B-ADR B-ADR
symptoms I-ADR I-ADR
in I-ADR O-ADR
patients I-ADR I-ADR
with I-ADR O-ADR
existing I-ADR O-ADR
ischemic I-ADR O-ADR
heart I-ADR O-ADR
disease I-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Allergic B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Supine O-ADR O-ADR
Hypertension O-ADR O-ADR
NORTHERA O-ADR O-ADR
therapy O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
or O-ADR O-ADR
exacerbate O-ADR O-ADR
supine B-ADR B-ADR
hypertension I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
NOH O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
GBCAs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Macular B-ADR B-ADR
edema I-ADR I-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
, O-ADR O-ADR
usually O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Sometimes O-ADR O-ADR
both O-ADR O-ADR
ovaries O-ADR O-ADR
are O-ADR O-ADR
removed O-ADR O-ADR
during O-ADR O-ADR
an O-ADR O-ADR
operation O-ADR O-ADR
before O-ADR O-ADR
natural O-ADR O-ADR
menopause O-ADR O-ADR
takes O-ADR O-ADR
place O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
For O-ADR O-ADR
All O-ADR O-ADR
Indications O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
potency O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
interchangeable O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
preparations O-ADR O-ADR
of O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
two O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
ranging O-ADR O-ADR
trial O-ADR O-ADR
was O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
511 O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
mild O-ADR O-ADR
persistent O-ADR O-ADR
asthma O-ADR O-ADR
taking O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
BOSULIF O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
provide O-ADR O-ADR
adequate O-ADR O-ADR
support O-ADR O-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
related O-ADR O-ADR
pain O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
next O-ADR O-ADR
cycle O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
platelet O-ADR O-ADR
count O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
75 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
were O-ADR O-ADR
all O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
incidences O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
AED O-ADR O-ADR
Withdrawal O-ADR O-ADR
Phase O-ADR O-ADR
and O-ADR O-ADR
Monotherapy O-ADR O-ADR
Phase O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
Titration O-ADR O-ADR
Phase O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
section O-ADR O-ADR
and O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
onset O-ADR O-ADR
tends O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
treatment O-ADR O-ADR
cycle O-ADR O-ADR
of O-ADR O-ADR
TREANDA O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
without O-ADR O-ADR
intervention O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
weight O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
urinary O-ADR O-ADR
retention O-ADR O-ADR
on O-ADR O-ADR
POTIGA O-ADR O-ADR
, O-ADR O-ADR
urologic O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
monitored O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Infections B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Malignancies B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
viral B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Underlying O-ADR O-ADR
etiology O-ADR O-ADR
not O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
elevated B-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
requiring O-ADR O-ADR
immediate O-ADR O-ADR
treatment O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
XenoPort O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
XENOPRT O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
936 O-ADR O-ADR
- O-ADR O-ADR
6778 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
displays O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
NORTHERA O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
greater O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
NORTHERA O-ADR O-ADR
group O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Hypercorticism O-ADR O-ADR
and O-ADR O-ADR
Adrenal O-ADR O-ADR
Suppression O-ADR O-ADR
Inhaled O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
is O-ADR O-ADR
absorbed O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
circulation O-ADR O-ADR
and O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
systemically O-ADR O-ADR
active O-ADR O-ADR
. O-ADR O-ADR
Congenital O-ADR O-ADR
, O-ADR O-ADR
familial O-ADR O-ADR
and O-ADR O-ADR
genetic O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
hypospadias B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Increased O-ADR O-ADR
Toxicity O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Presence O-ADR O-ADR
of O-ADR O-ADR
Moderate O-ADR O-ADR
or O-ADR O-ADR
Severe O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
The O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
deaths B-ADR B-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR B-ADR
impairment O-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
hepatic O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
treatment O-ADR O-ADR
discontinuations O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
death B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
if O-ADR O-ADR
not O-ADR O-ADR
responsive O-ADR O-ADR
to O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
emetics O-ADR O-ADR
or O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheals O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
requiring O-ADR O-ADR
oral O-ADR O-ADR
corticosteroids O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
weaned O-ADR O-ADR
slowly O-ADR O-ADR
from O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroid O-ADR O-ADR
use O-ADR O-ADR
after O-ADR O-ADR
transferring O-ADR O-ADR
to O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
of O-ADR O-ADR
HALAVEN O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Hold O-ADR O-ADR
ADCETRIS O-ADR O-ADR
dosing O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
suspected O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
ADCETRIS O-ADR O-ADR
dosing O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
vitro O-ADR O-ADR
studies O-ADR O-ADR
showed O-ADR O-ADR
no O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
cross O-ADR O-ADR
- O-ADR O-ADR
reactivity O-ADR O-ADR
between O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
antibody O-ADR O-ADR
positive O-ADR O-ADR
patient O-ADR O-ADR
sera O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
series O-ADR O-ADR
of O-ADR O-ADR
relevant O-ADR O-ADR
MMPs O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
five O-ADR O-ADR
years O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
90 O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
remained O-ADR O-ADR
seropositive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
antibody O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
rectal B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
gastric B-ADR B-ADR
ulcer I-ADR I-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
, O-ADR O-ADR
parotid B-ADR B-ADR
gland I-ADR I-ADR
enlargement I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Paradoxical O-ADR O-ADR
Bronchospasm O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
inhaled O-ADR O-ADR
medicines O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
can O-ADR O-ADR
produce O-ADR O-ADR
paradoxical B-ADR B-ADR
bronchospasm I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
rate O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
AMPYRA O-ADR O-ADR
were O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
balance B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
multiple B-ADR B-ADR
sclerosis I-ADR I-ADR
relapse I-ADR I-ADR
, O-ADR O-ADR
paresthesia B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
dyspepsia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pharyngolaryngeal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
risk O-ADR O-ADR
increases O-ADR O-ADR
with O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
over O-ADR O-ADR
35 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
cigarettes O-ADR O-ADR
smoked O-ADR O-ADR
. O-ADR O-ADR
By O-ADR O-ADR
Year O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
antihypertensive O-ADR O-ADR
medications O-ADR O-ADR
were O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
85 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
92 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cyclosporine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
56 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
negative O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
reassessed O-ADR O-ADR
approximately O-ADR O-ADR
7 O-ADR O-ADR
half O-ADR O-ADR
- O-ADR O-ADR
lives O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
tested O-ADR O-ADR
antibody O-ADR O-ADR
positive O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
section O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
RLS O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
a O-ADR O-ADR
sustained O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
PRISTIQ O-ADR O-ADR
, O-ADR O-ADR
either O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
trial O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
61 O-ADR O-ADR
years O-ADR O-ADR
; O-ADR O-ADR
61 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
GILOTRIF O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pemetrexed O-ADR O-ADR
/ O-ADR O-ADR
cisplatin O-ADR O-ADR
arm O-ADR O-ADR
were O-ADR O-ADR
younger O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
causative O-ADR O-ADR
organisms O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
identified O-ADR O-ADR
when O-ADR O-ADR
provided O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
physician O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
TECFIDERA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
experience O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
or O-ADR O-ADR
symptom O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
TECFIDERA O-ADR O-ADR
and O-ADR O-ADR
perform O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
diagnostic O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
Hyperglycemia O-ADR O-ADR
and O-ADR O-ADR
Diabetes O-ADR O-ADR
Mellitus O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
extreme O-ADR O-ADR
and O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ketoacidosis B-ADR B-ADR
or O-ADR O-ADR
hyperosmolar B-ADR B-ADR
coma I-ADR I-ADR
or O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
and O-ADR O-ADR
myalgia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
serum B-ADR B-ADR
phosphate I-ADR I-ADR
levels I-ADR I-ADR
increased I-ADR I-ADR
by O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
347 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
343 O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
50 O-ADR O-ADR
years O-ADR O-ADR
; O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Almost O-ADR O-ADR
all O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
received O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
azathioprine O-ADR O-ADR
( O-ADR O-ADR
AZA O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
mercaptopurine O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
MP O-ADR O-ADR
) O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
at O-ADR O-ADR
or O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
diagnosis O-ADR O-ADR
. O-ADR O-ADR
Atrioventricular O-ADR O-ADR
Blocks O-ADR O-ADR
Initiation O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
treatment O-ADR O-ADR
has O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
transient O-ADR B-ADR
AV B-ADR I-ADR
conduction I-ADR I-ADR
delays I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Bipolar O-ADR O-ADR
Disorder O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
( O-ADR O-ADR
Monotherapy O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
dysgeusia B-ADR B-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
paresthesia I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
weight I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Dysphagia O-ADR O-ADR
and O-ADR O-ADR
Breathing O-ADR O-ADR
Difficulties O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
61 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
27 O-ADR O-ADR
- O-ADR O-ADR
85 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
88 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
78 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
Grades O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
ALT B-ADR B-ADR
abnormalities I-ADR I-ADR
in O-ADR I-ADR
hepatitis O-ADR I-ADR
B O-ADR I-ADR
and O-ADR I-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
HIV O-ADR O-ADR
mono O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
50 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
- O-ADR O-ADR
daily O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
50 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
- O-ADR O-ADR
daily O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
FLAMINGO O-ADR O-ADR
trial O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
observations O-ADR O-ADR
in O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
SINGLE O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mechanism O-ADR O-ADR
and O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
complication O-ADR O-ADR
of O-ADR O-ADR
ptosis O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
steps O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Avoid O-ADR O-ADR
injection O-ADR O-ADR
near O-ADR O-ADR
the O-ADR O-ADR
levator O-ADR O-ADR
palpebrae O-ADR O-ADR
superioris O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
larger O-ADR O-ADR
brow O-ADR O-ADR
depressor O-ADR O-ADR
complexes O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
groups O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Hepatic O-ADR O-ADR
Toxicity O-ADR O-ADR
and O-ADR O-ADR
Hepatic O-ADR O-ADR
Failure O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
ratio O-ADR O-ADR
and O-ADR O-ADR
received O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
for O-ADR O-ADR
78 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
screening O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
postbronchodilator O-ADR O-ADR
percent O-ADR O-ADR
predicted O-ADR O-ADR
FEV1was O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
87 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
postbronchodilator O-ADR O-ADR
FEV1 O-ADR O-ADR
/ O-ADR O-ADR
forced O-ADR O-ADR
vital O-ADR O-ADR
capacity O-ADR O-ADR
( O-ADR O-ADR
FVC O-ADR O-ADR
) O-ADR O-ADR
ratio O-ADR O-ADR
was O-ADR O-ADR
47 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
88 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
percent O-ADR O-ADR
reversibility O-ADR O-ADR
was O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
- O-ADR O-ADR
41 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
152 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Laryngeal O-ADR O-ADR
Attacks O-ADR O-ADR
Given O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
airway O-ADR O-ADR
obstruction O-ADR O-ADR
during O-ADR O-ADR
acute O-ADR O-ADR
laryngeal O-ADR O-ADR
HAE O-ADR O-ADR
attacks O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
healthcare O-ADR O-ADR
facility O-ADR O-ADR
immediately O-ADR O-ADR
in O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
FIRAZYR O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
events O-ADR O-ADR
resolved O-ADR O-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
Investigations O-ADR O-ADR
- O-ADR O-ADR
Weight B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
liver B-ADR B-ADR
function I-ADR I-ADR
test I-ADR I-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
prolactin I-ADR I-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
ILARIS O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
clinical O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
ILARIS O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
other O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
eligible O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
plasma O-ADR O-ADR
methotrexate O-ADR O-ADR
level O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
mumol O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
42 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
methotrexate O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
plasma O-ADR O-ADR
level O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
standard O-ADR O-ADR
deviations O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
methotrexate O-ADR O-ADR
excretion O-ADR O-ADR
curve O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
12 O-ADR O-ADR
hours O-ADR O-ADR
following O-ADR O-ADR
methotrexate O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
was O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
12 O-ADR O-ADR
hours O-ADR O-ADR
following O-ADR O-ADR
methotrexate O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
Least O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Greater O-ADR O-ADR
than O-ADR O-ADR
Seen O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Receiving O-ADR O-ADR
Placebo O-ADR O-ADR
in O-ADR O-ADR
Controlled O-ADR O-ADR
Studies O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Placebo O-ADR O-ADR
ULORIC O-ADR O-ADR
allopurinolOf O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
allopurinol O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
received O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
145 O-ADR O-ADR
received O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1122 O-ADR O-ADR
received O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
level O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR B-ADR
. O-ADR O-ADR
JEVTANA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
cabazitaxel O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
formulated O-ADR O-ADR
with O-ADR O-ADR
polysorbate O-ADR O-ADR
80 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
modify O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Urinary O-ADR O-ADR
Tract O-ADR O-ADR
Infections O-ADR O-ADR
JARDIANCE O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
TANZEUM O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
pancreatitis O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
45 O-ADR O-ADR
days O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
final O-ADR O-ADR
dose O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
TANZEUM O-ADR O-ADR
causes O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
MTC B-ADR B-ADR
, O-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
, O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
PROGRESSIVE B-ADR B-ADR
MULTIFOCAL I-ADR I-ADR
LEUKOENCEPHALOPATHY I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
PROGRESSIVE B-ADR B-ADR
MULTIFOCAL I-ADR I-ADR
LEUKOENCEPHALOPATHY I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
JC B-ADR B-ADR
virus I-ADR I-ADR
infection I-ADR I-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
PML B-ADR B-ADR
and O-ADR O-ADR
death B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ADCETRIS O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
PROGRESSIVE B-ADR O-ADR
MULTIFOCAL I-ADR B-ADR
LEUKOENCEPHALOPATHY I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
See O-ADR O-ADR
Full O-ADR O-ADR
Prescribing O-ADR O-ADR
Information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
thromboembolic B-ADR B-ADR
complications I-ADR I-ADR
may O-ADR O-ADR
result O-ADR O-ADR
from O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
platelet I-ADR I-ADR
counts I-ADR I-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
modifications O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
delays O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
subjects O-ADR O-ADR
experienced O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
infections B-ADR B-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
subjects O-ADR O-ADR
experienced O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
neutropenia B-ADR B-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
379 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
203 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
hematuria B-ADR B-ADR
. O-ADR O-ADR
Opportunistic B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
opportunistic O-ADR B-ADR
pathogens O-ADR I-ADR
including O-ADR O-ADR
aspergillosis B-ADR B-ADR
, O-ADR O-ADR
blastomycosis B-ADR B-ADR
, O-ADR O-ADR
candidiasis B-ADR B-ADR
, O-ADR O-ADR
coccidioidomycosis B-ADR B-ADR
, O-ADR O-ADR
histoplasmosis B-ADR B-ADR
, O-ADR O-ADR
legionellosis B-ADR B-ADR
, O-ADR O-ADR
listeriosis B-ADR B-ADR
, O-ADR O-ADR
pneumocystosis B-ADR B-ADR
and O-ADR O-ADR
tuberculosis B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
Reported O-ADR O-ADR
thromboembolic B-ADR B-ADR
complications I-ADR I-ADR
and O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
at O-ADR O-ADR
low O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
normal O-ADR O-ADR
platelet O-ADR O-ADR
counts O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
ADCETRIS O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR O-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
TANZEUM O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
contraception O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
combined O-ADR O-ADR
oral O-ADR O-ADR
contraceptive O-ADR O-ADR
product O-ADR O-ADR
containing O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
norethindrone O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
are O-ADR O-ADR
vision B-ADR B-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dysgeusia B-ADR B-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
conducted O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
National O-ADR O-ADR
Cancer O-ADR O-ADR
Institute O-ADR O-ADR
( O-ADR O-ADR
NCI O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
enrolled O-ADR O-ADR
184 O-ADR O-ADR
patients O-ADR O-ADR
; O-ADR O-ADR
safety O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
149 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
irritation O-ADR O-ADR
persists O-ADR O-ADR
, O-ADR O-ADR
consult O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
CAPS O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
herein O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
ILARIS O-ADR O-ADR
in O-ADR O-ADR
104 O-ADR O-ADR
adult O-ADR O-ADR
and O-ADR O-ADR
pediatric O-ADR O-ADR
CAPS O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
20 O-ADR O-ADR
FCAS O-ADR O-ADR
, O-ADR O-ADR
72 O-ADR O-ADR
MWS O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
MWS O-ADR O-ADR
/ O-ADR O-ADR
NOMID O-ADR O-ADR
( O-ADR O-ADR
Neonatal O-ADR O-ADR
Onset O-ADR O-ADR
Multisystem O-ADR O-ADR
Inflammatory O-ADR O-ADR
Disorder O-ADR O-ADR
) O-ADR O-ADR
overlap O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
non O-ADR B-ADR
- O-ADR O-ADR
FCAS O-ADR O-ADR
non O-ADR I-ADR
- O-ADR O-ADR
MWS O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
misdiagnosed O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
( O-ADR O-ADR
35 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Corticosteroids O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
indicated O-ADR O-ADR
until O-ADR O-ADR
clinical O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
. O-ADR O-ADR
Diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
were O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Effects O-ADR O-ADR
on O-ADR O-ADR
Driving O-ADR O-ADR
HORIZANT O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
significant O-ADR O-ADR
driving B-ADR B-ADR
impairment I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Skin B-ADR B-ADR
discoloration I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
higher O-ADR O-ADR
frequency O-ADR O-ADR
among O-ADR O-ADR
emtricitabine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
; O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
manifested O-ADR O-ADR
by O-ADR O-ADR
hyperpigmentation B-ADR B-ADR
on I-ADR I-ADR
the I-ADR I-ADR
palms I-ADR I-ADR
and O-ADR O-ADR
was O-ADR O-ADR
generally O-ADR O-ADR
mild O-ADR O-ADR
and O-ADR O-ADR
asymptomatic O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Facial O-ADR O-ADR
Anatomy O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
Caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
surgical O-ADR O-ADR
alterations O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
facial O-ADR O-ADR
anatomy O-ADR O-ADR
, O-ADR O-ADR
excessive O-ADR O-ADR
weakness O-ADR O-ADR
or O-ADR O-ADR
atrophy O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
target O-ADR O-ADR
muscle O-ADR O-ADR
( O-ADR O-ADR
s O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
marked O-ADR O-ADR
facial O-ADR O-ADR
asymmetry O-ADR O-ADR
, O-ADR O-ADR
inflammation O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
site O-ADR O-ADR
( O-ADR O-ADR
s O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ptosis O-ADR B-ADR
, O-ADR O-ADR
excessive O-ADR O-ADR
dermatochalasis O-ADR O-ADR
, O-ADR O-ADR
deep O-ADR O-ADR
dermal O-ADR B-ADR
scarring O-ADR I-ADR
, O-ADR O-ADR
thick O-ADR O-ADR
sebaceous O-ADR O-ADR
skin O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
inability O-ADR O-ADR
to O-ADR O-ADR
substantially O-ADR O-ADR
lessen O-ADR O-ADR
glabellar O-ADR O-ADR
lines O-ADR O-ADR
by O-ADR O-ADR
physically O-ADR O-ADR
spreading O-ADR O-ADR
them O-ADR O-ADR
apart O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Psoriatic O-ADR O-ADR
arthritis O-ADR O-ADR
: O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
16 O-ADR O-ADR
week O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
/ O-ADR O-ADR
998 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
reported O-ADR O-ADR
depression B-ADR B-ADR
or O-ADR O-ADR
depressed B-ADR B-ADR
mood I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
495 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
malignancies O-ADR B-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
months O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
84 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Cardiac B-ADR B-ADR
toxicities I-ADR I-ADR
include O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
myocardial B-ADR B-ADR
ischemia I-ADR I-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
between O-ADR O-ADR
18 O-ADR O-ADR
and O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
approximately O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Bipolar O-ADR O-ADR
Disorder O-ADR O-ADR
Adults O-ADR O-ADR
( O-ADR O-ADR
Monotherapy O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
other O-ADR O-ADR
than O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
weight I-ADR I-ADR
. O-ADR O-ADR
INLYTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
untreated O-ADR O-ADR
brain O-ADR O-ADR
metastasis O-ADR O-ADR
or O-ADR O-ADR
recent O-ADR O-ADR
active O-ADR O-ADR
gastrointestinal O-ADR O-ADR
bleeding O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Demyelinating O-ADR O-ADR
Disorders O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
rare O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
exacerbation B-ADR B-ADR
of I-ADR I-ADR
central I-ADR I-ADR
nervous I-ADR I-ADR
system I-ADR I-ADR
( I-ADR I-ADR
CNS I-ADR I-ADR
) I-ADR I-ADR
demyelinating I-ADR I-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
multiple B-ADR B-ADR
sclerosis I-ADR I-ADR
( O-ADR O-ADR
MS B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
demyelinating I-ADR I-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
AFINITOR O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
and O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
suspending O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
reassess O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
reinitiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
procedure O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
new O-ADR O-ADR
major O-ADR O-ADR
safety O-ADR O-ADR
findings O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
50 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
uncontrolled O-ADR O-ADR
safety O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
Lysis I-ADR I-ADR
Syndrome I-ADR I-ADR
: O-ADR O-ADR
Acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
death B-ADR B-ADR
; O-ADR O-ADR
anticipate O-ADR O-ADR
and O-ADR O-ADR
use O-ADR O-ADR
supportive O-ADR O-ADR
measures O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
CLL O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
48 O-ADR O-ADR
) O-ADR O-ADR
using O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
420 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
occurring O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Tables O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
or O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
therapeutics O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
class O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
in O-ADR O-ADR
88 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
moderately O-ADR O-ADR
impaired O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
eGFR O-ADR O-ADR
82 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Activation O-ADR O-ADR
of O-ADR O-ADR
Mania O-ADR O-ADR
/ O-ADR O-ADR
Hypomania O-ADR O-ADR
During O-ADR O-ADR
all O-ADR O-ADR
MDD O-ADR O-ADR
phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
phase O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
mania B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
approximately O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
02 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
originally O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
and O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
generally O-ADR O-ADR
taken O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
long O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
ongoing O-ADR O-ADR
extension O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Includes O-ADR O-ADR
the O-ADR O-ADR
terms O-ADR O-ADR
feeling B-ADR B-ADR
cold I-ADR I-ADR
and O-ADR O-ADR
chills B-ADR B-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
BLINCYTO O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
transaminases O-ADR O-ADR
rise O-ADR O-ADR
to O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
bilirubin O-ADR O-ADR
rises O-ADR O-ADR
to O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
Key O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
All O-ADR O-ADR
NCI O-ADR O-ADR
CTCAE O-ADR O-ADR
Grades O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
Positive O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
ZYKADIAN O-ADR O-ADR
= O-ADR O-ADR
255 O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
% O-ADR O-ADR
Hemoglobin B-ADR B-ADR
decreased I-ADR I-ADR
84 O-ADR O-ADR
5 O-ADR O-ADR
ALT B-ADR B-ADR
) I-ADR I-ADR
increased I-ADR I-ADR
80 O-ADR O-ADR
27 O-ADR O-ADR
AST B-ADR B-ADR
) I-ADR I-ADR
increased I-ADR I-ADR
75 O-ADR O-ADR
13 O-ADR O-ADR
Creatinine B-ADR B-ADR
increased I-ADR I-ADR
58 O-ADR O-ADR
2 O-ADR O-ADR
Glucose B-ADR B-ADR
increased I-ADR I-ADR
49 O-ADR O-ADR
13 O-ADR O-ADR
Phosphate B-ADR B-ADR
decreased I-ADR I-ADR
36 O-ADR O-ADR
7 O-ADR O-ADR
Lipase B-ADR B-ADR
increased I-ADR I-ADR
28 O-ADR O-ADR
10 O-ADR O-ADR
Bilirubin B-ADR B-ADR
( I-ADR I-ADR
total I-ADR I-ADR
) I-ADR I-ADR
increased I-ADR I-ADR
15 O-ADR O-ADR
1 O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
or O-ADR O-ADR
Persistent O-ADR O-ADR
Gastrointestinal O-ADR B-ADR
Toxicity O-ADR I-ADR
: O-ADR O-ADR
Dose O-ADR O-ADR
modification O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
or O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
38 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Intracranial B-ADR B-ADR
hemorrhage I-ADR I-ADR
included O-ADR O-ADR
subdural B-ADR B-ADR
bleeds I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reaction O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
Ferriprox O-ADR O-ADR
represents O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
data O-ADR O-ADR
collected O-ADR O-ADR
from O-ADR O-ADR
642 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
single O-ADR O-ADR
arm O-ADR O-ADR
or O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
reduction O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
was O-ADR O-ADR
required O-ADR O-ADR
by O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
HALAVEN O-ADR O-ADR
. O-ADR O-ADR
